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The generation of induced pluripotent stem (iPS) cells is a useful tool for regenerative 
medicine. However, the risk of tumor development of the aforementioned cells should 
be addressed before they can be used for clinical applications. During the 
reprogramming process a number of signal pathways are activated, which may lead to 
direct differentiation of specific cell lineages prior to the cells reaching the pluripotent 
state. In order to test this hypothesis we designed a combined protocol of 
reprogramming and differentiation in an attempt to achieve direct differentiation of 
fibroblasts to specific cell lineages. Human fibroblasts were shortly reprogrammed by 
overexpression of four reprogramming factors (OCT4, SOX2, KLF4 and c-MYC) and 
maintained in reprogramming media on a gelatin substrate for four days. These cells 
were defined as partially induced pluripotent stem (PiPS) cells.  PiPS cells did not form 
tumours in vivo and differentiated into smooth muscle cells (SMCs) when seeded on a 
Collagen IV substrate and maintained in differentiation media (DM). The PiPS-SMCs 
expressed a panel of SMC markers such as SMA, SM22 and Calponin at mRNA and 
protein levels. Immunofluorescent staining of PiPS-SMCs showed positive staining for 
the above markers, demonstrating a typical SMC morphology. These cells displayed a 
greater potential to differentiate into SMCs than iPS cells. In order to elucidate the 
mechanism of PiPS cell differentiation into SMCs, data from a series of experiments 
indicated that the gene DKK3 was involved in SMC differentiation of PiPS cells. DKK3 
was expressed in parallel with SMC markers, while its overexpression or stimulation 
induced SMC marker expression. Furthermore, DKK3 silencing resulted in 




Finally, additional experiments revealed that the upregulation of SMC markers by 
DKK3 is mediated by activation of Wnt signalling through interaction of DKK3 with 
the transmembrane receptor Kremen 1. Therefore, we developed a protocol to generate 
SMCs from PiPS cells through a DKK3 signal pathway. These findings provide a new 
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Although stem cell research is a specialised field of developmental biology for the past 
140 years, it was not until recently, and due to the advent of interest in cellular therapy 
for degenerative diseases, that stem cell research has accelerated considerably. Their 
potential in recapitulating developmental paths to repair damaged tissues has made them 
invaluable tools in drug discovery, generation of transgenic animals and regenerative 
medicine (Klimanskaya et al., 2008) . However, our understanding of stem cell biology 
has been revolutionary as well as controversial. The limited success rate of stem cell 
therapy in clinical trials, with the exception of hematopoietic stem cell applications 
(Burt et al., 2008), has raised the possibility that stem cells require “adjuvant” 
molecules as enhancers during administration for tissue repair and regeneration, 
rendering the combination of ESC-based, high throughput screening and 3D tissue 
engineering approaches vital for the generation of the next tools in preclinical drug 
discovery (Nirmalanandhan and Sittampalam, 2009). The need for pluripotency has 
however lead to the expansion of stem cell research into new fields, such as the 
isolation of adult stem cells and the generation of induced pluripotent stem cells, 
opening up exciting new areas of research which hold great promise for applications in 









1.1 Embryonic stem cells 
 
Embryonic stem cells (ESC) are unspecialized (pluripotent) cells deriving from the 
inner cell mass of a blastocyst, an early stage embryo that contains 200 to 250 cells 
(Evans and Kaufman, 1981). Their pluripotent ability allows them to differentiate into 
any cell of the three germ layers (mesoderm, ectoderm, and endoderm). During 
development and in response to different stimuli, they give rise to specialized cells that 
will carry out specific functions of the body (Kleinsmith and Pierce, 1964). Although 
pluripotency is a key defining feature, ESCs also have another unique characteristic. 
Their self renewal properties give them the ability to be maintained as pure populations 
of undifferentiated cells in culture for extended periods of time, retaining normal 
karyotypes unlike tumor cell lines (Keller, 2005) (Figure 1). Over the past two decades, 
the different ESC lines have provided a model system for the study of the basic 
processes of early development and cellular differentiation making regenerative 
medicine and tissue engineering a real possibility for the future treatment of human 
disease. 
During the past few years, ESCs have become a major focus of translational medicine 
and a reference model for understanding key molecular mechanisms which control cell 
fate choice and organ differentiation (Teo and Vallier, 2010). Their importance has also 
been captured in regenerative medicine (Ehnert et al., 2009) as well as functional tissue 
engineering (Guilak et al., 2001), making it possible to screen millions of small-
molecule compounds available in industrial and academic centers using human primary 
cell lineages and “tissue constructs” or 3D cellular spheroids derived from stem cells 
(Nirmalanandhan and Sittampalam, 2009). 
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Future clinical applications of ESCs concern a broad number of degenerative diseases 
which could potentially be treated using ESC-based therapy such as major metabolic 
diseases, diverse brain and myelin disorders, heart disease and a number of other 




Figure 1.  Stem cell isolation, culture and differentiation. ESCs are isolated from the 
inner cell mass of early embryos and are then expanded and differentiated in vitro 







1.2 ESC specific networks 
 
Scientific research has been focused on a number of genes that are considered to be 
stem cell specific. Transcription factors such as OCT4 (Nichols et al., 1998), SOX2 
(Avilion et al., 2003), and NANOG (Chambers et al., 2003) are responsible for 
maintaining pluripotency in early embryos and ESCs. Furthermore, genes like cMYC 
(Cartwright et al., 2005) and KLF4 (Li et al., 2005) are frequently up-regulated in 
tumors and have been shown to contribute to the long time maintenance of ESCs. 
OCT4, SOX2 and NANOG are considered to be key components in ESC pluripotency 
as their inactivation leads to differentiation of the cell. Through a cooperative 
interaction, SOX2 and OCT4 can drive pluripotent-specific expression of a number of 
genes including NANOG. OCT4 and SOX2 interact with the NANOG promoter which 
contains a highly conserved SOX-OCT cis-regulatory element essential for NANOG 
transcription and therefore pluripotency (Rodda et al., 2005). 
Moreover, these transcription factors are essential for repressing a key set of genes 
needed for the development of the embryo and differentiation into different specialized 
cells and tissues (Figure 2). Therefore, OCT4, SOX2, and NANOG are master 
regulators, silencing genes that are waiting to create the next generation of cells (Boyer 











Figure 2. The core transcriptional regulatory network in ESCs. This model 
identifies OCT4, SOX2, and NANOG target genes that encode transcription factors and 
chromatin regulators as well as integrating knowledge of the functions of these 
downstream regulators based on comparison to multiple expression datasets and to the 





1.3 Limitations in ESC research 
 
ESC research has raised a number of ethical questions, as the isolation of human ESCs 
requires the destruction of the embryo.  
Furthermore, the issue of immune system rejection still stands due to the different 
genetic makeup between the patient and donor. Therefore, even after perfecting the 
differentiation process from the pluripotent stage to that of the desired cell type, the use 
of powerful anti-rejection drugs with serious side effects would be required to avoid 
immune rejection. 
Finally, teratoma formation, which is the creation of a non-cancerous tumour formed by 
the accumulation of undifferentiated cells, can cause a number of problems especially in 
cases of syngenic ESCs (cells with same genetic makeup as the host) where immune 
rejection does not protect the recipient (Nussbaum et al., 2007). 
In an attempt to find a solution to the obstacles concerning the use of ESCs, scientists 
focused their research into finding alternative sources of pluripotent cells, ultimately 









1.4 Adult Stem Cells 
Adult stem cells or somatic stem cells are multipotent stem cells which originate from 
differentiated organs and can reside in specific niches within the adult body that are 
essential to maintain their property of self-renewal and differentiation (Yin and Li, 
2006). The identification of such cells started about 40 years ago when hematopoietic 
stem cells and bone marrow stem cells (also known as mesenchymal stem cells) were 
identified by scientists and shown to be able to differentiate into all cellular lineages in 
blood and bone respectively, exhibiting multipotent potential (Nirmalanandhan and 
Sittampalam, 2009). Despite the great disbelief concerning the presence of multipotent 
stem cells within the adult tissues as recently as 20 years ago, it is now well established 
that adult stem cells are present in many adult tissues, including the adventitia (Hu et 
al., 2004), brain (Doetsch, 2003), skin (Bickenbach and Grinnell, 2004), muscle (Martin 
et al., 2006), liver (Kung and Forbes, 2009), heart (Beltrami et al., 2003) and lung 
(Neuringer and Randell, 2006) in addition to the bone marrow (Wilson and Trumpp, 
2006). Adult stem cells have been shown to self renew and usually differentiate into all 
the cell types constituting their organ of origin as well as other lineages in a limited 
fashion, and are involved in the continuing maintenance and repair of the tissues and 
organs throughout the life span of the individual (Nirmalanandhan and Sittampalam, 
2009; Teo and Vallier, 2010).  
Although adult stem cells represent an ideal target for regenerative medicine, since 
immunosuppressive treatments would not be required, their clinical use is currently 
limited for diverse reasons. Apart from their limited differentiation potential, their 
presence in several tissues still remains controversial, making their identification and 
characterization a challenging task (Teo and Vallier, 2010).  
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Furthermore, the results obtained in animal models might not be directly translated to 
humans, thus limiting the study of the mechanisms controlling the self-renewal and 
differentiation of adult stem cells, which is necessary for the development of future 
clinical treatments. Somatic stem cells could also be targeted by the disease itself, 
explaining why they appear to be incapable or insufficient in stopping the progression 
of the disease (Teo and Vallier, 2010). Finally, technical issues such as the loss of 
proliferative capacity and differentiation potential under standard culture conditions as 
well as the method for the delivery of adult stem cells to the patient, comprise 
limitations for their clinical applications (Sekiya et al., 2002). Recent studies however, 
have shown that such technical issues could be circumvented by induction of somatic 
stem cell mobilization and recruitment in injured tissues in response to specific 
stimulus. More specifically, it has been demonstrated that hematopoietic progenitor 
cells can be mobilized from the bone marrow upon stimulation with G-CSF (Levesque 
et al., 2003) and that discrete populations of progenitor cells can be differentially 
mobilized from the bone marrow as a response to different factors, suggesting selective 
recruitment of progenitor populations in different pathologies (Pitchford et al., 2009). 
Additionally, it has recently been demonstrated that a progenitor population of 
epicardial origin can give rise to de novo cardiomyocytes under the circumstances of a 
myocardial infarction and that the peptide thymosin β4 can enhance this process, thus 
suggesting a regenerative mechanism within the mammalian adult heart (Smart et al., 
2011). Further studies in the mobilization of specific subpopulations of progenitor cells 











Figure 3. Niches of adult stem cells. Adult stem cells have successfully been isolated 
from a variety of tissues such as bone marrow, the heart and the brain and differentiated 








1.5 Induced pluripotent stem cells (iPS cells) 
 
One of the newest and most exciting areas of stem cell research is the development of 
iPS cells. iPS cells are pluripotent cells artificially derived from terminally 
differentiated somatic cells through overexpression of four genes.  
The ethical and immunological problems often associated with the use of ESCs are 
bypassed as the origin of the iPS cells can be a somatic cell population isolated from the 
patient (such as dermal fibroblasts).  The potential of these cells is enormous, including 
their application in effective and safe drug screening, regenerative medicine as well as 
their contribution in constructing disease models (Figure 4). 
 
(Yamanaka, 2009) 
Figure 4. Applications of the iPS cell technology. iPS cells can produce various 
somatic cells with the same genetic information as the patient, which could be used to 





1.5.1 Generation of iPS cells 
 
Since 1997, it was already known that somatic cells can be reprogrammed into a 
pluripotent state by transferring their nuclear contents into oocytes (Wilmut et al., 1997) 
or by fusion with ESCs (Cowan et al., 2005), indicating that factors exist within the 
unfertilized eggs which are able to confer totipotency or pluripotency to somatic cells 
(Tada et al., 2001). 
Taking advantage of this knowledge, in 2006, Takahashi and Yamanaka, in a landmark 
paper, demonstrated that terminally differentiated mouse fibroblasts in culture, could be 
reprogrammed into pluripotent ESC like cells by retroviral transduction of four defined 
transcription factors, SOX2, OCT4, KLF4 and cMYC (Takahashi and Yamanaka, 
2006). These cells were named iPS cells and exhibited similarities with ESCs in cell 
morphology, proliferation, expression of some ESC genes and the ability to form 
teratomas. DNA demethylation of the promoter regions of OCT4 and NANOG was also 
observed indicating re-activation of endogenous genes associated with pluripotency. In 
addition, the somatically silent X chromosome was re-activated in female cells 
(Hochedlinger and Plath, 2009). However, differences were observed between their 
global gene expression pattern and that of ESCs. Furthermore, they failed to produce 
adult chimeric mice. 
One year later, further characterization identified a method to generate mouse iPS cells 
with phenotypes comparable to ESCs, including the ability to generate chimeric mice 





1.5.2 Generation of human iPS cells 
 
In November 2007, two separate teams generated iPS from human skin cells that were 
phenotypically indistinguishable from human embryonic stem cells, a milestone in the 
field of disease modelling and patient specific regenerative medicine. 
Shinya Yamanaka at the University of Kyoto showed that terminally differentiated 
human fibroblasts can be reprogrammed to an embryonic like state using the same 
formula previously used to reprogram mouse fibroblasts (retroviral transduction of 
SOX2, OCT4, KLF4,cMYC) (Takahashi et al., 2007). These cells could differentiate 
into any of the three cell types (Figure 5). 
Simultaneously, Thomson and Yu published the success of a similar approach. Starting 
from a panel of 14 genes known to be expressed in human ESCs and through the 
process of elimination, they generated pluripotent cells from terminally differentiated 
cells using a different combination to the one used by Yamanaka in that KLF4 and 
cMYC were replaced with NANOG and LIN28. These cells expressed genes and 
surface proteins characteristic of ESCs and were capable of teratomas formation or 
tumors with cells representing the three embryonic germ layers (Yu, Vodyanik et al. 
2007). 
As it was proven later on, this method of cellular reprogramming is not specific only to 
mouse or human fibroblasts, but can be applied in different species and kinds of 
terminally differentiated cells such as lymphocytes (Hanna et al., 2008), liver cells (Aoi 
et al., 2008), intestinal cells (Wernig et al., 2007) and neural progenitors (Eminli et al., 
2008). In addition iPS cells have been generated from both monkey (Liu et al., 2008) 
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and rat (Liao et al., 2009) proving  in vitro reprogramming to be a universal process. 
However, an alteration in the combination of factors might be required for successful 
reprogramming of different cell types depending on the endogenous expression pattern 





Figure 5. Generation of iPS cells. Schematic representation of a standard protocol for 
iPS cell generation. Skin cells are infected with viruses carrying a cocktail of 
reprogramming factors which integrate into the genome and alter the genetic program of 




1.5.3 iPS cell application challenges  
Even though iPS cell technology could potentially be the solution to obstacles 
concerning the use of ESCs, clinical application of the aforementioned cells faces many 
obstacles itself.  
Teratoma formation is one of the most prominent and common issues concerning the 
use of iPS cells. Even small numbers of undifferentiated cells can result in the formation 
of teratomas (Yamanaka, 2009). In addition, iPS cells derive from somatic cells which 
as we discussed, were subjected to forced reprogramming. Aberrant reprogramming 
might result to either an impaired ability to differentiate or might even increase the risk 
of immature teratoma formation after directed differentiation (Figure 6). 
In most cases, iPS cells are generated by transduction of the four genes by retroviruses 
or lentiviruses. By nature these transgenes can be integrated into the genome disrupting 
the normal gene expression. Unfortunately, this integration usually falls into an 
oncogene or tumor suppressor loci leading to malignant transformation(Cohen and 
Krause, 2009). The transgenes, although mostly silenced in iPS cells, can be reactivated 
and lead to tumorigenesis (especially cMyc, which is a known oncogene linked with 
tumorigenesis) (Okita et al., 2007). 
Another concern that was recently raised concerning the therapeutic application of iPS 
was their immunogenicity. While iPS cells were generally assumed to be immune-
tolerated by the recipient from whom they derived, it was demonstrated that in contrast 
to the derivatives of ESCs, abnormal expression in some cells derived from iPS cells 





Therefore it is advised that immunogenicity of these patient specific iPS cells is 
vigorously evaluated before their application into patients. 
Finally, most of the protocols used to date demonstrate reprogramming efficiencies as 
low as 0.01%. The low efficiency rate may reflect the need for rare genetic and/or 
epigenetic changes in the original somatic cell population or in the prolonged culture. It 
also suggests the methods utilised to generate iPS cells need to be improved and new 
strategies to be developed (Hochedlinger and Plath, 2009). 
 
1.5.4 Different methods of generating iPS cells 
Since the first generation of iPS cells and in an effort to optimize the reprogramming 
protocols as well as to overcome the various obstacles during the process, a number of 
techniques of generating these cells have been established (Figure 6). 
Retroviruses and lentiviruses: The standard protocol for generating iPS cells is the 
overexpression of any of the two combinations of four transcription factors 
(SOX2/OCT4/KLF4/cMYC or SOX2/OCT4/NANOG/LIN28) as part of a lentiviral or 
retroviral construct. The cells are infected with the four viruses and maintained in ESC 
medium for 1-2 weeks for mouse cells or 3-4 weeks for human cells before iPS cell 
colonies are picked up, expanded and characterised. However, the use of these viruses 
raises safety issues due to the possibility of random integration within the genome. In an 
attempt to minimize the amount of proviral integrations, iPS cells have also been 
generated from both human and mouse cells using a single polycistronic vector 
encoding the 4 factors simultaneously (Carey et al., 2009; Takahashi and Yamanaka, 
2006; Yu et al., 2007). 
35 
 
Adenoviruses: It has been shown that iPS cells can be generated from mouse 
hepatocytes using adenoviruses carrying the four reprogramming factors, a technique 
that eliminates viral integration (Stadtfeld et al., 2008b) but occurs at an even lower 
efficiency than previously stated. 
Plasmids: It has also been shown that iPS cells can be generated from mouse 
embryonic fibroblasts using large constructs containing three of the four genes within 
the same construct (SOX2/OCT4/KLF4). cMYC was administered in a different 
construct. Repeated transfection of the 2 constructs resulted in iPS cells without 
evidence of plasmid integration addressing a critical safety concern for potential use of 
iPS cells in regenerative medicine (Okita et al., 2008).  
Proteins: Another interesting technique is that of generating iPS cells using 
recombinant proteins. It was demonstrated that iPS cells can be generated from murine 
embryonic fibroblasts following culture with the reprogramming proteins tagged with 
peptide sequences which markedly enhance protein uptake by cells. The iPS cells 
generated were able to self-renew and were shown to be pluripotent in vitro and in vivo 
(Zhou et al., 2009). 
Cre-mediated excision reprogramming: Recently, iPS cells were generated by 
genomic integration of the four genes using plasmids (Kaji et al., 2009), lentiviruses 
(Soldner et al., 2009), or transposons (Woltjen et al., 2009) followed by transgene 
removal using Cre-mediated excision or re-expression of transposase (Yamanaka, 
2009). 
Chemicals and small molecules:  iPS cells have been generated by using chemicals 




which can replace cMyc, and BIX-01294 and BayK8644 which can replace Sox2  
(Huangfu et al., 2008; Shi et al., 2008). 
Synthesised mRNA reprogramming: Another non integrating strategy for 
reprogramming cell fate is based on administration of synthetic mRNA modified to 
overcome innate antiviral responses. This approach has the ability to reprogram a 
variety of human cell types to pluripotency with efficiencies that surpass already 
established protocols and represents a safe strategy with broad applicability for disease 
modelling and regenerative medicine (Warren et al., 2010). 
microRNA mediated reprogramming: One of the most recent strategies of generating 
iPS cells is the utilization of the rapidly expanding field of miRNAs. It has been shown 
that the expression of the miR302/367 cluster rapidly and efficiently reprograms mouse 
and human somatic cells to an iPS cell state without the requirement of exogenous 
transcription factors and with two orders of magnitude higher efficiencies that the 
standard transcription factor strategy (Anokye-Danso et al., 2011).     
 
(Yamanaka, 2009) 
Figure 6. Old and New Ways to Generate iPS cells. During the reprogramming and 
regardless of methodology, the derivatives can be fully reprogrammed cells that are 
comparable to ES cells, partially reprogrammed iPS cells that can self-renew and 
differentiate into certain cell lineages, or aberrantly reprogrammed cells that self-renew 
but are refractory to differentiation. 
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1.5.5 Epigenetic modifications and epigenetic memory in iPS cells. 
 
As mentioned above, iPS cell generation is a lengthy and inefficient process with many 
cells ultimately failing to be completely reprogrammed. Although several functional 
assays exist to determine the developmental potential and limitations of pluripotent cells 
in mice (Jaenisch and Young, 2008), such assays cannot be used for human ESCs and 
iPS cells, making a comprehensive characterization of the epigenetic state an essential 
substitute (Meissner, 2010).  In an attempt to elucidate the mechanisms by which 
ectopic transcription factors override the existing epigenetic state and change it into a 
specific alternative, extensive research has been focused into the complex process of 
epigenetic remodelling during reprogramming.  
Detection of epigenetic remodelling requires comprehensive genomic characterisation 
which can involve gene expression profiling, chromatin state maps of key activating and 
repressive marks and DNA methylation analysis. Studies have shown that 
reprogramming somatic cells into an ESC like phenotype requires suppression of 
somatic genes with concomitant activation of pluripotency genes (Mikkelsen et al., 
2008). Genomic analysis conducted by two separate groups has shown that successful 
reprogramming is dependent upon demethylation of pluripotency specific genes and 
methylation of promoters regulating somatic specific genes (Maherali et al., 2007; 






Comparison of stable iPS cell clones with partially reprogrammed iPS cells revealed 
that although fully reprogrammed iPS cells have similar gene expression and epigenetic 
state to ESCs, partially reprogrammed iPS cells display hypermethylation of 
pluripotency loci and are closer to mouse embryonic fibroblasts (Mattout et al., 2011; 
Mikkelsen et al., 2008).  
Finally, it has been reported that treatment with chemicals such as histone deacetylases 
and DNA methyltransferase inhibitors can facilitate the reprogramming and enable cells 
that are “trapped” in a partially de-differentiated state, to acquire an iPS cells genetic 
phenotype (Mikkelsen et al., 2008) 
Interestingly, it has recently been reported that low passage iPS cells generated by 
transcription factor based reprogramming of mouse somatic cells contain residual DNA 
methylation signatures characteristic of their tissue of origin. These signatures favour 
their differentiation along lineages related to the donor cell and restrict alternative cell 
fates. However, such epigenetic memory could be reset by differentiation and serial 
reprogramming or by treatment with chromatin modifying drugs (Kim et al., 2010). 
Notably, Hochedlinger and colleagues observed similar epigenetic memory in iPS cells 
from blood, fibroblasts and muscle sources which eventually becomes extinct after 
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1.6 ESC and iPS cell differentiation 
1.6.1 ESC differentiation 
 
Given the proper stimulus (growth factors or substrates), pluripotent cells can 
spontaneously differentiate and generate various lineages in culture. Over the past few 
years mesoderm-derived lineages have been successfully generated from ESCs. For 
instance, under optimised culture conditions, following serum induction, mouse ESCs 
underwent hematopoietic differentiation (Keller, 1995). Furthermore, it has recently 
been shown that mouse ESCs plated on matrigel, but not collagen or gelatine, could 
form embryonic bodies and differentiate into blood vessels in the absence of additional 
growth factors (Nakagami et al., 2006). Vascular progenitors (Yamashita et al., 2000), 
cardiomyocytes (Kehat et al., 2001), endothelial cells (ECs) (Levenberg et al., 2002) as 
well as smooth muscle cells (SMCs) (Xiao et al., 2007) have also been generated, 
offering a broad spectrum of cell lineages for clinical use in transplantation and 
replacement therapy. 
Specifically for the cardiovascular field, the generation of vascular endothelial cells, 
SMCs and cardiomyocytes from ESCs demonstrated a novel mechanism of cell 
differentiation as well as a potential source for cardiovascular tissue repair (Gepstein, 
2002). Endothelial cell differentiation from ESCs has been induced within the three-
dimensional tissue of embryoid bodies (EBs) by Wartenberg (Wartenberg et al., 1998). 
When mouse ESC-derived cardiomyocytes were generated, it was found that the 
aforementioned cells expressed tissue-specific markers such as structural cardiac 
proteins, receptors and transcription factors (Boheler et al., 2002). 
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Importantly, human ESCs displayed the potential to generate cardiomyocytes based on 
optimised protocols from murine ESCs (Mummery et al., 2003). It has also been 
demonstrated that CD34
+
 cells (differentiation molecule present in mesenchymal cells) 
isolated from differentiated hESCs, function as vascular progenitor cells capable of 
producing both ECs and SMCs elucidating their developmental origin and revealing the 
relationship between these two cell types (Hill et al., 2010). 
 
1.6.2 iPS cell differentiation 
A variety of protocols applied in the differentiation of ESCs towards an array of 
different cell lineages have been used in order to differentiate iPS cells.  
Taura et al have investigated the features of the directed differentiation of human iPS 
cells into vascular ECs and mural cells (MCs). Their studies have revealed that the 
properties of human iPS cell differentiation into vascular cells are nearly identical to 
those of hESCs (Taura et al., 2009b). 
Additionally, Xie et al. have also demonstrated that iPS cells have the ability to 
differentiate into SMCs. In the aforementioned study, iPS cell monolayers were treated 
with retinoic acid for 8 days, after which they successfully expressed SMC specific 
markers and acquired SMC functional characteristics including contraction and calcium 
influx in response to stimuli (Xie et al., 2009). 
In a similar study, murine iPS cells were differentiated into Flk1
+
 progenitor cells and 
their mesodermal progeny, including cells of the cardiovascular and hematopoietic 




Cells of the endoderm layer have also been successfully generated by iPS cells. When 
iPS cells were differentiated on Collagen IV in the present of both Activin A and 
Lithioum Cloride (LiCl), the aforementioned cells differentiated to definitive endoderm 
through mesendoderm (Inami et al., 2011).Additional treatment with Fgf8 followed by 
Fgf7, Fgf10 and BMP4 differentiated the iPS cells to thymic epithelial progenitor cells 
(TEPCs) by phenotype (Inami et al., 2011). 
Moreover, using methods shown to be effective at generating motor neurons from 
human embryonic stem cells (hESCs), it was found that once induced to a neural 
lineage, human iPS cells could be differentiated to form motor neurons with a similar 
efficiency as hESCs (Karumbayaram et al., 2009).   
In addition to the above studies, human iPS cell lines obtained from human fetal, 
neonatal, and adult fibroblasts through reprogramming were differentiated towards 
hematopoietic and endothelial cells using an OP9 differentiation system. Their 
differentiation potential was compared to that of five human ESC lines. It was then 
shown that although some variations in the efficiency of hematopoietic differentiation 
between different hiPS cells existed, the pattern of differentiation was very similar in all 
seven tested lines obtained through reprogramming. These findings provide strong 
evidence that hiPS cells are quite similar to hESCs and differentiation systems 
established for hESCs can be readily applied to hiPS cells (Choi et al., 2009).  
Similarly, four human iPS cell lines underwent adipogenic differentiation and their 
properties were compared to the differentiation properties of human ESC lines. It was 
demonstrated that human iPS cells have an adipogenic potential comparable to human 




Finally, cardiomyocytes have successfully been generated from murine iPS cells in vitro 
which exhibited functional cardiomyocyte characteristics, with established hormonal 
regulation pathways and expression of cardiac ion channels (Kuzmenkin et al., 2009).  
In summary, iPS cells have been differentiated into a variety of cell lineages including 
the ones mentioned above as well as pancreatic beta-cells (Zhang et al., 2009), and 
several neuronal cell types (Wernig et al., 2008) paving the way for generating patient-
specific pluripotent cells that could be used for research and therapy (Figure 7). 
 
 
(Amabile and Meissner, 2009) 
Figure 7. Direct differentiation of iPS cells. iPS cells can differentiate into a variety of 
cell lineages such as cardiomyocytes, neurons, and pancreatic β cells, upon specific 





1.7 Direct differentiation between lineages 
 
The use of a combination of transcription factors and the generation of iPS cells caused 
a cascade of questions and ideas in scientists which lead to a whole new field of 
research. One of the latest and most exciting fields of iPS cell related research is the 
direct conversion of somatic cells, such as fibroblasts, into other somatic cell fates. 
Although direct reprogramming, or otherwise known as lineage reprogramming, has 
been investigated since the early 90s, terminally differentiated cells had been limited to 
transforming into skeletal muscle via MyoD. This transcription factor became 
recognized as a ‘‘master regulator gene’’ because it was able to convert fibroblasts, 
chondrocytes and retinal epithelium into contracting muscle in culture (Choi et al., 
1990). Additional examples included the conversion of sensory hair cells by Math1 
(Izumikawa et al., 2005), B lymphocytes into macrophages by CEP/B (Laiosa et al., 
2006), as well as fibroblasts into macrophage-like cells by C/EBPalpha/beta and PU.1 
(Feng et al., 2008). 
However, despite years of research, master regulators for other lineages still remained 
elusive. To answer the question of whether transcription factors could directly induce 
other defined somatic cell fates besides pluripotency, Ieda and colleagues showed that a 
combination of three developmental transcription factors, Gata4, Mef2c and Tbx5 could  
rapidly and efficiently reprogram postnatal cardiac or dermal fibroblasts directly into 





In a similar report, Efe et al showed that transgenic expression of the Sox2, Oct4, Klf4, 
cMyc in mouse embryonic fibroblasts (MEFs) could directly reprogram fibroblasts to 
spontaneously contracting patches of differentiated cardiomyocytes. Furthermore, 
several lines of evidence suggested that a pluripotent intermediate during the transition 
was not involved (Efe et al., 2011).  
Although all the studies mentioned above involve conversion of one cell type to 
another, this conversion occurs within the same lineage. In 2010, Verbuchen et al 
showed that differentiated mouse cells have the capacity to change lineage by showing 
direct conversion of dermal fibroblasts into neurons. Starting from a pool of nineteen 
candidate genes, three factors, Ascl1, Brn2 (also called Pou3f2) and Myt1l were 
ultimately found to be sufficient to rapidly and efficiently convert mouse embryonic and 
postnatal fibroblasts into functional neurons in vitro (Vierbuchen et al., 2010).  
Within the same lines of work, it was recently shown that adult human fibroblasts could 
differentiate into functional neurons with a combination of microRNA miR-124 and 
thetranscription factors MYT1L and BRN2 (Ambasudhan et al., 2011) and that both 
mouse and human fibroblasts could be directly differentiated to functional spinal motor 
neurons by overexpression of select transcription factors (Son et al., 2011).  
Finally, in one of the most recent studies, Marro et al. investigated the potential of a 
more homogenous cell type, like hepatocytes, to differentiate into functional neurons by 
using a specific combination of transcription factors (Marro et al., 2011).  
All the above findings have major implications for cell-replacement strategies in various 




1.8 Differentiation towards vascular lineages is governed by growth 
factors and the extracellular matrix 
As it was previously mentioned, pluripotent cells can differentiate into vascular lineages 
responding to the right stimulus which can be cytokines or growth factors, the 
extracellular matrix, mechanical forces and communication with adjacent cells (Xiao et 
al., 2010). Previous studies in our laboratory have shown that ESCs can successfully 
differentiate into functional SMCs under an established differentiation protocol utilizing 
Collagen IV and platelet derived growth factor (PDGF) (Xiao et al., 2007). Hence, this 
section will focus on the role of PDGF and Collagen IV in the differentiation towards 
vascular lineages. 
1.8.1 PDGF and its role in SMC differentiation 
Cytokines are molecules released from progenitor/stem cells or mature SMCs and in 
turn stimulate other stem cells or progenitor cells to differentiate into specific lineages. 
Recent studies have indicated that among others, vascular endothelial growth factor 
(VEGF) and PDGF-BB are two factors essential for the development and maturation of 
the vascular lineages. which is produced close to forming vessels (Rafii, 2000). VEGF 
is a key molecule in vascular development which acts as a survival factor and a mitogen 
for vascular ECs (Isner, 2001). Administration of the above factors has lead to 
differentiation of stem cells into vascular cells. VEGF induced expression of EC 
markers such as von Willebrand factor (vWF) while the addition of PDGF-BB 
increased the expression of SMC markers such as smooth muscle actin (SMA), 
Calponin and smooth muscle myosin heavy chain (SMMHC) (Gerecht-Nir and 




migratory factor that regulates the tyrosine phosphorylation of a variety of signalling 
proteins via intracellular production of H2O2.  
It is a major mitogen for fibroblasts, SMCs and other cell types. Although a-granules of 
platelets are a major storage site for PDGF, further studies have shown that it can be 
synthesized by a number of different cells. It is a dimeric molecule consisting of 2 
structurally similar A and B polypeptide chains which can combine into homo- or 
heterodimers (PDGF-AA, PDGF-BB, PDGF-AB). These isoforms act by binding to and 
activating two structurally related protein tyrosine kinase receptors, receptor –α and 
receptor –β (Heldin and Westermark, 1999) (Figure 8).  
Although PDGF is expressed at low levels in arteries from healthy adults, its expression 
is increased in conjunction with the inflammatory response that characterizes 
atherosclerosis. Studies in naturally occurring atherosclerosis and experimentally 
induced atherosclerosis revealed that the expression of PDGF and PDGF receptors 
appears to be increased in these lesions. These observations suggest that PDGF, 
produced by activated macrophages, SMCs or ECs or released from platelets in 
thrombi, is important for the lesion formation (Heldin and Westermark, 1999). 
Members of the PDGF family have been implicated in different pathophysiological 
conditions such as vascular development, neointima formation, wound healing during 
atherogenesis and atherosclerosis. For instance, inhibition of PDGF or its receptors in 
adults have reduced neointimal hyperplacia in response to injury (Raines, 2004). In 
addition to the above roles of PDGFs, PDGF-BB has been associated with induction of 





However, its role in mature SMCs appears to be completely different since it negatively 
regulates the transcription of multiple SMC differentiation marker genes, a clear 
indication of its involvement in the SMC phenotypic switching (Dandre and Owens, 
2004). 
 
(Heldin and Westermark, 1999) 
Figure 8. Processing and action of platelet-derived growth factor (PDGF) isoforms. 
A- and B-chains of PDGF are synthesized as precursor molecules that form disulfide-
bonded dimers and undergo proteolytic processing. Different PDGF isoforms bind to 
and dimerize a- and b- receptors with different specificities. Intracellular parts of 
receptors contain tyrosine kinase domains, with characteristic inserted sequences 




1.8.2 Collagen IV 
 
The extracellular matrix (ECM) seems to be as critical in directing differentiation of 
pluripotent cells as cytokines and other soluble factors. The ECM is a complex 
structural entity which surrounds and supports cells that are found within mammalian 
tissues. It is an important factor affecting a variety of cell functions such as adherence, 
growth, migration, apoptosis and differentiation (Choy et al., 2004; Flaim et al., 2005; 
Hutchings et al., 2003). Collagens are the most abundant proteins in the animal 
kingdom and the major components of ECM. There are at least 12 types of collagens, 
with Collagen IV appearing important for vascular biology. 
Collagen IV forms a two-dimensional reticulum and is a major component of the basal 
lamina (a layer secreted by the epithelium upon which the epithelium resides). In 
normal embryogenesis, ESCs differentiate along different lineages in the context of 
complex three dimensional (3D) tissue structures. It has been demonstrated that a 3D 
collagen matrix can mimic the aforementioned 3D tissue structure in vitro, inducing 
differentiation of rhesus monkey stem cells into various cell lineages (Chen et al., 
2003). It has also been shown that Collagen IV has a crucial role in the early stages of 
differentiation of F9 stem cells (Watanabe et al., 2002). Finally, additional studies have 
within our laboratory have shown that cells positive for the VEGF receptor (VEGFR
+
) 
can differentiate into SMCs when cultured on a Collagen IV substrate in α-minimal 
essential medium (α-MEM) containing 10% FBS. It was demonstrated that Collagen IV 
has a functional role in SMC differentiation of ES cells and that the Collagen IV-
integrin signalling pathways mediate SMC differentiation from Sca-1+ progenitor cells 
(Xiao et al., 2007). 
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 1.9 The vascular system 
 
The cardiovascular system is one of the largest organs in the body, involved in the 
transport of blood and nutrients to the various tissues of the body as well as the removal 
of waste products and carbon dioxide. It is also the first organ to be formed in the 
developing embryo since, as soon as an embryo grows bigger than about 2 mm, it 
critically depends on a functional vasculature because passive diffusion is not sufficient 
to supply all cells with oxygen and nutrients. Blood cells and vessels arise from 
common precursor cells (hemangioblasts) which differentiate into blood cell precursors 
and vascular precursors (angioblasts). These angioblasts then migrate, ultimately 
forming a lumen. This process of vessel formation is called vasculogenesis and is 
dominant in very early embryogenesis (Risau and Flamme, 1995). The generation of 
additional vessels sprouting from pre existing vessels is called angiogenesis. It can be 
induced by hypoxia and can also occur in multiple diseases including many forms of 
cancer (Carmeliet, 2003) as well as arteriosclerosis, which involves remodelling of the 
existing vasculature and expansion of collateral vessels (Carmeliet, 2000b).  
Blood vessels are generally composed of two cell types: ECs which form the intimal 
region of the vessel and SMCs which surround the intima, generating the medial layer 
and controlling the blood flow. Larger blood vessels also contain a third layer of cells 
(fibroblasts) which form the adventitia (Figure 10). However, vessels within the 
microvascular system only contain an intimal region and cells not joined in layers, 





Initially, it was considered that endothelial and SMCs arise from separate ‘precursor’ 
cells through rounds of cell division and specialization, however, in 2000 Yamashita 
and his colleagues described a type of blood-vessel precursor from which both ECs and 
SMCs could be developed in vitro and in vivo (Yamashita et al., 2000) 
Endothelial precursors have also been found in adults and most of them divide and 





















Figure 9: A common origin for the two types of blood-vessel cells. Centre, ECs are 
the cells that make up the interior walls of a blood vessel. SMCs or pericytes encase the 
endothelial channels. These basic cell types have been thought to arise from separate 
types of precursor. ECs arise from precursors called angioblasts or haemangioblasts in 
the embryo (top), or from circulating endothelial progenitors in the adult (not shown). 










Figure 10. Anatomy of the arterial wall. Schematic representation of the arterial wall 
and the layers it is composed of. The endothelial cells comprise of the intima, the inner 
most layer of the vessel while the contracting SMCs are part of the media layer and 









1.10 Vascular SMCs 
 
Vascular SMCs have a critical function in maintaining the integrity of the vascular 
system. Heterogeneity both during development as well as in the adult vasculature is 
one of the most characteristic features of vascular SMC. However, when talking about 
heterogeneity the basic question of whether we are dealing with a SMC heterogeneity in 
origin or with a spatiotemporal heterogeneity in expression of differentiation markers 
should be addressed (Majesky, 2007).  
Lineage tracking studies have revealed that vascular SMCs in different vessels have 
distinct embryological origins (Majesky, 2007). In the developing embryo, the first 
mural cells investing the endothelial tubes derive from transdifferentiated endothelium 
(mesodermal origin) during nascent vascular and cardiac valve development (Nakajima 
et al., 1997). Subsequently, there is evidence of additional sources of origin of SMCs. 
For example, vascular SMCs in coronary arteries derive from the epicardial lining in a 
similar way to the transdifferentiation of adventitial cells of the coronary vessel wall.  
However, SMCs from the aortic arch are likely of neuroectodermal origin namely, from 
the mesectoderm of the neural crest and the cells constituting the descending aorta 
originate predominantly from the local mesenchyme (Gittenberger-de Groot et al., 
1999). The diversity of SMC origins may in part contribute to the site specific 
localization of vascular diseases and explain the regional susceptibility to 
atherosclerosis (DeBakey et al., 1985; Haimovici and Maier, 1964) 
During the late fetal and post natal development, SMCs are characterized by a very high 
proliferative rate and by the expression of significant and unique serum-independent 
growth capabilities in vitro (Cook et al., 1994).  
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Furthermore, there is a rapid induction in the expression of multiple mature SMC 
marker genes as well as high rates of synthesis of ECM components such as collagen, 
elastin, proteoglycans, cadherins and integrins, which comprise a major portion of the 
blood vessel mass. Therefore, this stage of development (synthetic) is crucial for the 
formation of abundant gap junctions with ECs as well as the process of investment of 
endothelial tubes with SMCs or pericytes, an important process towards vessel 
maturation and remodelling (Hungerford and Little, 1999).  
In contrast to the embryonic and fetal/postnatal phenotypes, in the adult blood vessels 
SMCs display an exceedingly low proliferative rate, a mainly non-migratory phenotype 
and an extremely low rate of synthesis of ECM components. They have now become 
highly specialised cells responsible for contracting and regulating the blood tone-
diameter, blood pressure and blood flow distribution with higher densities in arteries 
when compared to veins (Owens, 1995). In this fully differentiated state, they express a 
subset of appropriate receptors, ion channels, signal transduction molecules, calcium 
regulatory proteins and contractile proteins necessary for the unique contractile 
properties of the SMC (Owens et al., 2004).  
Upon vascular injury the contractile “non synthetic” SMCs can undergo a phenotypic 
switch as a response to appropriate cues and transform into the synthetic phenotype, 
playing a critical role in the repair of the vascular injury. After successful repair and 
again in response to the appropriate cues, they will re-aquire their contractile phenotype 
and return to normal. (Owens et al., 2004). The factors that regulate the expression and 
loss of this SMC growth phenotype are likely to be important components of a 
developmental system controling vascular morphogenesis and possibly SMC replication 




Despite compelling evidence that phenotypic modulation of the SMC plays a key role in 
vascular injury repair and in the development and/or progression of atherosclerosis, 
relatively little is known about how this process is regulated in vivo. 
Although it is now known that SMC derive from at least 8 independent vascular SMC 
progenitors, it is not yet clear how they can later become specified for a common 
smooth muscle fate and how they are maintained as smooth muscle myoblasts during 
the migration, proliferation and heterotypic cell-cell interactions required to position 
them for differentiation around nascent blood vessels (Majesky, 2007). Moreover, 
recent evidence suggests that in perinatal and adult vessels, SMC progenitor cells reside 
in a privileged signalling domain or niche environment within the tunica adventitia (Hu 
et al., 2004). Their persistence in this perivascular location throughout adult life 
suggests that cells and matrix components of the adventitial niche provide important 
signals that maintain the progenitor phenotype and prevent premature SMC 
differentiation (Passman et al., 2008). 
It is now known that maintenance of SMC progenitor pools requires signals that allow 
for proliferative expansion during tissue development, growth and repair together with 
activation of redundant transcriptional silencing mechanisms to maintain the SMC 
progenitor phenotype and prevent SMC differentiation. However, a more complete 
understanding of the molecular mechanisms used to form and maintain vascular SMC 
progenitor cells is both fundamentally important at a basic level and will enable 
advances such as the iPS cell technology to be more effectively applied to disorders of 




1.11 Neovessel formation 
 
The process of neovessel formation is an important event both during embryonic 
development as well as in the adult tissues where ischemic infarction occurs. 
Neovessels from the neighbouring normal tissues are needed to form the vessel network 
and restore the blood supply to the damaged tissues. Both ECs and SMCs are essential. 
However, the detailed mechanism of SMC migration and differentiation is not fully 
understood. 
Until recently, it was accepted that vessels in adult ischemic tissues could only grow by 
angiogenic mechanisms, i.e. the sprouting of mature ECs from pre-existing vessels, 
likely in response to angiogenic factors. However, recent studies have revealed that 
endothelial progenitor cells (EPCs) circulate postnatally in peripheral blood. These may 
be recruited from the bone marrow and incorporate into sites of active 
neovascularisation in ischemic hindlimbs, ischemic myocardium, injured corneas and 
tumor vasculature (Asahara et al., 1999). This process is termed postnatal 
vasculogenesis (Luttun et al., 2002).  
It has previously been indicated that adult bone-marrow-derived mesenchymal stem 
cells (BMSCs/MSCs) and multipotent adult progenitor cells (MAPCs) can be 
differentiated into endothelial-like cells in vitro and contribute to neoangiogenesis in 
vivo (Al-Khaldi et al., 2003; Oswald et al., 2004; Reyes et al., 2002). Furthermore, 
BMSCs can increase collateral remodelling and perfusion in ischemic models through 
paracrine mechanisms rather than by cellular incorporation upon local delivery 




Recently, it has been shown that adult BMSCs, under appropriate in vitro environmental 
cues, can be induced to undergo vasculogenic differentiation culminating in microvessel 
morphogenesis. When rat BMSCs were seeded onto a three-dimensional (3D) tubular 
scaffold, the maturation and co-differentiation into endothelial and/or SMC lineages 
which lead to successful microvessel formation was observed (Valarmathi et al., 2009).  
A separate study showed that locally delivered, activated cardiac progenitor cells 
(CPCs), could generate de novo coronary vasculature by dividing and differentiating in 
both ECs and SMCs, restoring blood supply to ischemic myocardium (Tillmanns et al., 
2008). 
Elucidation of the contribution of each vascular population to neovascularisation as well 
as the cues which stimulate their maturation or/and differentiation is essential for their 












1.12 Tissue engineering of vascular grafts 
 
Cardiovascular disease is the leading cause of death in many developing countries. Each 
year, more than 570.000 coronary artery bypass graft procedures are performed in the 
Unites States alone, creating an important demand for small diameter (<6 mm) vascular 
grafts (Mitchell and Niklason, 2003). The challenge of tissue engineering blood vessels 
with the mechanical properties of native vessels, and with the anti-thrombotic properties 
required, is immense. Recent advances, however, indicate that the goal of providing a 
tissue-engineered vascular graft that will remain patent in vivo for substantial periods of 
time, is achievable (Ratcliffe, 2000). 
The basic concept of tissue engineering consists of three basic components, which 
include: a) cells (either seeded in vitro or mobilized in vivo), b) scaffolds onto which the 
extracellular matrix is organized in neotissue formation and c) signals (humoral and 
mechanical) (Bell, 1991). All three factors are interdependent and are indispensable to 
the formation of highly organized vascular tissue. 
The synthetic vascular grafts currently used have several limitations including 
thrombogenicity, increased risk of infection, and lack of growth potential. However, the 
first clinical trial evaluating the feasibility of using tissue engineered vascular grafts 
(TEVG) created by seeding autologous bone marrow-derived mononuclear cells (BM-
MNC) onto biodegradable tubular scaffolds has recently been completed. Naito et al 
showed that despite an excellent safety profile the primary graft related complication 
affecting approximately 16% of grafts within the first seven years after implantation of 




In a different study, banked porcine SMCs that were allogeneic to the intended recipient 
were used to generate tissue engineered vessels (TEVs) by utilization of a biomimetic 
perfusion system. The vessels were decellularised, leaving behind the mechanically 
robust extracellular matrix of the graft wall and then seeded with cells that were derived 
from the intended recipient (either EPCs or ECs) on the graft lumen. TEVs were then 
implanted in the porcine carotid artery. The results revealed that the generated graft is 
capable of resisting both clotting and intimal hyperplasia and that engineered connective 
tissues can be grown from banked cells, rendered acellular, and then used for tissue 
regeneration in vivo (Quint et al., 2011) 
Finally, in one of the most recent studies, sheets created from iPS cell derived vascular 
cells were evaluated as potential sources for the construction of TEVGs. It was shown 
that differentiated iPS cells provide an alternative and attractive cell source for 
constructing TEVGs using the sheet engineering technique and that sheet seeding of 
TEVG represents a viable model of iPS cell delivery over time (Hibino et al., 2012). 
The development of the TEVG represents a major breakthrough for the future of 
medicine. Although basic science innovations and clinical research studies will be 
needed for continued improvement of this exciting area, the combination of tissue 












(Naito et al., 2011) 
Figure 11. The basic concept of tissue engineering. The three components required 
for the construction of a TEVG are cells, scaffolds onto which the extracellular matrix 
will be organized to support the neotissue and finally the appropriate signals which are 










1.13 Wnt signalling in the vascular system 
 
Wnt signalling is a key regulator of multiple aspects of tissue development. It comprises 
of a group of cysteine-rich glycoproteins which regulate cell proliferation, cell 
morphology, cell motility and cell fate (Dale, 1998).  
An increasing body of evidence indicates that the Wnt signalling pathway is likely to 
play an important role in angiogenesis and vessel remodelling, with reports from a 
variety of investigators pointing to a role of Wnt signalling in the vasculature in both 
normal and pathologic vessel growth (Goodwin and D'Amore, 2002). It has recently 
been shown that activation of Wnt signalling in mouse Flk1
+
 cells (cell with a 
developmental potential restricted to hematopoietic and endothelial lineages) was able 
to expand vascular progenitor populations, whereas suppression of Wnt activity reduced 
Flk1
+ 
populations and inhibited the formation of matured vascular capillary-like 
structures during late stages of embryoid body differentiation (Wang et al., 2006). 
Furthermore, recent studies have demonstrated that the ligand Wnt7b regulates a 
program of mesenchymal differentiation through a Wnt/Tenacin C/ PDGFR signalling 
axis in the mouse lung that is essential for SMC development and disease progression in 
the lung (Cohen et al., 2009). 
Although there are three branches to the Wnt signalling pathway, only the canonical 
Wnt signalling (or otherwise known as β catenin pathway) will be mentioned for the 
purposes of this thesis.  A simple outline of the current model of the canonical Wnt 




In vertebrates, several secreted proteins have been described, that can modulate Wnt 
signalling by either binding to Wnts or binding to a Wnt receptor protein. The 
extracellular antagonists of the Wnt signalling pathway can be divided into two groups 
both of which prevent ligand-receptor interactions, but by different mechanisms. The 
members of the first class, which include the sFRP (secreted Frizzled-related protein) 
family, WIF (Wnt inhibitory factor)-1 and Cerberus, primarily bind to Wnt proteins. 
The second class comprises certain members of the Dickkopf (DKK) family, which 
bind to one subunit of the Wnt receptor complex. However, certain sFRPs and DKKs do 
















(Reya and Clevers, 2005) 
Figure 12. The canonical Wnt signalling pathway. In the absence of Wnt signalling 
(left panel), β catenin is in a complex with Αxin, APC and GSK3-β, where it is 
subjected to phosphorylation and is targeted for degradation. β catenin also exists in a 
cadherin-bound form and regulates cell–cell adhesion. In the presence of Wnt signalling 
(right panel), β catenin is uncoupled from the degradation complex and translocates to 






1.14 DKK3, a member of the Dickkopf family of Wnt inhibitors 
1.14.1 The DKK family 
 
The human DKK family comprises of four members, DKK1-4 and a unique DKK3- 
related protein SOGGY (DKKL1 or SGY1). DKK proteins are secreted glycoproteins 
with a molecular weight between 25kDa and 29kDa for DKK1, DKK2 and DKK4 or 
38kDa for DKK3. All the members of the family share an N-terminal signalling peptide 
and two concerved cystein-rich domains (CRD) (Cys1 and Cys2) separated by a linker 
region, while other members of the family show only weak amino acid (aa) sequence 
similarities (Figure 13) (Glinka et al., 1998). The Cys1 domain is unique to the DKK 
family and is not found among other vertebrate proteins whereas the Cys2 domain 
pattern relates to a functional domain called colipase fold. Colipases are characteristic 
for lipid hydrolysis and for that reason it has been suggested that Cys2 in DKKs may 
enable proteins to interact with lipids and thus regulate Wnt function (Aravind and 
Koonin, 1998). Colipase folds can also be found in toxins and protease inhibitors (Kaser 
et al., 2003; Szeto et al., 2000). No functional domains have been identified in SGY and 
to date its biological role is mainly restricted to its expression in human 
spermatogenesis where it mediates pubertal spematocyte apoptosis (Kohn et al., 2005). 
Finally, in contrast to the highly conserved CRDs, the linker region between Cys1 and 
Cys2 is highly variable between DKKs and it is notably larger in DKK1, DKK2 and 





Furthermore, DKK3 contains four potential N-glycosylation sites which are not 
conserved in the other members and contains an extended N-terminal domain which 
precedes Cys1 and an extended C-terminal domain following Cys2 making DKK3 the 
most divergent member of the family (Krupnik et al., 1999). 
 
 
(Veeck and Dahl, 2012) 
Figure 13. Structural homology of the human DKK family. DΚΚ proteins contain 
two highly conserved cysteine-rich domains (Cys1 and Cys2), which are separated by a 
non-conserved linker region of variable length. Within the DΚΚ family, the structural 
diversity of DKK3 is pronounced by its larger protein size, a shorter linker region and a 
high N-terminal sequence similarity with DKKL1, but not with DKK1, DKK2 or 
DKK4. Additionally, DKK3 possesses four putative posttranslational N-glycosylation 
sites, whereas DKK1 and DKK2 only harbor one site. Numbers refer to the modified 






1.14.2 The biological role of DKK3 
 
Developmental studies in mural embryos have demonstrated that expression of the 
DKK family members is temporally and spatially regulated with overlapping  
expression patterns in mesenchymal lineages, suggesting a coordinated mode of action 
and cell fate decisions in tissues mediating epithelial-to-mesencymal transition 
(Monaghan et al., 1999). Furthermore DKK3 seems to have a decisive function in 
myogenic cell fate since it was recently found to be highly expressed in different 
skeletal muscle subtypes. (de Wilde et al., 2010). Further evidence for a role in 
myogenesis adds from the evidence that DKK3 negatively regulates expression of 
myf5, a transcription factor regulating muscle differentiation. Interestingly, a regulatory 
microRNA (miR-ln300) encoded in the first intron of the myf5 gene directly 
downregulates DKK3, pointing to an interesting negative feedback loop between DKK3 
expression and muscle tissue differentiation (Hsu et al., 2010). 
Concerning Wnt signalling, while DKK1, DKK2 and DKK4 negatively regulate the 
aforementioned pathway by binding to LRP5/6 or the Kremen co-receptor proteins with 
high affinity, to date, no corresponding cell surface membranous receptor has been 
identified for DKK3 (Mao et al., 2002; Mao et al., 2001; Semenov et al., 2001). 
Although DKK3 inhibited Wnt7a in pheochromocytoma PC12 cells(Caricasole et al., 
2003) and also exhibited a Wnt-inhibitory activity in the osteosarcoma Saos-2 cell 
line(Hoang et al., 2004), it was unable to inhibit Wnt reporter Tcf-luciferase acrivity in 





Furthermore, it was shown that ectopic expression of DKK3 in prostate cancer cells, 
lead to apoptosis via c-Jun NH2-terminal kinase (JNK) activation suggesting a role of 
DKK3 in the Wnt/PCP (polar Wnt pathway) and not in the canonical Wnt signalling 
pathway (Abarzua et al., 2005). In addition to its secretory role, DKK3 could also have 
an intracellular function, since it was recently shown that there is a direct interaction 
between DKK3 and βTrCP (a negative regulator of β catenin). In this study, a new 
model of cytosolic Wnt inhibition where DKK3 directly targets β catenin was suggested 
(Lee et al., 2009). Finally, it was recently shown that DKK3 can potentiate Wnt3a 
through interactions with the transmembrane protein Kremen 1, a protein located in 
intracellular membranus compartments such as the endoplasmatic reticulum (ER) 
(Nakamura and Hackam, 2010). 
Therefore, it can be concluded that the ability of DKK3 to inhibit or potentiate Wnt 
signalling as well as its effect on a particular Wnt pathway branch appears to be 
context-specific. Further studies are necessary in order to elucidate the precise 










1.14.3 DKK3 and its role in cancer  
 
DKK3 or otherwise known as REIC (Reduced Expression in Immortalised Cells) was 
first implicated with tumorigenesis when during the search for immortalization-related 
genes, Tsuji and his colleagues found a gene that was downregulated in immortalised 
cell lines and a number of established human cancer lines. Cloning of the cDNA and 
analysis of the predicted amino acid sequence revealed that that gene was identical to 
the human DKK3 (Tsuji et al., 2000). 
Soon thereafter, the differential expression of DKK3 was confirmed in lung cancer 
where in 57 matched pairs of NSCLC (non-small cell lung cancer) and adjacent normal 
lung tissues, it was revealed that DKK3 mRNA expression was substantially reduced in 
63% of the tumor specimens (Nozaki et al., 2001). This was followed by identification 
of DKK3 downregulation in virtually any human solid cancer type including prostate, 
colon and breast cancer (Abarzua et al., 2005; Veeck et al., 2008; Yu et al., 2009). 
Although other member of the DKK family are also differentially expressed in certain 
tumor tissues, they are not consistently downregulated like DKK3 which emphasizes 
the exceptional role of DKK3 within the family (Veeck and Dahl, 2012). 
The molecular mechanisms by which DKK3 expression is abolished in human cancers 
has been comprehensively studied. The first report about the DKK3 gene regulation 
showed that its promoter is hypermethylated in lung cancer cell lines as well as in a 
large fraction of the NSCLC tissues with significant loss of DKK3 expression in these 




DKK3 methylation-mediated suppression was assessed in numerous tumor entities 
where it was revealed that DKK3 methylation is a tumor-specific event which is absent 
or significantly lower in non-malignant tissue (Chim et al., 2007; Ding et al., 2009; 
Fujikane et al., 2010; Lodygin et al., 2005; Veeck et al., 2008; Yang et al., 2010; Yu et 
al., 2009; Yue et al., 2008). Additionally, global DNA epigenetic demethylation by 
epigenetic drugs revealed that DNA methylation is directly associated with gene 
expression loss of DKK3, where it was shown that abolished DKK3 expression was 
reversible in a number of cancers (lung/breast/gastric/prostate cancer and leukemia) 
except from malignant melanoma cells (Kobayashi et al., 2002; Kuphal et al., 2006; 
Lodygin et al., 2005; Valencia et al., 2009; Veeck et al., 2008; Yu et al., 2009). 
Furthermore, it has recently been reported that post-transcriptional factors may play a 
role in suppression of DKK3. Two independent studies revealed that upregulation of the 
oncogene MYCN lead to the upregulation of microRNA clusters which directly targeted 
the 3’UTR sequence of the DKK3 mRNA and inhibited its translation in neuroblastoma 
cells (De Brouwer et al., 2011; Haug et al., 2011) 
Finally, there is compelling in vitro and in vivo evidence that DKK3 is a natural tumor 
suppressor gene in human tissues. The most evident and consistent anti-tumor effect of 
DKK3 is that of its inhibitory capacity on cancer cell growth, as determined by 
proliferation and anchorage-independent growth assays in a variety of cancer cell line 
models (Veeck and Dahl, 2012). The consistent loss of expression of DKK3 in the 
various tumor entities as well as its ability to strongly inhibit tumor growth, qualify 





1.14.4 The role of DKK3 in tumor angiogenesis 
 
In order to meet the elevated need for oxygen and nutrients, growing tumors require an 
extensive vasculature. Therefore they stimulate surrounding stromal tissue to produce 
novel blood vessels, a process which is known as tumor angiogenesis (Folkman, 1971). 
RNA expression analysis of normal and tumor activated endothelium revealed that 
DKK3 was one of the most strongly upregulated genes in the tumor endothelium of 
colorectal cancer (Untergasser et al., 2008). DKK3 exerted a differentiating effect on 
tumor-associated ECs while still clearly acting as a growth inhibitor on epithelium-
originated tumor cells. Therefore, it was considered a putative pro-angiogenic factor in 
vascularization and a possible marker for neo-angiogenesis (Zitt et al., 2008). Further 
studies revealed that in comparison to normal tissue, there was a higher number of 
DKK3 positive vessels in a variety of cancers (Veeck and Dahl, 2012). Finally, in vitro 
cell proliferation and migration assays revealed that while endothelial colony forming 
cells (ECFCs) were not affected by DKK3 expression, tube formation in Matrigel® 
increased after enforced DKK3 expression and deceased after its downregulation. 
Additionally, stable overexpression of DKK3 in B16F10 melanoma cells significantly 
increased microvessel density in the C57/BL6 melanoma mouse model suggesting that 
DKK3, suggesting the involvement of DKK3 in the remodelling of the tumor 
vasculature, as a differentiation factor (Untergasser et al., 2008). Taking the above 
studies under consideration, it would therefore be interesting to further examine the role 





1.15. Hypothesis and aim of the study 
 
The generation of iPS cells is a gradual process where terminally differentiated cells are 
transformed into pluripotent cells capable of recapitulating the characteristics of ESCs. 
The utilisation of a cocktail of transcription factors as well as the epigenetic 
modifications that occur in the somatic cells during that transition, suggested that a 
cascade of events such as activation or de-activation of signalling pathways takes place 
in order to eventually lead the cells to pluripotency. The inception of this project 
originated by the hypothesis that within the aforementioned cascade of events, specific 
pathways could be activated early during the reprogramming, which would lead to 
direct differentiation towards specific lineages, in particular SMCs, prior to the cells 
reaching the pluripotent stage. That would mean that given the appropriate stimulus 
after an initial “reprogramming activation” phase, somatic cells would be directly 
differentiated into SMCs by bypassing the pluripotency stage. 
In order to test that hypothesis, a microarray analysis of cells in different time points 
during the reprogramming was conducted, where it was identified that the expression of 
a great number of genes associated with key functions of the cell, was altered from as 
early as day 4. Therefore, the aim of the present study was to initially investigate the 
ability of 4 days reprogrammed cells to differentiate into SMCs by bypassing 
pluripotency. Specifically, the 4 days reprogrammed cells were characterised and 
named Partially induced Pluripotent Stem cells (PiPS). They were then placed under 
established SMC differentiation conditions as previously shown in our laboratory for 




The differentiation potential of PiPS to SMCs was therefore investigated. A schematic 
representation of the experimental design is presented in Figure 14. 
Successful differentiation of PiPS cells into SMCs lead to investigation of the molecular 
mechanisms which regulate the induction of SMC markers. DKK3, a gene indicated by 
the microarray to have an altered expression during the reprogramming and also 
previously shown to be associated with neo-angiogenesis in cancer vasculature (Zitt et 
al., 2008) was found to be significantly upregulated during the PiPS-SMC 
differentiation. Therefore, in this part of the study the role of DKK3 in PiPS-SMCs 
differentiation as well as the signalling pathway by which DKK3 is regulating 
SMC gene expression was investigated.  The experimental design included 
overexpression, stimulation and silencing of DKK3 during PiPS-SMCs differentiation, 
investigation of its effect on  the Wnt signalling pathway with which it has previously 
been associated (Mao et al., 2002) as well as examination of the transcriptional 













                   
 
Figure 14. Schematic representation of the protocol used to generate PiPS-SMCs. 
Human neonatal fibroblasts were forced to overexpress the four transcription factors 
and maintained in reprogramming media for 4 days on a gelatine substrate. An empty 
vector is used as a mock control. After 4 days of reprogramming (PiPS cell stage) the 
cells are transferred on a Collagen IV substrate and maintained in DM containing PDGF 
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Cell culture media, serum and cell culture supplements were purchased from ATCC, 
Invitrogen, Life technologies and PAA. Basic FGF-2 was purchased from MACS 
(Miltenyi Biotech Cat No: 130-093-837), aliquoted into 10.000x stock solutions of 
100μg/mL in sterile water and stored at -20oC. PDGF was purchased from R&D 
systems (Cat No: 220-BB), aliquoted into 10.000x stock solutions of 100μg/mL in 
sterile 4mM HCL and stored at -20
o
C. Human recombinant DKK3 cytokine was 
purchased from R&D systems (Cat No: 1118-DK), aliquoted into 5000x stock solutions 
of 250μg/mL in sterile PBS and stored at -20oC. Purchased antibodies used for 
immunoblotting and their recommended dilutions are shown in Table 5. Primary 
antibodies used for immunoblotting were diluted in PBS containing 5% milk, 0.05 
Tween
®
 20 (Sigma-Aldrich, Cat No P2287) and 0.02% sodium azide and stored at -
20
o
C. Buffers made for the methods herein are shown in Table 6. 
2.2 Methods 
2.2.1 Cell culture of human embryonic fibroblasts 
Prenatal human embryonic fibroblasts purchased from ATCC (catalogue number: CCL-
153™) were cultured on gelatin coated flasks (0.04% of 2% Solution Type B from 
Bovine Skin, Sigma G1393) in ATCC F-12K Medium (Kaighn's Modification of Ham's 
F-12 Medium, Cat No: 30-2004) supplemented with 10% ATCC Fetal Bovine Serum 
(Cat No: 30-2020) and 100 U/mL penicillin and streptomycin in a humidified incubator 
supplemented with 5% CO2. Cells were passaged every three days in a ratio of 1:3 or 




2.2.2 Restriction digestions 
A polycistronic plasmid (OSKM) containing all four factors (OCT4, SOX2, KLF4 and 
cMYC) on one vector, was purchased from Addgene (Plasmid 20866: 
pCAG2LMKOSimO (Kaji et al., 2009)) (Figure 15) and was used for the generation of 
Partially iPS (PiPS) as described in the following paragraph. Before transfection the 
plasmid was linearised with the PVU1 restriction enzyme for 2 hours at 37
o
C and then 
purified using SureClean (Bioline, Cat No: 37042).  
A restriction digestion was performed to generate a control vector from the 
aforementioned OSKM plasmid. Restriction enzymes BamHI and BspEI were used to 
remove the ORF from the pCAG2L backbone vector. The plasmid and enzymes were 
incubated at 37 
o
C for 2 hours. The samples were then loaded on a 1.5% agarose gel, 
electrophorated, and subsequently cloned (paragraph 2.2.4).  
A restriction digestion was also performed to generate a control vector from the 
lentiviral TetO-FUW-OSKM (Figure 17). ClaI was utilised to remove the ORF from the 
Teto-FUW vector backbone. After incubation of the plasmid and enzymes at 37
o
 for 1 
hour, the samples were electrophorated and subsequently cloned (2.2.4). The plasmid 
was purchased from Addgene Cat No 20321. 
 
2.2.3 Agarose gel electrophoresis and gel purification 
Agarose gels (1.5%) were prepared by melting 1.5g agarose (Invitrogen, Cat. 
No.15510027) for 2 minutes in an 800W microwave with 100ml 1x Tris-base Acetic 
acid EDTA (TAE) buffer diluted from a 50xTAE (National Diagnostics, Cat. No, EC- 
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872) stock (2.0M Tris Acetate plus 100mM Na2 EDTA) conical flask.7.5μl of EtBr 
10mg/ml (Sigma, Cat. No. E1510) were added to the solution to a final concentration of 
0.75 μg/ml. The mix was then poured into the Horizon® 11.14 horizontal gel cast 
electrophoresis apparatus (Biometra) and was allowed to cool at room temperature for 
30 minutes, after which it was immersed in 1xTAE. 5μl of 6x Loading Buffer (0.25% 
(w/v) Bromophenol blue, 0.30% (v/v) glycerol) was added per 25μl of the digested 
vector and then loaded into the wells.  
The electrophoresis was performed at 160V for ~25 minutes visualised under ultraviolet 
light with the Biospectrum® Imaging System 500 and captured with the Vision Works 
Software (Ultra-Violet Products Ltd). The target fragments were identified and then cut 
and purified using the QIAgen Gel Extraction kit as instructed by the manufacturer 
(Qiagen Cat. No. 28704). 
 
2.2.4 Cloning of pCAG2L-ctl and Teto-FUW-ctl (Ligation and transformation) 
The digested vectors were self ligated in the presence of T4 DNA ligase (Promega, Cat. 
No. M18041) after overnight incubation at room temperature. Transformation was 
performed in JM109 competent cells (E.Coli) (Promega, Cat. No. L2001). The ligation 
reactions were incubated on ice and the competent cells were thawed for a few seconds. 
100μl of competent cells were added to each ligation reaction and then incubated on ice 
for 30 minutes. Heat shock was then performed at 42 
o
C for 90 seconds after which the 
tubes were returned on ice.  1 ml of sterile L.B (Luria-Bertani) medium was added to 
each tube and incubated for 1 hour at 37 
o
C after which the tubes were centrifuged at 
4000 rpm for 5 minutes.   
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850μl of the supernatant were discarded, the pellet was resuspended in the remaining 
L.B medium and then transferred on Ampicilin LB Agar sterile plates (50μg/ml) for 
overnight incubation at 37
o
C. Colonies were picked up and amplified in LB Ampicilin 
medium (100μg/ml) overnight after which plasmid purification was performed using a 
QIAprep Spin Miniprep kit (Qiagen, Cat. No. 27016) as instructed by the manufacturer. 
Verification of the plasmids was performed by restriction digestion reaction after which 
DNA sequencing was employed for further verification. 
2.2.5 Nucleofection of fibroblasts using the polycistronic OSKM plasmid or four 
expression vectors each carrying one transcription factor 
 
The polycistronic OSKM plasmid was overexpressed in embryonic fibroblasts as part of 
the reprogramming method (Figure 15). Fibroblasts were transfected with the OSKM 
plasmid by electroporation using an NHDF nucleofector Kit (Lonza,Cat No: VPD-
1001). The control (ctl) vector generated as described in paragraphs 2.2.2-2.2.4 was 
used to transfect fibroblasts using the same method. Each transfection required 2x10
6
 
cells and 4μg of ctl or OSKM plasmid. Cells were washed with PBS, trypsinized and 
counted. Aliquots of 2x10
6
 cells per falcon tube were pelleted at 1000 rpm for 5min and 
the supernatant medium was discarded. The cell pellet was then resuspended in 100 μl 
of nucleofection solution containing the plasmid and the mix was transferred in a 
nucleofection cuvette as provided by the company. The cuvette was then placed in the 
Lonza nucleofection machine and a specific for NHDFs nucleofection program was 
used. 500μl of culture medium were added immediately after the electroporation in the 
cuvette and the total solution was then transferred in 0.04% gelatin coated T25 flasks 
containing 5ml of reprogramming medium the contents of which are mentioned in detail 
in paragraph 2.2.7. 
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An identical protocol was utilised for nucleofection of the individual four transcription 
factors in fibroblasts. Each nucleofection required 2x10
6
 cells and 1μg per factor (Ex-
SOX2, Ex-OCT4, Ex-KLF4, Ex-cMYC) to a total of 4μg per transfection. 4μg of an Ex-
GFP vector was utilised as a control. The Ex vectors are shown in Figure 16 and were 
purchased from GeneCopia Ink. 
 
 
Figure 15. Map of the pCAG2LMKOSimO vector. Sox2, Oct4, Klf4 and cMyc 
coding regions are linked by three different 2A peptide sequences, F2A, T2A and E2A 
(reprogramming cassette) are transcribed from the CAG enhancer/promoter. The 
reprogramming cassette is followed by ires mOrange. The reprogramming cassette and 





        
Figure 16. Expression Clone (EX) construct map 
 
2.2.6 Lentiviral induction of TetO-FUW-OSKM 
A lentiviral construct containing all four factors in one vector was also utilised for 
induction of SOX2, OCT4, KLF4 and cMYC in human neonatal fibroblasts. An empty 
Teto-FUW vector generated as described above was used as control. The lentiviral 
particles were kindly generated by Dr. Andriana Margariti. ~500.000 cells were seeded 
on gelatine coated dishes 24 hours prior to infection. The next day, fibroblasts were 
incubated with 10
7
 TU/ml Teto-FUW-OSKM or Teto-ctl in complete reprogramming 
medium supplemented with 10μg/ml of polybrene for 16-24 hours. Subsequently, fresh 
medium was added to the cells and the dishes remained in the incubator under the 












Figure 17. Map of the Teto-FUW-OSKM vector. This construct comprises a four-
factor 2A (4F2A) doxycycline (DOX)-inducible lentivirus encoding mouse cDNAs for 
Oct4, Sox2, Klf4 and cMyc separated by three different 2A peptides (P2A, T2A, and 








24 hours after nucleofection the reprogramming medium which comprised of Knockout 
DMEM medium optimized for embryonic stem cells (Life technologies (Gibco®) Cat. 
No. 12660-012), 20% Knockout Serum Replacement (Life technologies (Gibco®), Cat. 
No. 10828-028), 10ng/ml basic Fibroblast Growth Factor-2 (bFGF-2) (MACS Miltenyi 
Biotech Cat No. 130-093-837), 100 U/ml penicillin and streptomycin (Life technologies 
(Gibco®) Cat. No 15070-063), 0.2 mM L-glutamine (Life technologies (Life 
Technologies™) Cat. No. 25030-024), 0.1mM β-mercaptoethanol (Life technologies 
(Life Technologies™) Cat. No. 31350-010) and 0.1mM MEM Non Essential Amino 
Acids (Life technologies (Gibco®) Cat. No. 11140-050). The cells were maintained 
under these conditions for another 72 hours (in total 4 days after nucleofection) as part 
of the reprogramming process. 
 
2.2.8 PiPS cell differentiation 
PiPS cells were seeded on Collagen IV coated dishes (5μg/ml) and maintained in 
differentiation medium (DM) which contained MEM α (Life technologies (Gibco®) 
Cat. No. A10490-01) supplemented with 10% FBS (PAA Cat. No A15-151), 100U/ml 
penicillin and streptomycin (Life technologies (Gibco®) Cat. No. 15070-063), 0.2 mM 
L-glutamine (Life technologies (Life Technologies™) Cat. No. 25030-024), 0.1mM β-
mercaptoethanol (Life technologies (Life Technologies™) Cat. No. 31350-010) and  
10ng/ml Platelet Derived Growth Factor BB (PDGF-BB) (R&D systems Cat No: 220-
BB). The cells were maintained under these conditions for 2, 3 and 4 days after which 




2.2.9 Harvesting cells 
The supernatant medium was removed or collected from the flasks or dishes and cells 
were washed with cold PBS (4
o
C). An additional volume (5-10ml) of cold PBS was 
added and cells were scraped off, descanted into 15ml tubes and centrifuged at 1000 
rpm for 5 minutes. Supernatant PBS was discarded and cells were resuspended in 1ml 
of which 750μl and 250μl were transferred to micro centrifuge tubes and centrifuged 
shortly at 4
o
C (high speed) for protein and RNA extraction respectively. 
 
2.2.10 RNA extraction 
RNA extraction was performed using RNeasy Mini Kit for isolation of total RNA from 
animal cells (Qiagen Cat. No 74106). It was performed according to the manufacturer’s 
protocol at room temperature with a centrifugal force of at least 10.000 rpm unless 
otherwise stated. The cell pellet was resuspended in 350μl of RLT lysis buffer to disrupt 
the cell membrane and organelles and release the total RNA contained in the sample. 
The lysate was then transferred into a QIAshredder spin column and was centrifuged for 
2 minutes to create a homogenous lysate by shearing high-molecular-weight genomic 
DNA and other cellular components. An equal volume of 70% ethanol was added to the 
homogenized lysate to provide appropriate binding conditions for the RNA to bind to 
the RNeasy spin column membrane. 700μl of the sample were applied to the RNeasy 
mini column and placed in a 2ml collection tube. The samples were centrifuged for 30 
sec and the flow though obtained was discarded. 700μl of RW1 washing buffer 





The flow through was once again discarded and 2 more washes were carried out with 
500μl of RPE buffer which was provided in the kit. The washing buffers are applied to 
make sure all contaminants are removed. The flow through was discarded and an 
additional centrifugation of 1 minute took place to remove all remaining solution that 
could dilute the RNA extract.  To elute the RNA, the RNeasy column was transferred to 
a clean 1.5ml autoclaved micro centrifuge collection tube and 25μl of RNase-free water 
was added to the RNeasy column membrane followed by spinning for 1 minute. The 
RNA concentration was measure by using a Nanodrop Spectrophotometer.  
 
2.2.11 Reverse transcription (RT) of RNA to obtain cDNA 
cDNA was synthesised from 1μg of total RNA for each RT reaction. RT was performed 
using the Improm-II reverse transcription system (Promega Cat. No A3800) in a 20μl 
reaction outlined below. Mix A was heated at 70
o
C for 5 minutes to allow denaturation 
of RNA. The samples were briefly placed on ice before Mix B was added. After adding 
Mix B, the samples were kept at 25
o
C for 5min and then at 42
o
C for 1 hour and 30 
minutes for extension to take place. Finally a temperature of 70
o
C was applied in order 
for the reverse transcriptase enzyme to be deactivated (Table 1). The cDNA obtained 










Component Volume (μl) Final concentration 
MIX 
A 
Random primers 0.1 0.5 μg 
RNA X 1 μg 
DEPC water to 10 - 
MIX 
B 
Improm II 5x reaction buffer 4 1x 
25mM MgCl2 2.4 3mM 
25mM dNTPs 0.8 1mM 
RNasin ribonuclease inhibitor 1 40U/μl 
Improm II RT enzyme 1 1U/μl 
DEPC-treated water 0.8 - 
 
Table 1. Reverse transcription reaction solutions and concentrations 
 
2.2.12 Conventional polymerase chain reaction (PCR) 
50ng of cDNA were used to perform polymerase chain reactions using recombinant Taq 
DNA Polymerase (Invitrogen, 10342-53). The reaction mix and primer parameters are 







Component Volume (μl) 
Final 
concentration 
cDNA 5 50ng 
10x PCR Buffer 2.5 1x 
25mM dNTPs 0.2 0.17mM 














Table 2. PCR solutions and concentrations 
Primers specific to the PCR template were designed from human mRNA sequences 
using the Primer-BLAST tool (www.ncbi.nlm.gov.uk/tools/primer-blast). All primers 
were ordered from Sigma-Aldrich, resuspended in 1mM EDTA and the stocks 
(100mM) were stored at -80 
o














































































































































































































1451 1797 58 30 350 
 





The PCR protocols were optimized: Initial denaturation, 95
o
C for 5 minutes; 30-35 
cycles of 94 
o
C for 30 seconds, 58 
o
C for 30 seconds and 72
 o
C for 1 minute; Final 
extension 72 
o
C for 10 minutes 
 
2.2.13 Quantitative real time polymerase reaction (Q-PCR) 
Relative gene expression was detected by Q-PCR using the Eppendorf Mastercycler® 
ep realplex. 20ng of cDNA were combined with 10μl of SYBR Green (Qiagen, Cat. No. 
204057) and combined forward and reverse primers for the target gene in a final 
concentration of 0.75μM. The final volume was adjusted to 20μl per sample with DEPC 
water and the samples were loaded on 96 well plates (Eppendorf, twin.tec real-time 
PCR plates). The Q-PCR conditions were 5min at 95
o
C and then 40 cyles of 95
 o
C for 
15 seconds and 60
o
C for 30 seconds followed by 10 minutes of 95
o
C to establish the 
melting curve of the primers. The threshold cycle (Ct) values were automatically 
obtained in excel format and the 18s RNA Ct values served as the internal endogenous 
control. For every sample, Q-PCR was performed in duplicate. The primers used for Q-
PCR were designed using a software provided by DNA Integrated Technologies (IDT) 
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2.2.14 Protein extraction 
The cell pellet was resuspended in 30-50μl of a protein lysis buffer. The lysate was then 
sonicated with the Branson Sonifier 150 at the lowest setting for 12 sec at 4
o
C and 
incubated on ice for at least 30 minutes. The lysate was then centrifuged at 13.000 rpm 
for 10 min at 4
o
C. The supernatant was transferred to a new micro-centrifuge tube and 
the protein level was detected using a Biorad Protein Assay. 2μl of the protein lysate 
was mixed with 998μl of the Bio-Rad Reagent (1:5) and incubated at room temperature 
for 5 minutes. Duplicates were measured using the Bio-Rad Spectrophotometer 3000. 
2μl of lysis buffer was used as the blank measurement. 
 
2.2.15 Immunoblotting 
25-50μg of protein were boiled in 1xSDS loading buffer for 10 minutes before loading 
onto NuPage®, 4-12% Bis-Tris gel immersed in NuPage® MOPS SDS running buffer 
in a XCell SureLock™ Mini-Cell (Life technologies (Novex®) Cat. No. NP0335BOX). 
In the case of supernatants, 20μl of medium were boiled with 1xSDS and prepared as 
described above. Protein ladder (Precision Plus Protein Ladder, Bio-Rad) was loaded 
simultaneously and the samples were run at 160V. The gel was then transferred onto a 
PVDF membrane (Amersham, hypond-P) with the XCell™ Blot Module (Invitrogen) at 
30V for 2 hours and 30 minutes immersed in transfer buffer. The membrane was 
blocked with 5% milk in PBS-Tween containing 0.02% sodium azide, for 1 hour at 
room temperature and then incubated in the primary antibody solutions overnight at 
4
o
C. The antibodies used are listed in Table 5 and a representative blot of antibody 




Secondary antibodies diluted in 5% milk PBS-Tween (1:3000) were incubated in room 
temperature for 1 hour after washing with PBS-Tween (10minutes x3). Further washing 
was then carried out before addition of ECL detection solutions (3min). Exposure of 
films (Amersham, Kodak) was carried out using the Compact X4 (Xograph Imaging 
System). 
 
2.2.16 Indirect Immunofluorescence Assay (IIFA) 
Cells were trypsinized and resuspended in medium and ~10.000 cells were seeded on an 
8-chamber slide coated with Collagen IV. The staining took place at least 24 hours after 
seeding. Medium was discarded and cells were washed twice with warm PBS.  The 
cells were then fixed with 4% paraformaldehyde (PFA) in PBS for 10 minutes in room 
temperature. They were then washed x3 with cold PBS and permeabilized with 0.1% 
Triton-X-100 in PBS for 10 minutes in room temperature. An additional wash with cold 
PBS took place in room temperature for 5 minutes. For the frozen sections of vessels 
harvested from the ex-vivo and in-vivo experiments, the samples were fixed in 100% 
acetone for 10min and then washed x3 with PBS. All slides were then blocked with 5% 
normal swine serum in PBS and incubated for 30 minutes in room temperature. The 
primary antibodies used and the dilutions in which they were used are shown in Table 5. 
The samples were once again washed with cold PBS (10minutes x3) and secondary 
antibodies were applied in the concentrations shown in Table 5 for 30 minutes at 37 
o
C. 
Samples were washed 3 x 5 minutes before counterstaining with DAPI (1:1000 in PBS) 
for 2 minutes at room temperature. They were then mounted with fluorescent mounting 
media (Dako) and images were taken with the Axio Imager.M2 microscope and 
AxioVision Digital Imaging System (Carl Zeiss Ltd) or SP5 confocal microscopy. 
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2.2.17 Quantification of fluorescence area by Volocity 
Images for figures 39, S1 and S6 were captured with a 20x dry objective on an Olympus 
IX81 wide field inverted microscope with the use of the imaging program Volocity. For 
every set of experiments figures were captured at the same levels of exposure, gain and 
offset. Quantification of fluorescence was then performed through Volocity. For every 
set of experiments a threshold of fluorescence of SD+1 of the image mean was set 
between ctl and treated sample and fluorescence was calculated as total fluorescence 
area divided by the total number of cells. For example Sum of Calponin area per 
number of nuclei (μm2/ cell). 









SMMHC - 1:100 Abcam Ab683 





SM22 1:2000 1:200 Abcam 14106 
β catenin 1:200 1:50 Santa Cruz  
sc-7199 




GSK3 1:1000 - Cell signalling 
5676 





Kremen 1 1:1000 - - R&D AF1647 
Α-
Fetoprotein 




β-tubulin ΙΙΙ - 1:50 R&D MAB1195 
 





2.2.18 Transient overexpression of DKK3 in PiPS-SMCs 
PiPS-SMCs were trypsinized and counted, and 2x10
6
 cells were aliquoted in 15ml tubes 
and centrifuged at 1000 rpm for 5 minutes. They were then nucleofected with 2μg of 
DKK3 plasmid (Figure 18) (Addgene, plasmid 15496 (Krupnik et al., 1999)) as 
described in paragraph 2.2.5. A pCMV5 vector (Margariti et al., 2009) was also 
nucleofected in PiPS-SMCs as a mock control. The cells were then seeded on Collagen 
IV coated plates (5μg/ml) and harvested 48 hours later. The medium was refreshed 24 
hours after nucleofection. 
           






2.2.19 Lentiviral particle generation 
For the generation of Lentiviral particles, 293-T cells were transfected with the 
lentiviral vector and the packaging plasmids (obtained by Genecopoeia) according to 
the protocol provided. The supernatant containing the lentivirus was harvested 48 hours 
later, filtered, and the transduction unit (TU) was calculated, as previously described 
(Margariti et al., 2010). The non-targeting shRNA vector was used to generate the 
control particles. 
2.2.20 DKK3 shRNA lentivirus transduction  
For lentiviral infection, 500.000 PiPS-SMCs were seeded on Collagen IV coated plates 
and left to adhere overnight. The next day, cells were incubated with shDKK3 or the 
non targeting control (10
7
TU/ml) complete growth medium supplemented with 10μg/ml 
of polybrene for 16-24 hours. Subsequently, fresh serum free medium was added to the 
cells and the plates were returned to the incubator and harvested 24 or 48 hours later. 
The shDKK3 lentivirus was kindly generated by Dr. Andriana Margariti. 
2.2.21 Enzyme-linked immunosorbent assay (ELISA) 
Supernatant was collected from the cells, aliquoted and stored at -80 
o
C until used. The 
concentration of the DKK3 released glycoprotein in the supernatant was detected by an 
R&D DKK3 ELISA kit (R&D, Cat. No. DY1118). The capture antibody was diluted to 
working concentration in PBS without carrier protein. A 96-well microplate was 
immediately coated with 100μl per well of the diluted Capture antibody and  was sealed 
and incubated overnight at room temperature. The solution was then removed and the 
wells were washed x3 with Wash Buffer (0.05% Tween® 20 in PBS). Each well was 
then blocked with 300μl of Reagent Diluent (1% BSA in PBS) and maintained in room 
temperature for at least 1 hour. The wells were once again washed with Wash Buffer x3. 
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100μl of the supernatant sample or standards in Reagent Diluent were added per well 
(Standards comprised human recombinant DKK3 in 7 2-fold serial dilutions with 
2000pg peak and were used for the generation of a standard curve). The plate was 
covered with an adhesive strip and incubated at room temperature for 2 hours. Each 
well was washed 3x with Wash buffer. 100μl of Detection antibody (working 
concentration of 200ng/ml in Reagent Diluent) were added in per well, the plate was 
covered again with an adhesive strip and incubated at room temperature for 2 hours. 
100μl of Streptavidin-HRP were added per well following x3 washes with Wash Buffer 
and incubated at room temperature for 20 minutes avoiding direct exposure to light. The 
wells were once again washed x3 and 100μl of Substrate Solution (1:1 mixture of Color 
Reagent A (H2O2) and Color Reagent B (Tetramethylbenzidine)) were added per well 
and incubated at room temperature for another 20 minutes. Finally, the reaction was 
stopped using 50μl of Stop Solution (2N H2SO4). The optical density of each well was 
determined immediately using a Teecan microplate reader set to 450 nm. Wavelength 
correction was set to 540 nm and was used for normalisation of the readings. A standard 
curve was generated and the concentration of release DKK3 glycoprotein of each 
sample was calculated in ng/ml. 
2.2.22 BrdU Assay 
PiPS cells were differentiated for 2 days and then nucleofected with the DKK3 plasmid 
or with an empty pCMV5 vector as described in paragraph 2.2.18. They were then 
seeded on Collagen IV coated 12 well plates and Cell Proliferation ELISA, BrdU 
(colorimetric) (Roche Cat. No. 11647229001) was performed as according to the 
provided protocol. The optical density of each well was determined by using a Teecan 
microplate reader set to 450 nm. Wavelength correction was set to 690 nm and was used 




2.2.23. Treatment with human recombinant DKK3 cytokine 
PiPS cells were seeded on Collagen IV for differentiation for 2 days. The medium was 
removed and refreshed with serum free medium in which the cells were maintained 
overnight. The following day the cells were stimulated with 50ng/ml human 
recombinant DKK3 cytokine (R&D, Cat. No. 1118DK) overnight or for 6 hours for the 
β catenin translocation and co-immunoprecipitation experiments as described next. 
 
2.2.24 Transient transfection and Luciferase Reporter Assay 
For the Luciferase Reporter Assays, ~10.000 PiPS cells were seeded per well in 
Collagen IV coated 12-well plates. 48 hours later, transfections of the reporter plasmids 
pGL3-Luc-SM22 (Margariti et al., 2009) (Figure 19) and TopFlash (Milipore, Cat. No. 
21-170) (Figure 20) (0.33μg/well) together with the DKK3 expression vector 
(paragraph 2.2.16 and Figure 18) (0.16μg/well) were set up using FuGene®6 reagent 
(Promega, Cat. No. E2691) as instructed by the manufacturer. pGL3-Luc-Renilla 
(0.1μg/ well) was also included in all transfections as an internal control and a pCMV5 
vector was also used as a mock control. The Luciferase (Luciferase Assay System, 
Promega, Cat. No. E1501) and Renilla (Coelenterazine, Promega, Cat. No. S200A)  
enzymatic activities were detected 48 hours after transfection using the Lumat LB 9507 
illuminometer. Relative luciferase unit (RLU) was defined as the ratio of luciferase 
activity to Renilla activity with that of control set as 1.0. For verification of the DKK3 
expression vector, HEK293-T cells (Immortalized Human Kidney Cells, ATCC) were 
transfected with 2μg per T75 flask at 50-60% confluence with FuGene®6 followed by 








Figure 19. Map of the pGL3-Luc-Basic vector 
 
(Millipore) 




2.2.25 DKK3 shRNA and β catenin shRNA lentiviral transduction and Luciferase 
Reporter Assay 
~10.000 PiPS cells per well were seeded on Collagen IV coated 12-well plates. 24 hours 
later the cells were virally transduced with DKK3 shRNA or β catenin shRNA as 
previously described and were returned to the incubator for 24 hours. Cells were also 
infected with non targeting shRNA which comprised the control sample. 24 after 
infection with the DKK3 shRNA, the cells were transiently transfected with pGL3-Luc-
SM22 or TopFlash vectors (0.33μg/well) simultaneously with pGL3-Luc-Renilla 
(0.1μg/well) while the β catenin shRNA infected cells were transiently transfected with 
pGL3-Luc-SM22 (0.33μg/well) together with the DKK3 expression vector 
(0.16μg/well) and the pGL3-Luc-Renilla (0.33μg/well). A pCMV5 vector was used as a 
mock control. The samples were harvested 48 hours after transfection and the 
Luciferase and Renilla enzymatic activity was measure as described in paragraph 
2.2.22. Verifications of suppression of DKK3 and β catenin were performed by 
lentiviral transduction of PiPS-SMCs or PiPS-SMCs overexpression DKK3 respectively 
followed by Q-PCR and western blot analysis. 
2.2.26 Co-immunoprecipitation 
HEK293-T cells were seeded in T75 flasks 24 hours prior to transient transfection in a 
number sufficient to reach 50-60% confluence the following day. One hour prior to 
transfection the medium was refreshed and the cells were transfected with 4μg of a 
DKK3 expression or a pCMV5 vector (mock control) using the FuGene®6 Reagent. 48 
hours later the cells were harvested and lysed by 1 hour rotation at 4
o
C. For the PiPS-
SMC experiments, PiPS or ctl cells were seeded on Collagen IV coated T75 flasks 
where they were differentiated for 3 days.  
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The medium of a portion of the 3 day differentiated PiPS-SMCs was refreshed to serum 
free medium overnight while the rest were refreshed with complete medium as per 
usual. The following day the serum starved cells were stimulated with 50ng/ml human 
recombinant DKK3 for 6 hours and subsequently all the samples were harvested and 
lysed by 1 hour rotation at 4
o
C. 200μg to 1mg of whole cell lysate were subjected to a 
standard co-immunoprecipitation procedure. Lysates were pre-cleared with normal 
rabbit IgG and then incubated with a rabbit DKK3 antibody (Santa Cruz, sc-25518) (0.2 
to 1μg) for 2 hours at 4oC and precipitated for a further 2 hours with protein G beads 
(EZview™ Red Protein G Affinity Gel, Sigma, Cat. No. E3403). The bound proteins 
were then eluted with 20μl 2 x SDS-sample elution buffer and 5μl of 6x Loading Buffer 
by boiling for 30 minutes at 70
o
C. The samples were then centrifuged at 5000 rpm for 5 
minutes and the supernatant was transferred in new microcentrifuge tubes. They were 
then resolved by SDS gel electrophoresis simultaneously with 50μg of unprecipitated 
lysate which comprised the input samples and analysed by immunoblotting with 
Kremen 1 and DKK3 antibodies (both Goat raised). 
 
2.2.27 Deglycosylation and Luciferase Reporter Assay 
PiPS-SMCs were seeded in 12-well plates and transiently transfected with reporter 
(pGL3-Luc-SM22 TopFlash) (0.33μg/well) and Renilla (pGL3-Luc-Renilla) vectors 
(0.1μg/well) as previously described. The cells were then treated with PNGase F from 
Elizabethkingia miricola (Sigma, Cat. No. P7367) for 6 hours in a final concentration of 
1U/ml. Cells were also treated with inactivated PNGase F after inactivation of the 
enzyme at 90
o




The samples were then harvested and the Luciferase and Renilla enzymatic activity was 
detected as previously described. Successful deglycosylation of DKK3 was assessed by 
immunoblotting of supernatants with DKK3 (data not shown). 
 
2.2.28 Selection of PiPS cells 
Human neonatal fibroblasts were nucleofected with the polycistronic OSKM plasmid 
containing all four factors as described in paragraph 2.2.5. Neomycin selection (Sigma 
G418, Cat. No. G8168) at a concentration of 25 μg/ml, was initiated 24 hours after the 
nucleofection and continued up to day 4 when a pure population of PiPS cells 
expressing an mOrange marker as well as the four transcription factors was obtained. 
The cells were used for ex vivo applications in a specially constructed bioreactor as 
described in the following paragraph. In all the other experiments the cells were not 
selected in order to obtain a sufficient number of cells to perform further analysis.  
2.2.29 Cell seeding and vascular bioreactor 
PiPSs or fibroblasts were seeded on aortic grafts, which were previously decellularized 
(with sodium dodecyl sulfate (SDS) at 0.075 % and washed in PBS), in a special 
constructed bioreactor and sheer stress was applied. Briefly, a roller pump (Masterflex: 
Standard Drive, model 7520; Standard Pump Head, model 7018-20; Codane Tubing, 
Cole-Parmer UK) was used to produce mean flow in the bioreactor, the grafts were 
fixed between two 25 G needles after hosting them on plastic tubes fixed by 8-0 silk 
sutures (8-0 black virgin silk, Ethicon Inc., Johnson & Johnson, Norderstedt, Germany). 
The complete setup was maintained in a standard CO2 incubator at 37 °C. The scaffolds 
were placed for the seeding process in a self constructed incubation chamber and 
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preconditioned with culture media for 2 hours. Then, 2 x 10
6
 cells of PiPSs or 
fibroblasts in DM containing 25ng/ml PDGF-BB were seeded on the scaffolds via direct 
injection and allowed to seed for 12 hours before the initial flow was set up. 
Decellularized vessels have also been used as a second control. Shear stress was applied 
at stepwise rates ranging from 5 to 20 dynes/cm
2 
over a period of 48 hours. After this 
time point no increase in the shear stress rate was conducted and the grafts remained 
under constant shear stress of 20 dynes/cm
2
 until they were harvested by day 5. For the 
last 24 hours 100 Units of heparin per ml of total circulating reactor media volume 
(heparin sodium salt diluted, from porcine gastrointestinal mucosa, Sigma Aldrich) was 
added every 12 hours. For the double seeded PiPS cells tissue engineered vessels, 
decellularized vessel scaffolds were placed in a self constructed incubation chamber and 
preconditioned with DM medium containing 25ng/ml PDGF-BB for 2 hours. After this 
period 2 x 10
6
 PiPS cells in DM/PDGF-BB were directly injected and allowed to seed 
for 12 hours at a continuous rotational movement before initial flow was set up. Shear 
stress was applied at 10 dynes/sqcm
2
 over a period of 48 hours. Then, the circulating 
media was exchanged to EGM-2 media and a second seeding step was initiated with 1 x 
10
6
 PiPS cells and after another 12 hours seeding period the shear stress rate was 
stepwise adjusted up to 35 dynes/sqcm
2
. The grafts remained under constant shear stress 
of 35 dynes/sqcm
2
 and harvested on day 5.The engineered vessels were harvested and 
used for further analysis in vitro or immediately grafted to animals. 
2.2.30 Statistical analysis 
Data expressed as the ±SEM were analysed with a two-tailed student’s t-test for 2 
groups or pair wised comparisons using the Graphpad Prism v5.0 software. A value of 





2X SDS Sample 
Elution Buffer 
4% sodium dodecyl sulphate, 20% glycerol, 
0.04% bromophenol blue, 
125mM Tris-HCl (ph6.8) 
5X SDS 
Loading Buffer 
10% sodium dodecyl sulphate, 50% glycerol, 
0.05% bromophenol blue, 
10mM β-mercaptoethanol in 500mM Tris-
hydrochloride (pH 6.8) 
6x DNA 
Loading Buffer 
30% glycerol, 0.3% bromophenol blue in 
distilled water 
IP-A 
25mM Tris-HCl (pH7.5), 150mM NaCl, 
1mM EDTA (pH 8.0), 1.0% Triton 
X, cocktail of protease inhibitors (Roche; 1 
tablet in 50ml) 
IP-B 
25mM Tris-HCl (pH7.5), 150mM NaCl, 
1mM EDTA (pH 8.0), cocktail of 
protease inhibitors (Roche; 1 tablet in 50ml) 
Phosphate 
Buffered Saline 
137 mM NaCl, 2.7mM KCl, 8.1mM 
Na2HPO4 • 2 H2O, 1.76mM 
KH2PO4 to pH 7.4 
Protein Lysis 
Buffer 
1mM EDTA, 50mM tris-hydochloride 
(pH7.4), 150mM NaCl, 1% Triton 
X, cocktail of protease inhibitors (Roche;1 
tablet in 50ml) 
Transfer Buffer 25mM Tris, 192mM glycine, 10% methanol 
in ddH2O. 
 



































3.1 Gene expression is altered during fibroblast cell reprogramming        
from as early as day four.   
Over recent years human and mouse iPS cells have successfully been generated in our 
laboratory. However, the molecular mechanisms as well as the pathways regulating the 
transition of terminally differentiated cells into pluripotent cells have not yet been 
elucidated. In order to explore the molecular changes taking place during the 
complicated process of reprogramming, human neonatal fibroblasts were virally 
transduced to overexpress the four transcription factors SOX2, OCT4, KLF4 and 
cMYC. This introduction of the four factors was coupled with culturing in 
reprogramming media to initiate a standard reprogramming protocol (Figure 21A). 
Samples were then harvested at different time points (4, 7, 14 and 21 days) and 
subjected to microarray analysis. The results revealed that during the process of 
reprogramming, the expression of 198 genes was altered on day 4, 107 on day 7, 97 on 
day 14 and 131 on day 21 (Table S1). Interestingly, further analysis revealed that during 
the first four days of reprogramming, the expression of a greater number of genes 
involved in cell movement, proliferation, cellular growth and development were altered 
when compared to days 7, 14 and 21. Finally, the expression of genes associated to 
differentiation was found to be altered from as early as day 4 (Figure S1). The 
differential expression profile of a number of these genes was confirmed by 
conventional PCR (Figure 21B, result representative of three experiments). These 
results reveal that specific gene expression patterns are altered from as early as day 4 






                   
                                                 
       
Figure 21: (A) Confirmation of induction of the four genes during the 
reprogramming, for the samples subjected to microarray analysis. Human 
embryonic fibroblasts were infected with lentiviral constructs encoding the four 
genes SOX2, OCT4, KLF4 and cMYC or a control construct (10
7
TU/ml) and 
maintained in reprogramming medium for different timepoints. (B) Confirmation 
of differential expression of selected genes from the microarray during the 
reprogramming process, using Q-PCR and conventional PCR. TEK and 
HBA2 were found to be induced after 4 days (4D) (the mean ±SEM of 3 
individual experiments is shown) and TGFBi was confirmed to be downregulated 
during all the time points. Anexxin3 was confirmed to only be upregulated during 
the first 7 days (7D) of reprogramming while STMN2 was significantly 























3.2 Characterization of four day reprogrammed cells or Partially-iPS 
(PiPS) 
Based on the result of the microarray analysis, where altered gene patterns appear very 
early during the reprogramming, four day reprogrammed cells were generated and then 
fully characterized. Human fibroblasts were nucleofected with a linearised 
pCAG2LMKOSimO plasmid encoding all four genes, by nucleofection with four 
plasmids each containing one of the genes (Ex-SOX2, Ex-OCT4, EX-KLF4 and Ex-
cMYC) or by lentiviral infection with viruses encoding all four genes in one vector. 
They were then maintained in reprogramming media for four days and were defined as 
Partially-iPS (PiPS) cells. Simultaneously, fibroblasts were nucleofected or infected 
with empty vectors, they were maintained in the same culture conditions and were used 
as controls (ctl). Although PiPS cells did not form colonies at this stage of 
reprogramming, they displayed morphological differences when compared to ctl cells 
(Figure 22). PiPS cells expressed the four genes at both the mRNA (Figure 23A) and 
protein levels (Figure 23B). However, significant differences on the levels of expression 
of progenitor markers such as cKIT, CD34 and CD133 were not detected. Interestingly, 
PiPS cells expressed VEGFR2 (KDR) (Figure 24A), results which were also confirmed 
by FACS analysis (Figure 24B). Finally, PiPS cells were negative for the ESC marker 
alkaline phosphatase (Fig 25A) and did not form teratomas in vivo 2 months after 
subcutaneous transplantation in SCID mice (Figure 25B) as recently shown by 







                  
 
 
Figure 22. Morphological differences between Partially-iPS (PiPS) cells and 
control (ctl) cells. Human embryonic fibroblasts were nucleofected with a 
pCAG2LMKOSimO vector (4μg/2x106 cells) containing SOX2, OCT4, KLF4 
and cMYC and were maintained in reprogramming conditions for four days while 
the ctl cells were nucleofected with the pCAG2L control vector (4μg/2x106 cells) 
and were also maintained in reprogramming media. Light microscope images 
reveal that the morphology of the PiPS cells is different than that of the ctl cells at 
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Figure 23. (A) Confirmation of overexpression of the four factors after 4 days 
of reprogramming at the mRNA level and (B) the protein level. Human 
embryonic fibroblasts were nucleofected with a pCAG2LMKOSimO vector 
(4μg/2x106 cells) containing SOX2, OCT4, KLF4 and cMYC and were 
maintained in reprogramming conditions for 4 days while the ctl cells were 
nucleofected with the pCAG2L control vector (4μg/2x106 cells) and were also 
maintained in reprogramming media. Samples were harvested 4 days later and 
subjected to Q-PCR (the mean ±SEM of 3 individual experiments is shown) and 

















                            
                                
































      
 
  
Figure 24. (A)VEGFR2 (KDR) is upregulated in PiPS cells after 4 days of 
reprogramming. Human fibroblasts were reprogrammed for four days and the 
mRNA levels of the progenitor markers CD34, CD133, C-KIT and KDR were 
assessed by Q-PCR. KDR was found to be upregulated in PiPS cells after four 
days of reprogramming when compared to the ctl cells (the mean ±SEM of 3 
individual experiments is shown). (B) FACS analysis confirmed the 
upregulation of KDR expression in PiPS cells (mean ±SEM of 3 individual 











































        
Figure 25.  (A) PiPS cells are negative for alkaline phosphatase. Human 
fibroblasts were reprogrammed for four days and then stained for alkaline 
phosphatase to assess their pluripotent state. PiPS cells were found to be negative 
for the aforementioned marker. iPS cells were used as a positive ctl for alkaline 
phosphatase. (B) PiPS did not form teratomas in vivo. Subcutaneous 
transplantation of PiPS cells (G-L) in SCID mice did not result in teratoma 
formation 2 months after the procedure, unlike iPS (A-F) cell transplantation 
where all three germ layers were generated as shown by hematoxylin and 
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3.3 PiPS cells can differentiate into SMCs 
To assess the potential of PiPS cells to differentiate into different lineages in response to 
specific stimulus and based on observations of expression of VEGFR2 in the 
aforementioned cells, we questioned whether they could differentiate into vascular 
lineages and specifically SMCs. Previous studies in our laboratory have demonstrated 
that Collagen IV induces differentiation of ESCs into SMCs (Xiao et al., 2007). 
Therefore, we speculated if application of this protocol of differentiation could result in 
differentiation of PiPS cells into SMCs. In order to test this, PiPS cells were seeded on a 
Collagen IV substrate and maintained in differentiation medium (DM) for different 
timepoints. It was revealed that 4 days under the aforementioned conditions were 
sufficient to change the morphology of PiPS cells into one that resembled the 
morphology of SMCs as opposed to the control (ctl) population where cells maintained 
their fibroblast morphology (Figure 26). Differentiation of cells reprogrammed for 2, 4, 
7, 14 and 21 days confirmed that 4 days of reprogramming is the optimal time point for 
obtaining SMC in higher efficiencies (Figures S2, S3). Furthermore, the differentiated 
PiPS cells expressed SMC specific markers such as SMA and Calponin in a time 
dependant manner at the mRNA level (Figure 27). More specifically, on day 4 of 
differentiation PiPS-SMCs expressed a full panel of SMC specific markers at the 
mRNA level (Figure 28A) and the SMC markers Calponin and SM22 at the protein 
level (Figure 28B). Interestingly, induction of SMC marker mRNA at day 4 of PiPS cell 
differentiation was found to be greater than that of 6 day differentiated iPS cells under 
the same differentiation conditions (Figure S4). Finally, indirect immunofluorescent 
staining for Calponin and SM22 demonstrated a SMC-like morphology when compared 




 Calponin and 26.4% for SM22 (Figure S4). These results demonstrate that PiPS cells 




Figure 26. PiPS cells display a SMC-like morphology after 4 days in 
differentiation conditions. PiPS (B) or ctl cells (A) were seeded on a Collagen 
IV substrate and maintained in DM for 4 days. Light microscope images reveal 
that PiPS-SMCs have adopted a SMC-like morphology as comparable to native 
SMCs (C). Images were taken with the Nikon Eclipse TS100. (Image 






























































Figure 27. SMC markers are upregulated in a time dependant manner 
during the differentiation of PiPS cells into SMCs. PiPS or ctl cells were 
seeded in differentiation conditions and samples were harvested at different 
timepoints (2, 3 and 4 days). Q-PCR revealed that there is an upregulation of 
SMC specific markers during PiPS cell differentiation in a time dependant 
























                        

























































































                                              
        
 
Figure 28. PiPS cells express SMC specific markers after 4 days in 
differentiation conditions. PiPS cells or ctl cells were differentiated on Collagen 
IV and maintained in DM medium. Samples were harvested after 4 days and 
mRNA and total protein were extracted. Q-PCR (A) (the mean ±SEM of 3 
individual experiments is shown) and western blot analysis (B) revealed an 
upregulation of SMC specific markers in PiPS-SMCs at the mRNA and protein 
levels respectively, when compared to the ctl cells. SMCs were used as a positive 
ctl (image representative of 3 experiments). (C) Quantification of SMC marker 




















   





Figure 29. Four days differentiated PiPS cells were positive for Calponin and 
SM22 and demonstrated a typical SMC-like morphology. PiPS or ctl cells 
were differentiated for 4 days and then stained for the SMC markers Calponin and 
SM22. DAPI was used as counterstaining for identification of the nucleus. The 
cells were positive for the aforementioned SMC markers and exhibited a SMC-
like morphology. Images of indirect immunofluorescent staining were captured 
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3.4 DKK3 is involved in the differentiation of PiPS cells into SMCs. 
To elucidate the mechanism involved in the PiPS-SMCs differentiation, selected genes 
identified in the microarray analysis were screened at the mRNA level (Figure 30A). 
Among the many candidates, a member of the Dickkopf family, DKK3, was selected to 
be studied further. DKK3 was found to be upregulated in parallel with SMC markers 
during the PiPS-SMC differentiation at both the mRNA (Figure 30B) and protein levels 
(Figure 30C). Furthermore, indirect immunofluorescent staining confirmed the 
concomitant expression of DKK3 with the SMC specific markers Calponin and SM22 
and revealed a stronger perinuclear pattern of DKK3 in the differentiated PiPS-SMCs 
when compared to the ctl cells (Figure 31). To investigate whether DKK3 is involved in 
PiPS-SMC differentiation, DKK3 was transiently overexpressed via nucleofection in 
PiPS-SMC during differentiation, for 48 hours. PiPS-SMCs were also nucleofected with 
a pCMV5 empty vector and were used as a control (ctl). Upregulation of DKK3 lead to 
further induction of SMC specific markers at both the mRNA (Figure 32A) and protein 
levels (Figure 32B). Preliminary results show that upregulation of DKK3 in PiPS cells 
does not increase proliferation. Although total cell count shows a small increase in cell 
numbers, employment of BrdU assay upon overexpression of DKK3 does not reveal a 
significant induction of proliferation (Figure S4). These results suggest that DKK3 is 
involved in PiPS-SMC differentiation. The next crucial point was to investigate whether 
DKK3 is sufficient to drive the mechanism of PiPS-SMC differentiation. In order to 
address this question, the aforementioned gene was suppressed via lentiviral delivery of 
DKK3 shRNA for 48 and 72 hours during differentiation. PiPS-SMCs infected with the 
non targeting shRNA lentivirus were used as the ctl population. Interestingly, SMC 
specific markers were found to be downregulated at both the protein (Figure 33A) and 







Indirect immunofluorescence also revealed that there is a reduced differentiation 





    
 
        
 
 
                
Figure 30. DKK3 is upregulated during differentiation of PiPS-SMCs. (A) 
Figure representative of conventional PCR investigating the expression of a 
number of genes identified in the microarray analysis, for their involvement 
during PiPS-SMCs differentiation. DKK3 was found to be significantly 
upregulated during 3 and 4 days of PiPS-SMCs differentiation along with 
Annexin3 and TGFβi. DKK3 expression was upregulated in parallel with SMC 
specific markers on day 4 of differentiation in PiPS-SMCS at both the mRNA and 
protein levels as revealed by Q-PCR (B) (the mean ±SEM of 3 individual 
experiments is shown) and western blot analysis (C) (image representative of 3 
experiments) respectively. 
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Figure 31. DKK3 is expressed in a perinuclear pattern concomitant with 
SMC specific markers. Double indirect immunofluorescent staining for (A) 
Calponin-DKK3 and (B) SM22-DKK3 revealed a concomitant expression of 
SMC markers and DKK3 in PiPS-SMCs. PiPS or ctl cells were differentiated for 
4 days and then double stained for Calponin-DKK3 and SM22-DKK3. DAPI was 
used as counterstaining for identification of the nucleus. The staining revealed a 
perinuclear DKK3 expression concomitant with Calponin and SM22 expression. 













         
   













































































Figure 32. DKK3 overexpresssion further induces the expression of SMC 
markers in PiPS-SMCs during differentiation. PiPS cells were seeded on a 
Collagen IV substrate and differentiated in DM for 2 days. They were then 
nucleofected with DKK3 or a pCMV5 empty vector (2μg/2x106 cells) and 
samples were harvested after 48 hours. (A) Western blot analysis (image 
representative of 2 experiments) accompanied by quantification by densitometry 
(C) as well as Q-PCR (B) (the mean ±SEM of 3 individual experiments is shown) 
revealed a further induction of SMC markers Calponin and SM22 after 





















                      
 
 
   
 
                               



































        
































Figure 33. DKK3 downregulation leads to dowregulation of SMC markers in 
PiPS-SMCs during differentiation. PiPS cells were infected with shDKK3 or 
non targeting shRNA (10
7
TU/ml complemented with 10μg/ml polybrene) 24 
hours after being seeded on Collagen IV and DM. Samples were harvested 48 and 
72 hours post infection and were subjected to (A) western blot analysis for SMC 
specific markers. (C) Quantification of the protein for the 48 hour timepoint 
revealed downregulation of a panel of SMC specific markers. mRNA was also 
extracted 72 hours post infection and the relative expression of SMC specific 
markers was determined on the transcriptional level by (B) Q-PCR (the mean 



















3.5 The cytokine role of DKK3 in PiPS-SMC differentiation 
DKK3 is a secreted glycoprotein which is expressed in a variety of tissues and its role as 
a cytokine has previously been reported (Watanabe et al., 2009). However, its 
physiological role remains unclear. To investigate the potential role of DKK3 as a 
cytokine in the differentiation of PiPS-SMC, the supernatant of 4 day differentiated 
PiPS and ctl cells was collected and then subjected to western blot analysis. The results 
revealed that there was an increased release of DKK3 glycoprotein in the supernatant of 
PiPS-SMCs when compared to the supernatant of the ctl cells (Figure 34A and 34B). 
These findings were further confirmed by DKK3 ELISA measurements, where the 
concentration of released DKK3 was detected. Quantification of the released DKK3 
showed a higher concentration of the glycoprotein in the supernatant of PiPS-SMCs 
when compared to that of the ctl cells (concentrations as high as 80ng/ml) (Figure 34C).  
To assess whether the changes in expression of DKK3 at the protein and mRNA level 
were linked to its secretion, western blot analysis of the supernatant was also performed 
in samples where DKK3 was transiently overexpressed in PiPS-SMCs during 
differentiation. Quantification via DKK3 ELISA revealed that upregulation of DKK3 at 
the mRNA level lead to extracellular secretion of the glycoprotein. The supernatant of 
the differentiated PiPS cells which were nucleofected with an empty pCMV5 vector was 
used as a control (Figure 35A). Furthermore, supernatant of PiPS-SMCs in which 
DKK3 was suppressed via lentiviral delivery of DKK3 shRNA in PiPS-SMCs during 
differentiation, was analysed. PiPS-SMCs were also infected with non targeting shRNA, 
the supernatant of which was used as a control. Western blot analysis of the 
aforementioned samples revealed that there is a decreased release of the glycoprotein in 
the supernatant after successful downregulation at the mRNA (Figure 35B). 
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Finally in order to ascertain whether DKK3 has a cytokine effect in our system of 
differentiation, a human recombinant DKK3 cytokine was utilized in order to stimulate 
PiPS-SMCs. PiPS cells were seeded on a Collagen IV substrate and maintained in DM 
for 3 days. They were then stimulated with 50ng/ml of human recombinant DKK3 for 
24 hours. The activity of human recombinant DKK3 protein is confirmed by western 
blot analysis in Figure S7. Unstimulated PiPS-SMCs cells served as the control. 
Analysis of the samples harvested 24 hours following stimulation, revealed an 
upregulation of SMC specific marker expression at both the mRNA (Figure 36A) and 
protein (Figure 36B) levels between stimulated and unstimulated PiPS-SMCs, as shown 
by Q-PCR and western blot analysis respectively.  
These results suggest that DKK3 secretion plays an important role in PiPS-SMC 
differentiation and that stimulation of PiPS-SMCs with recombinant DKK3 leads to 












                                 






































































Figure 34. Secretion of DKK3 is increased during differentiation of PiPS into 
SMCs. PiPS and ctl cells were differentiated on Collagen IV and maintained in 
DM for 4 days. The supernatant from both populations was collected and 20μl of 
each sample were subjected to western blot analysis as described in paragraph 
2.2.15. (A) Immunoblotting for DKK3 revealed an increased release of DKK3 in 
the differentiated PiPS-SMCs when compared to the ctl cells. (B) Densitometry of 
3 independent experiments (the mean ±SEM of 3 individual experiments is 
shown). (C) Quantification of DKK3 concentartion in the supernatant of both 
populations by ELISA, reveals that there is a higher concentration of DKK3 
glycoprotein in the supernatant of PiPS-SMCs when compared to the supernatant 
of the ctl cells. 
 
 


















Figure 35. Transcriptional upregulation or downregulation of DKK3 is 
related to its secretion to the supernatant. (A) PiPS cells were differentiated for 
2 days and were then forced to overexpress DKK3 or an empty pCMV5 vector 
(2μg/2x106 cells) via nucleofection for an additional 2 days. Supernatants from 
both samples were collected and the concentraton of DKK3 was detected by 
DKK3 ELISA. Quantification of DKK3 in the supernatant revealed an increased 
release of the glycoprotein after forced expression of DKK3 at the mRNA level. 
(B) PiPS cells were seeded on Collagen IV and 24 hours later were infected with 
DKK3 shRNA or non targeting shRNA (10
7
TU/ml complemented with 10μg/ml 
polybrene). The supernatants were collected 72 hours later and 20μl of each 
sample were subjected to western blot analysis as described in paragraph 2.2.15. 
Silencing of DKK3 via lentiviral delivery of DKK3 shRNA lead to decreased 































































































Figure 36. DKK3 stimulation leads to upregulation of SMC markers. PiPS 
cells were differentiatied on Collagen IV and DM. They were then stimulated with 
50ng/ml human recombinant DKK3 cytokine for 24 hours. Treated and untreated 
samples were harvested and RNA and protein were extracted. Q-PCR (A) and 
western blot analysis (B) after densitometry (C) revealed that there is a further 
induction of SMC markers such as Calponin and SM22 at the mRNA and protein 
levels respectively (the mean ±SEM of 3 individual Q-PCR experiments is 
shown). 















3.6 DKK3 regulates the transcriptional activation of SM22 
Thus far, we have shown that DKK3 overexpression and stimulation lead to 
upregulation of SMC markers at both the transcriptional and protein level. In order to 
shed light into the molecular mechanism regulated by DKK3 during PiPS-SMCs 
differentiation, the effect of DKK3 in the transcriptional activation of SMC specific 
markers was evaluated. Luciferase assays were performed and the promoter activity of 
SM22 was detected.  PiPS cells were seeded on Collagen IV for 24 hours in order to 
initiate differentiation. The cells were then transfected with a reporter gene PGL3-Luc-
SM22 vector (Margariti et al., 2009) (0.33μg/well) together with the DKK3 plasmid in a 
dose response manner (0.8/0.16/0.25μg/well). A PGL3-Renilla vector (0.1μg/well) was 
included in all transfection assays as the internal control. Simultaneously, cells were 
transfected with an empty pCMV5 vector (0.16μg/well), a PGL3-Luc-SM22 vector 
(0.33μg/well) and PGL3-Renilla (0.1μg/well) and comprised the control population. 
The samples were harvested 48 hours later and the Luciferase and Renilla enzymatic 
activities were detected (Promega Luciferase assay). Analysis of the results revealed 
that there was an upregulation of the SM22 promoter activity upon DKK3 
overexpression suggesting that DKK3 induced activation of SM22 at the transcriptional 
level (Figure 37). 
To further confirm the effect of DKK3 in the transcriptional activation of SM22, the 
promoter activity of SM22 was also measured after DKK3 silencing. PiPS cells were 
seeded on Collagen IV for 24 hours to initiate differentiation after which DKK3 was 
suppressed by lentiviral delivery of DKK3 shRNA. Simultaneously, 24 hour 
differentiated PiPS cells were infected with non targeting shRNA and comprised the 




with PGL3-Luc-SM22 (0.33μg/well) and PGL3-Renilla vectors (0.1μg/well).  
The samples were harvested 48 hours post transfection and the luciferase enzymatic 
activity was measured. The renilla enzymatic activity was used as an internal control. 
Interestingly, the results revealed that downregulation of DKK3 in the differentiated 
PiPS cells lead to downregulation of the SM22 promoter activity, confirming the effect 
of DKK3 in the transcriptional activation of SM22 (Figure 38). 
Finally in order to further evaluate the response of SM22 after DKK3 stimulus, indirect 
immunofluorescent staining was performed during different timepoints of stimulation 
with human recombinant DKK3. PiPS-SMCs were stimulated with 50ng/ml of human 
recombinant DKK3 cytokine and were then stained for both DKK3 and SM22. 
Surprisingly, it was found tha 4 hours are sufficient to further induce SM22 expression 
in PiPS-SMCs as revealed by SM22 staining (Figure 39A) and estimation of 
differentiation efficiency after cell counting (Figure 39B). 
The above findings show that DKK3 induces SMC differentiation of PiPS cells by 



















Figure 37. DKK3 overexpression leads to promoter activation of SM22. PiPS 
cells were seeded on Collagen IV for differentiation and 24 hours later they were 
co transfected with different concentrations of DKK3 (0.08/0.16/0.25 μg/well)  or 
an empty pCMV5 vector (0.16μg/well), a PGL3-Luc-SM22 vector (0.33μg/well) 
and a PGL3-Renilla vector (0.1μg/well). The samples were harvested 48 hours 
later and their luciferase enzymatic activity was measured with the Lumat LB 
9507 Luminometer. The readings showed that there was an increased SM22 
promoter activation in the samples overexpressing DKK3 at concentrations 0.08 
and 0.16 μg/well when compared to the control samples. The Renilla readings 
were used as an internal control (the mean ±SEM of 3 individual experiments is 
shown) (Relative luciferase unit (RLU) was defined as the ratio of luciferase 














































Figure 38. DKK3 silencing leads to downregulation of the SM22 promoter 
activity. PiPS cells were seeded on Collagen IV and 24 hours later were infected 
with DKK3 shRNA or non targeting shRNA(10
7
 TU/ml complemented with 
10μg/ml polybrene). 24 hours after the infection the differentiated PiPS cells were 
co transfected with a PGL3-Luc-SM22 vector (0.33μg/well) and a PGL3-Renilla 
vector (0.1μg/well). Both samples were harvested 48 hours after transfection and 
the luciferase enzymatic activity was measured with the Lumat LB 9507 
Luminometer. Renilla readings were used as an internal control. The results 
revealed that DKK3 silencing leads to downregulation of the SM22 promoter 
activity suggesting that DKK3 directly regulates the transcriptional patterns of 
SM22 (the mean ±SEM of 2 individual experiments is shown) (Relative luciferase 
unit (RLU) was defined as the ratio of luciferase activity to Renilla activity with 















































































Figure 39. DKK3 stimulation leads to increased expression of SM22 from as 
early as 4 hours. (A) PiPS-SMCs were stimulated with 50ng/ml human 
recombinant cytokine for 4 hours and then double stained for SM22 and DKK3 
while DAPI was used as counterstaining to identify the nucleus. Images were 
captured using confocal SP5 microscopy. (B) Cell counting for SM22 positive 
cells. The efficiency of differentiation was calculated as the ratio of SM22 












3.7 DKK3 activates Wnt signalling during differentiation of PiPS cells 
into SMCs. 
It has previously been shown that β catenin, the downstream mediator of Wnt 
signalling, directly regulates the transcription of SM22 by binding to its −213 to −192 
upstream promoter region (Shafer and Towler, 2009). Furthermore, DKK3 as part of the 
Dickkopf family of Wnt inhibitors has been implicated in activation or deactivation of 
Wnt signalling. Its role however remains unclear (Nakamura et al., 2007; Yue et al., 
2008). According to our findings, DKK3 regulates the transcriptional activation of 
SM22. Therefore, in order to test if DKK3-induced PiPS cell differentiation to SMCs 
occurs through interaction of DKK3 with the Wnt signalling pathway, the activation 
status of Wnt was initially assessed. A TopFlash vector (TCF reporter plasmid) was 
utilised to measure the promoter activity of the target genes of Wnt signalling. PiPS 
cells were seeded on Collagen IV and 24 hours later were co transfected with DKK3 
(0.08/0.16/0.25μg/well), the TopFlash vector (0.33μg/well) and a PGL3-Renilla vector 
(0.1μg/well). At the same time, 24 hour differentiated PiPS were co transfected with an 
empty pCMV5 vector (0.16μg/well), the TopFlash vector (0.33μg/well) and a PGL3-
Renilla vector (0.1μg/well) which comprised the control population. The samples were 
harvested 48 hours later and the luciferase enzymatic activity was measured. The 
reading for the Renilla enzymatic activity was used as an internal control. Analysis of 
the results revealed that there is an upregulation in the enzymatic activity of the 
TopFlash reporter genes after overexpression of DKK3 (Figure 40). These findings 
suggest that upregulation of DKK3 leads to activation of Wnt signalling during the 





To confirm  the activation of Wnt signalling during PiPS-SMCs differentiation, the 
transcriptional patterns of the Wnt signalling mediator β catenin was assessed during 
PiPS cell differentiation to SMCs. PiPS cells were differentiated on Collagen IV for 4 
days, mRNA was extracted and the samples were subjected to Q-PCR. Analysis of the 
results revealed that there was an upregulation of the expression of β catenin in PiPS-
SMCs concomitant to the upregulation of DKK3 (Figure 41).  
To further investigate the Wnt signalling activation status in PiPS-SMCs and the 
involvement of DKK3 in that process, the transcriptional patterns of additional targets 
of the aforementioned signalling pathway were assessed after DKK3 overexpression. 
DKK3 or an empty pCMV5 vector (2μg/2x106 cells) were transiently overexpressed in 
PiPS-SMCs via nucleofection and mRNA and protein were extracted from both 
samples. Q-PCR revealed that there is an upregulation in the expression of the Wnt 
signalling targets  β catenin, TCF1 and Axin2 at the transcriptional level after forced 
expression of DKK3 in PiPS-SMCs (Figure 42). Furthermore, the transcriptional levels 
of the aforementioned genes were assessed after DKK3 silencing in PiPS-SMCs. PiPS-
SMCs were viraly infected with DKK3 shRNA or non targeting shRNA and samples 
were harvested 72 hours later. mRNA and protein were harvested and samples were 
subjected to Q-PCR and western blot analysis respectively. Interstingly it was found 
that β catenin, TCF1 and Axin2 were downregulated at the transcriptional level after 
downregulation of DKK3 in PiPS-SMCs (Figure 43A). Finally, β catenin was also 
found to be downregulated at the protein level after DKK3 downregulation (Figure 
43B). These results interestingly show that DKK3 can regulate Wnt signalling during 





While trying to further investigate the upregulation of β catenin, the penultimate and 
key downstream component of Wnt signalling, the expression levels of the upstream 
Wnt component, GSK3, were assessed. It has been shown that when Wnt signalling is 
not activated, GSK3 as part of the axin/GSK-3/APC complex promotes the proteolitic 
degredation of β catenin. Downregulation of GSK3 leads to inhibition of β catenin 
degradation and therefore its accumulation into the cell and ultimately its translocation 
to the nucleus (Miller et al., 1999). 
The expression of GSK-3 levels were therefore identified in PiPS-SMCs. After 4 days 
of differentiation, both isoforms of GSK-3, GSK-3a and GSK-3b, were found to be 
downregulated in PiPS-SMCs when compared to the control cells (Figure 44). These 


























Figure 40. DKK3 activates Wnt signalling during PiPS-SMC differentiation. 
PiPS cells were seeded on Collagen IV for differentiation and 24 hours later they 
were co transfected with different concentrations of DKK3 (0.08/0.16/0.25 
μg/well) or an empty pCMV5 vector (0.16μg/well), a TopFlash vector 
(0.33μg/well) and a PGL3-Renilla vector (0.1μg/well). The samples were 
harvested 48 hours later and their luciferase enzymatic activity was measured with 
the Lumat LB 9507 Luminometer. The readings showed that there is an 
upregulation in the enzymatic activity of the TopFlash reporter genes in the cells 
overexpressing DKK3 at a concentration of 0.08 μg/well when compared to the 
control cells. The Renilla readings were used as an internal control (the mean 
±SEM of 3 individual experiments is shown) (Relative luciferase unit (RLU) was 
defined as the ratio of luciferase activity to Renilla activity with that of control set 













































      
















































Figure 41. β catenin is upregulated in PiPS-SMCs in parallel with DKK3. 
PiPS or ctl cells were differentiated on Collagen IV for 4 days after which mRNA 
and protein were extracted. (A) Q-PCR revealed that there was an upregulation of 
β catenin in PiPS-SMCs concomitant to the upregulation of DKK3 (the mean 
±SEM of 3 individual experiments is shown). Western blot analysis (B) and 
quantification of the protein by densitometry (the mean ±SEM of 2 individual 
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Figure 42. DKK3 overexpression leads to transcriptional upregulation of 
Wnt signalling target genes. DKK3 or an empty pCMV5 vector (2μg/2x106 
cells) were transiently overexpressed in PiPS-SMCs via nucleofection and the 
samples were harvested 48 later. Q-PCR revealed that there is an upregulation of 
Wnt signalling target genes such as β catenin, TCF1 and Axin 2 at the 
transcriptional level concomitant with the upregulation of DKK3 (the mean ±SEM 







        
 



























           




































Figure 43. β catenin is downregulated after DKK3 silencing. PiPS cells were 
seeded on Collagen IV for differentiation and 24 hours later were infected with 
DKK3 shRNA or non targeting shRNA (10
7
TU/ml complemented with 10μg/ml 
polybrene). The samples were harvested 72 hours later and mRNA and protein 
were extracted for Q-PCR and wetsrn blot analysis respectively. (A) Q-PCR 
revealed that there is a downregulation of the Wnt signalling targets β catenin, 
TCF1 and Axin 2 after DKK3 silencing in PiPS-SMCs at the transcriptional level 
and (B) western blot analysis and quantification of the protein by densitometry 




















                                                   







































Figure 44. Downregulation of both isoforms of GSK3 during PiPS-SMC 
differentiation. PiPS were differentiated on Collagen IV for 4 days after which, 
protein was extracted and subjected to western blot analysis (A). Quantification of 
the protein by densitometry (B) revealed that there is a downregulation of both 
isoforms of GSK3 after 4 days of differentiation (Image representative of 2 
























3.8 DKK3 induced PiPS-SMC differentiation through β catenin 
It has previously been shown that after the inhibition of the β catenin destruction 
complex, the cytoplasmic β catenin is stabilized and can enter the nucleus in order to 
interact with the TCF/ LEF family of transcription factors, promoting specific gene 
expression (Novak and Dedhar, 1999). According to our findings DKK3 forced 
expression can lead to transcriptional activation of SM22 as well as β catenin and its 
downstream targets. Therefore, we postulated if DKK3 could induce the translocation of 
β catenin into the nucleus and subsequently the transcriptional regulation of SM22 and 
the Wnt signalling target genes. Thus, we examined the localization of β catenin in 
untreated PiPS-SMCs and PiPS-SMCs upon DKK3 stimulation. Since human 
recombinant DKK3 is received by the cells from as early as 1 hour (Figure S6), PiPS 
cells were seeded on Collagen IV for differentiation and 3 days later were stimulated 
with 50ng/ml of human recombinant DKK3 for up to 6 hours. The samples were then 
stained for β catenin and DKK3. Indirect immunofluorescent staining revealed that 
while β catenin appears to be localized in mainly in the cell junctions in PiPS-SMCs, in 
the cells stimulated with the DKK3 cytokine for 4-6 hours, β catenin has translocated to 
the nucleus (Figure 45). These results combined with our previous findings suggest that 
DKK3 may regulate the transcriptional activation of SM22 though activation of Wnt 
signalling and translocation of its key mediator β catenin to the nucleus. Furthermore, 
the translocation of β catenin to the nucleus is not a permanent event but instead a 







In order to confirm that the DKK3 induced regulation of SM22 is mediated by β catenin 
the reporter activity of SM22 was assessed after DKK3 overexpression with 
simultaneous suppression of β catenin by shRNA. PiPS cells were seeded on Collagen 
IV for differentiation and 24 hours later they were infected with β catenin shRNA or 
non targeting shRNA. 24 hours after the infection the cells were transiently transfected 
with DKK3 (0.16μg/well), a PGL3-Luc-SM22 vector (0.33μg/well) and a PGL3-Renilla 
vector (0.1μg/well) and were maintained in DM for 48 hours. The samples were then 
harvested and their luciferase enzymatic activity was measured. Interestingly, analysis 
of the results revealed that silencing of β catenin not only abolished the induction of the 
transcriptional activity of SM22 after DKK3 overexpression but also causes 
downregulation of the SM22 promoter activity when compared to the control samples 
(Figure 46).  These results support our previous findings and confirm that the 















































Figure 45. DKK3 stimulation induces β catenin translocation. PiPS cells were 
differentiated on Collagen IV for 3 days and then stimulated with 50ng/ml human 
recombinant DKK3 for 6 hours. The cells were then stained for β catenin while 
DAPI was used as counterstaining to identify the nucleus. (A) Indirect 
immunofluorescent staining revealed that while in the untreated PiPS-SMCs β 
catenin remains mainly in the cell junctions, in the stimulated cells, β catenin has 
translocated to the nucleus. (B) Quantification of cells where β catenin has been 
translocated to the nucleus. In the unstimulated cells, β catenin was translocated to 
the nucleus whereas in the stimulated cells 13 out of 26 were positive for the 
aforementioned translocation. Images were captured using SP5 confocal 













































                                                       
 
Figure 46. Transcriptional activation of SM22 by DKK3 is mediated by β 
catenin. (A) SM22 and TopFlash reporter activity during β catenin silencing. 
PiPS cells were seeded on Collagen IV and 24 hours later were viraly infected 
with β catenin shRNA or non targeting shRNA (107TU/ml complemented with 
10μg/ml polybrene). 24 hours post infection the cells were forced to overexpress 
DKK3 (0.16μg/well), PGL3-Luc-SM22 (0.33μg/well) and PGL3-Renilla 
(0.1μg/well) for 48 hours after which the samples were harvested. The luciferase 
enzymatic activity of both samples was measured using the Lumat LB 9507 
Luminometer. The enzymatic activity of Renilla comprised the internal control. 
Analysis of the results revealed that β catenin silencing abolished the effect of 
DKK3 in the promoter activity of SM22 (the mean ±SEM of 3 individual 
experiments is shown). (B) Confirmation of downregulation of β catenin after 
lentiviral delivery of β catenin shRNA. Western blot analysis revealed that there 
is a downregulation of β catenin in PiPS-SMCs-DKK3 after lentiviral delivery of 













3.9 DKK3 activates Wnt signalling through interaction with the 
transmembrane protein Kremen 1 
Thus far our data have demonstrated that transcriptional activation of SM22 by DKK3 
was mediated by β catenin. In order to elucidate the underlying mechanisms of this 
regulation, the interaction of DKK3 with proteins of the Wnt signalling pathway were 
assessed. It has recently been reported that DKK3 can potentiate Wnt signalling through 
interaction with the transmembrane protein Kremen 1 (Nakamura and Hackam, 2010). 
Thus, we wondered whether the potentiation of Wnt by DKK3 in our system of 
differentiation is mediated through interaction of DKK3 with Kremen 1. 
In order to test that hypothesis, a series of co-immunoprecipitation (CoIPs) experiments 
were performed. Initially, an easy transfectable cell line such as HEK293-T cells was 
utilised to test the interaction of DKK3 and Kremen 1. DKK3 or an empty pCMV5 
vector was transiently transfected in HEK293-T cells and both samples were harvested 
48 hours later. Whole cell lysate was then extracted, followed by immunoprecipitation 
of DKK3 with a DKK3 antibody. Samples were then subjected to western blot analysis 
in order for binding partners of DKK3 to be identified. Immunoblotting with Kremen 1 
revealed that indeed DKK3 can interact with the aforementioned receptor and 
interestingly an increased binding of DKK3 and Kremen 1 in the samples 
overexpressing DKK3 was observed (Figure 47A). These results confirm previously 







After establishing the interaction of DKK3 with Kremen 1 in 293-T cells, the same 
interaction was assessed in our system of differentiation following DKK3 stimulation. 
Whole cell lysate from ctl cells, PiPS-SMCs and PiPS-SMCs stimulated with 50ng/ml 
human recombinant DKK3 for 24 hours were subjected to immunoprecipitation using a 
DKK3 antibody which was followed by western blot analysis. Immunoblotting with 
Kremen 1 showed that while no binding between DKK3 and Kremen 1 was revealed in 
the ctl cells, the aforementioned proteins show binding in PiPS-SMCs and PiPS-SMCs 
DKK3 stimulated cells (Figure 47B). Therefore, these findings postulate that the 
response of PiPS-SMCs to DKK3 stimulation and the subsequent activation of Wnt 






































Figure 47. DKK3 binds Kremen 1 during PiPS-SMC differentiation. (A) 
Confirmation of DKK3 and Kremen 1 binding in HEK293-T cells. DKK3 or 
an empty pCMV5 vector (4μg/60% confluent T75 flask) were transiently 
overexpressed in HEK293-T cells for 48 hours, after which the samples were 
harvested and immunoprecipitated with a rabbit DKK3 antibody. Immunoblotting 
with Kremen 1 revealed binding of DKK3 with Kremen 1 with increased binding 
in the cells overexpressing DKK3. (B) DKK3 binds on Kremen 1 during PiPS-
SMCs differentiation. Ctl and PiPS cells were seeded on Collagen IV for 
differentiation. 3 days later a portion of the differentiated PiPS cells were 
stimulated for 6 hours with 50ng/ml human recombinant DKK3. The samples 
were then harvested and the whole cell lysates were immunoprecipitated with a 
rabbit DKK3 antibody. Immunoblotting with Kremen 1 revealed that although no 
binding between DKK3 and Kremen 1 is revealed in the control cells, both 
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3.10 The glycosylation status of DKK3 plays a role in PiPS-SMCs 
differentiation. 
DKK3 is a glycosylated secreted protein with 4 glycosylation sites. Therefore we 
wondered whether the glycosylation status of DKK3 was important for the 
differentiation of PiPS cells towards SMCs. In order to examine that hypothesis, a 
luciferase assay as well as PNGase F deglycosylation enzyme where utilised. PiPS cells 
were seeded for differentiation of Collagen IV and 24 hours later were transiently 
transfected with a PGL3-Luc-SM22 vector (0.33μg/well) and a PGL3-Renilla vector 
(0.1μg/well) or a TopFlash vector (0.33μg/well) and a PGL3-Renilla vector 
(0.1μg/well). The cells where maintained in DM for an additional 48 hour after which 
they were treated with a concentration of 1 unit/ml of PNGase F for 5 hours. 
Confirmation of successfull deglycosylation of DKK3 is shown in Figure S7. The 
samples were then harvested and the luciferase activity of SM22 and the Wnt reporters 
were measured. Analysis of the samples revealed that deglycosylation of the 
supernantant of PiPS-SMCs during differentiation significantly dereased the reporter 
activity of SM22 (Figure 48). These findings suggest that glycosylation of DKK3 is 
important for transcriptional regulation of SM22 during PiPS-SMCs differentiation. 
Furthermore, the reporter activity of TopFlash was found to be downregulated during 
deglycosylation of DKK3 (Figure 48) postulating that the post translational 
modifications of DKK3 are important for the interactions of the afforementioned protein 















































Figure 48. The reporter activity of SM22 and the Wnt target genes is affected 
by deglycosylation during PiPS-SMC differentiation. PiPS cells were 
differentiated on Collagen IV for 24 hours after which they were transciently 
tranfected with the reporter expression vectors PGL3-Luc-SM22 or ToPFlash 
(0.33μg/well) as well as a PGL3-Renilla expression vector (0.1μg/well). 48 hours 
later the cells were treated with 1unit/ml PNGase F deglycosylation enzyme for 5 
hours after which the samples were harvested and the luciferase enzymatic 
activity was read. The Renilla reading comprised the interal control. The results 
revealed that there is a downregulation in the activity of both the SM22 reporter 
and the reporters of the Wnt target genes (the mean ±SEM of 2 individual 










3.11 PiPS-SMCs displayed SMC properties ex vivo 
To test the functionality of the PiPS-SMCs, an ex vivo model generated in our lab was 
utilised. Fibroblasts or PiPS cells selected with neomycin (25μg/ml) were seeded on a 
decellularised vessel scaffold in a specially constructed bioreactor in which they were 
differentiated using low sheer stress, in DM containing 25ng/ml PDGF-BB. Both 
vessels were harvested 5 days later. The ex vivo PiPS-SMC vessels were then fixed and 
stained positive for a number of SMC markers and exibited the characteristic 
morphology and localization of SMCs in the media of the vessels. However, such 
staining was not obtained after staining of the fibroblast derived vessels (Figure 49). 
Additionally, and in co-operation with Dr. Andriana Margariti, the functionality of 
PiPS-SMCs and PiPS derived ECs (PiPS-ECs) as well as their potential to generate 
functional potent vessels was investigated. A pure population of PiPS cells after 
selection with neomycin (25μg/ml) was seeded on a decellularized vessel in DM 
medium containing PDGF-BB where it was initially differentiated towards SMCs for 48 
hours. The circulating medium was then exchanged to EBM-2 (endothelial specific 
medium) and a second seeding of pure PiPS cells was initiated. The vessels remained 
under constant sheer stress for 5 days after which they were harvested and fixed. 
Normal mouse vessels, decellularized vessles as well as the ex vivo double seeded 
vessels were then stained for Hematoxylin (HE) staining (Figure 50A). The results 
revealed that the re-cellularization of the vessles with PiPS-SMCs and PiPS-ECs 
resulted in vessels that greatly resembled a native mouse artery. Furthermore, double 
indirect immunofluorescence revealed a characteristing staining for the EC specific 
markers CD31 and CD144 and SMC markers SMA and SM22 as well as characteristic 




respecitively)(Figures 50A and 50B). These results indicate the ability of PiPS cells to 
differentiate into both vascular lineages as well as to display vascular properties ex vivo. 
Finally, they also signify the potential of PiPS-SMCs and PiPS-ECs to generate potent 




























Figure 49. PiPS-SMC display SMC properties ex vivo. Ctl cells or PiPSs were 
seeded on a decellularised vessel scaffold which was connected to a specially 
constructed bioreactor and were differentiated for 5 days. The vessels were then 
harvested, fixed and stained for SMA, Calponin, SM22 and SMMHC while DAPI 
was used to indentify the nucelus. Indirect Immunofluorescent imaging revealed a 
characteristic SMC-like morphology and localization of the PiPS-SMCs within 
the media of the vessels. Representative cells that have incorporated withing the 
scafford are annotated with a white arrow. Images were captured using the 

















            
               
 
Figure 50. PiPS-SMCs and PiPS-ECs display SMC and EC properties 
respectively, as well as re-cellularization properties in tissue engineered 
vessels. (A) HE staining of the native, decellularised and double seeded tissue 
engineered vessels. HE staining of the double seeded vessels revealed an 
architecture similar to the one of the native vessel with multiple layers of SMCs 
and a monolayer of ECs. Successful decellularisation is confirmed by the absence 
of cells in the decellularised artery HE staining. (B) and (C) Double seeded 
tissue engineered vessels stained positive for EC and SMC markers. The 
vessels were harvested fixed and stained for SM22/CD31 and SMA/CD144. The 
concomitant expression of SMC and EC markers as well as characteristic 
morphology and localisation of PiP-SMCs and PiPS-ECs withing the media and 
intima respectively was revealed. Images were captured using SP5 confocal 




























The development of iPS cell technology has become a fascinating tool for regenerative 
medicine and may represent an alternative strategy to overcome the limitations that the 
human ESCs present with regards to therapeutic applications in humans. However, the 
exact molecular mechanisms that govern the process of complete transformation of a 
terminally differentiated somatic cell to a pluripotent one are still largely unknown. 
In an attempt to elucidate the molecular changes which fibroblasts undergo on the way 
to pluripotency, a microarray analysis was employed in order to investigate the global 
gene expression of genes in different timepoints during the reprogramming. 
Investigation of the gene expression patterns revealed that during somatic cell 
reprogramming the expression of genes involved in differentiation into specific cell 
lineages is altered from as early as day 4. Further study of the 4 day reprogrammed cells 
revealed that although they display an alternate morphology and express the four 
reprogramming factors (SOX2, OCT4, KLF4, cMYC), they are negative for alkaline 
phosphatase and most importantly they do not form teratoma after transplantation in 
vivo. These cells were thus named Partially iPS or PiPS. Interestingly, although no 
significant changes in the expression of progenitor markers such as CD34, CD133 and 
cKIT were observed, the VEGFR2 (KDR) was found to be upregulated suggesting the 
activation of vascular associated pathways. 
The potential of PiPS cells to differentiate into vascular lineages would provide the 
opportunity to bypass the time consuming generation of iPS cells and obtain functional 
cells without the tumor inducing likelihood of iPS-SMCs.  Therefore, the ability of PiPS 
cells to differentiate toward vascular lineages was assessed by use of a standardized 




PiPS cells successfully differentiated towards SMCs expressing a subset of SMC 
specific markers and exhibiting a characteristic SMC-like morphology. 
While trying to identify the mechanism by which PiPS cells are differentiated to SMCs, 
the expression of a number of genes which were differentially expressed during the 
reprogramming was assessed, and DKK3 was found to be upregulated in PiPS-SMCs. 
Investigation into the mechanism by which DKK3 could be involved in PiPS-SMC 
differentiation revealed that DKK3 is important for PiPS-SMC specific differentiation, 
Furthermore it acts as a cytokine and induces SMC specific regulation by transcriptional 
regulation of SM22 as revealed by Luciferase Reporter Assays. 
Association of DKK3 with the Wnt signalling pathway as a member of the Dickkopf 
family of Wnt inhibitors lead to further investigation of the activation status of the 
aforementioned pathway and possible interaction of DKK3 with any of the Wnt 
components. We found that DKK3 can activate Wnt signalling in PiPS-SMCs leading to 
translocation of the pathways key mediator, β catenin, and induce Wnt specific gene 
expression. Furthermore, we found that DKK3 interacts with the transmembrane protein 
Kremen 1 in PiPS-SMCs suggesting that the activation of Wnt signalling and 
subsequently activation of Wnt specific expression occurs through DKK3-Kremen 1 
binding.  
After elucidation of the molecular mechanism by which DKK3 is regulating PiPS-SMC 
differentiation, ex vivo and in vivo experiments were performed in order to assess the 
SMC properties of the generated cells. A specially constructed bioreactor which hosted 
a decellularized vessel scaffold was utilised for this procedure. Seeding of the PiPS-
SMCs in the decellularized scaffolds and appropriate mechanical stress from the 
bioreactor, lead to incorporation of the aforementioned cells into the media of the 
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 vessels. The cells also exhibited SMC specific properties such as expression of SMC 
specific markers and morphology.  
Finally, decellularized scaffolds which were seeded with PiPS-SMCs, and PiPS-ECs 
generated by Dr. Andriani Margariti were successfully generated, exhibiting properties 
of a potent and functional vessel ex vivo, similar to a native vessel. These findings 
demonstrate not only that PiPS cells can successfully differentiate into both vascular 
lineages, but they are also capable of recapitulating the properties of developmentally 
derived SMCs and ECs ex vivo.  
Therefore, we have developed a method to generate PiPS cells from human fibroblasts 
that can differentiate into vascular cells without the risk of tumorigenesis. PiPS-SMC 
can be generated via a DKK3-Wnt pathway and have a great potential for tissue 













4.1 Short term reprogramming and generation of PiPS cells 
ESCs have been monopolising the field of regenerative medicine for the past decades 
because of their ability to be extensively expanded in culture as well as to differentiate 
into any cell of the 3 germ layers, making them an ideal tool for recapitulating 
developmental processes (Thomson et al., 1998). However, bioethical concerns, 
immunogenicity as well as the possibility of tumor formation rendered the cells risky 
for cell therapy and clinical applications (Knoepfler, 2009). Furthermore, the emergence 
of adult stem cells, despite their self renewal potential and their multipotential 
differentiation abilities which would make them ideal targets for regenerative medicine, 
is not without its limitations. Apart from the evident restricted capacity of 
differentiation when compared to ESCs, their identification and isolation can be 
challenging and those that can be isolated quickly become senesce in vitro (Digirolamo 
et al., 1999)  or generate abnormal karyotypes (Li et al., 2007). 
The generation of iPS cell technology was a breakthrough in the field of regenerative 
medicine. However, even though their differentiation potential seems limitless, issues 
such as low efficiency, tumor formation in vivo, random integration of retroviral vectors 
and the lengthy process of iPS cell line establishment, still needs to be addressed (Okita 
et al., 2007; Yamanaka, 2009).  
Induced pluripotency is a gradual process established in a step-wise and stochastic 
manner. Studies with inducible vectors have shown that during reprogramming, 
intermediate populations that have the ability to ultimately give rise to iPS cells are 
generated (Hanna et al., 2009; Stadtfeld et al., 2008a). We therefore hypothesised that 




to differentiate towards the desired cell type (in this case vascular) under the appropriate 
stimulus or environmental cue.  
Interestingly, microarray analysis revealed that during the early stages of 
reprogramming a number of genes associated with differentiation of specific lineages 
were changed. For instance, genes associated with differentiation of connective tissue, 
muscle cell lines, adipocytes, bone cell, mononuclear cells, osteoclast-like cells or even 
adhesion of endothelial cells, were altered from as early as day 4. Furthermore, 
induction on day 7 of genes such as DNA (cytosine-5-)-methyltransferase 3-like 
(DNMT3L), a gene encoding a nuclear protein with similarities to DNA 
methylatransferase, reinforced the evidence by which reprogramming is supported by 
genome wide remodelling such as DNA methylation and histone modifications. That in 
turn leads to suppression or activation of specific gene subsets (Mikkelsen et al., 2008). 
Finally, during the later stages of reprogramming, like days 14 and 21, a series of genes 
associated with cell lineage differentiation were found to be altered reinforcing the 
hypothesis that during reprogramming, the cells exist in a transient state. 
In accordance to our findings, recent studies have demonstrated that direct conversion 
of fibroblasts into a number of terminally differentiated cells such as blood progenitors 
(Szabo et al., 2010), cardiomyocytes (Efe et al., 2011; Ieda et al., 2010) and neurons 
(Ambasudhan et al., 2011) using defined transcription factors or direct reprogramming, 
is achievable and can prove to be useful for clinical applications. Specifically, Efe and 
his colleagues virally transduced mouse embryonic fibroblasts (MEFs) harbouring a 
Nebulette-LacZ reporter expressed in nascent myocardium with the four reprogramming 
factors and colorimetrically monitored early cardiogenesis. Their results showed that 4 
days of transgenic expression of these factors were sufficient to directly reprogram 
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MEFs into spontaneously contracting patches of differentiated cardiomyocytes over a 
period of 11–12 days (Efe et al., 2011). The aforementioned studies therefore broaden 
the already existing field of iPS cell-factor reprogramming introducing direct 
reprogramming or otherwise known as lineage reprogramming as a new and promising 
field of regenerative medicine.  
In the present study, in an attempt to investigate the transient “unstable” phase the cells 
enter during early reprogramming, a thorough characterisation of 4 day reprogrammed 
human neonatal fibroblasts (PiPS) was conducted. The four transcription factors need 
only be expressed transiently, thus eliminating one of the most prominent limitations of 
iPS cell technology such as viral integration and reactivation of transgenes thus leading 
to tumorigenesis (Okita et al., 2007). Most importantly, both in vitro and in vivo tests 
revealed that PiPS cells, as opposed to their pluripotent derivatives which form 
teratomas (Okita et al., 2008; Yu et al., 2007), have not yet entered the pluripotency 
stage and thus are unable to result to tumorigenesis even after 2 months of being 
transplanted into SCID mice. Finally, despite the lack of alteration in the expression 
patterns of vascular progenitor markers such as CD34 and cKIT, increased expression 
of KDR, the first molecule to be secreted during development with specificity to the 
endothelium (Carmeliet et al., 1996) indicates that a vascular program in PiPS cells has 
already been initiated after 4 days of reprogramming.  
It is therefore safe to presume that during the four days of reprogramming and due to the 
expression of the four transcription factors, epigenetic modifications which allow the 
PiPS cells to enter a transient state with increased plasticity, take place. As previously 
shown, such epigenetic events could be demethylation of pluripotency specific genes 
and methylation of promoters governing somatic specific genes (Maherali et al., 2007).  
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It has previously been demonstrated that when stable iPS  clones and aberrantly 
reprogrammed iPS cells were compared to ESCs, the stable iPS cell clones existed in an 
epigenetically similar state as ESCs whereas the semi-reprogrammed iPS cells 
presented with hypermethylation of pluripotency loci and were closer to MEFs (Mattout 
et al., 2011). Therefore, it could be suggested that in the case of PiPS, epigenetic 
modifications which allow the activation of cell fate determining genes may occur 
without being followed by activation of pluripotency loci, which is a later event during 
reprogramming (Stadtfeld and Hochedlinger, 2010) making the cells more susceptible 
to receiving specific cell lineage stimulus and differentiate into the desired cell line. 
Naturally, a series of experiments assessing the epigenetic status of PiPS cells would be 
required to elucidate the reason behind their plasticity.  
The results discussed above provide for the first time a thorough characterisation of 
semi-reprogrammed cells, presenting a cell type that has the plasticity to directly 
differentiate towards a variety of cells but lacks the limitations of re-differentiated iPS 











4.2 Differentiation of PiPS cells to SMCs 
4.2.1 Collagen IV and PDGF 
As previously mentioned, the microenvironment in which stem cells reside during 
development, determines their differentiation into different cell types. Such 
microenvironment cues include cytokines or growth factors, the ECM, mechanical 
forces and communication with adjacent cells (Xiao et al., 2010). In the present study, a 
model of differentiation established in our laboratory (Xiao et al., 2007) including 
Collagen IV and PDGF was utilised in order to induce differentiation of PiPS to SMCs. 
Accumulating evidence concerning Collagen IV suggest that the aforementioned 
component of the ECM plays an important role in SMC differentiation from pluripotent 
cells. More specifically, it has been demonstrated that Sca-1
+
 progenitor cells isolated 
with magnetic beads form pre-differentiated ESCs could differentiate into SMCs 
through interaction with Collagen IV and integrin. Pre-treatment of ECS with antibodies 
against Collagen IV significantly inhibited SMC marker expression (Xiao et al., 2007). 
Further studies have also demonstrated that Collagen IV induced the expression of 
mesodermal genes specific to hematopoietic, endothelial, and SMCs and also a panel of 
trophoectoderm-restricted markers (Schenke-Layland et al., 2007).  In our study, 
Collagen IV seemed to favour the PiPS cell differentiation to SMCs with PiPS-SMCs 
expressing a number of specific SMC markers such as SMA, Calponin and SM22 
reinforcing the notion that Collagen IV is a key regulator of SMC differentiation.  
PDGF-BB has previously been reported to be a key regulator of SMC differentiation 
(Nishishita and Lin, 2004). Additional studies have also demonstrated that a high purity 
of SMC was obtained by ESCs (>95% of cells were positive of SMC markers) after 
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PDGF-BB treatment (Xiao et al., 2007). In contrast, reports showed that treatment of 
mature SMCs with PDGF-BB dramatically reduced SMA synthesis in the prolonged 
absence of serum thus suppressing SMC differentiation (Holycross et al., 1992). In the 
present study, no significant changes in expression of SMC specific markers were 
identified when PDGF-BB was omitted from the culture medium possibly suggesting 
that the PDGF pathway is not one of the key effectors during PiPS-SMC differentiation. 
 
4.2.2 Generation of PiPS-SMCs 
As shown above PiPS cells were successfully differentiated to SMCs using a Collagen 
IV/PDGF differentiation protocol. The cells expressed a panel of SMC specific markers 
and also exhibited a SMC-like morphology. The efficiency of PiPS-SMCs was 
approximately 30% reflecting the efficiency of the successfully reprogrammed cells. 
Upon selection of PiPS cells, the PiPS-SMCs efficiency appears to be higher (Margariti 
et al., 2012). Interestingly, induction of SMC marker mRNA at day 4 of PiPS cell 
differentiation was found to be greater than that of 6 day differentiated iPS cells under 
the same differentiation conditions. However, a more thorough investigation of the 
relative efficiency of SMC generation via the PiPS versus iPS cell is essential and is yet 
to be determined. Vascular SMCs play a critical role in both the physiological 
maintenance of the cardiovascular system as well as in the pathogenesis of vascular 
diseases, such as atherosclerosis, in adults (Campbell and Campbell, 1994; DeRuiter et 
al., 1997; Gittenberger-de Groot et al., 1999). 
It has previously been shown that ESCs (Xiao et al., 2007; Xie et al., 2009), adult stem 
cells (Suzuki et al., 2010) and iPS cells (Moretti et al., 2010; Taura et al., 2009b) can 
successfully differentiate to SMCs. Although iPS cell and adult stem cell differentiation 
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to SMCs would provide an autologous source of SMC for patient treatment without risk 
of rejection, aberrant differentiation of iPS cells and danger of tumor formation as well 
as the need for optimization and isolation of adult stem cells and in vitro culturing 
techniques, renders them unsafe and inefficient for clinical applications.  
Furthermore, the immunogenicity issue of ESC derived SMCs as well as the possibility 
of tumorigenesis after in vivo transplantation remains a concern.   
As mentioned in the results section, although PiPS cells did not display changes in 
expression of progenitor markers such as cKIT, CD34 and CD133, the VEGFR2 (KDR) 
was found to be significantly upregulated after 4 days of reprogramming, suggesting a 
potential of these cells to differentiate into vascular cells. However, parallel studies 
within our laboratory have shown that PiPS can differentiate into cell lineages such as 
chondrocytes, adipocytes, chondrocytes and neurons in response to specific stimulus, 
indicating a more broad differentiation potential, beyond the limits of vascular lineages. 
Further studies will demonstrate the functional abilities of these cells.   
Therefore, the generation of PiPS-SMCs has several implications. Initially, the time 
from reprogramming to obtaining SMC is significantly shorter (less than 2 weeks) when 
compared to the time consuming generation of iPS cells and re-differentiation to the 
desired cell line. This offers the opportunity to generate patient specific cells quickly 
and efficiently for personalised cell therapy. Additionally, one of the main concerns of 
stem cell and iPS cell therapy, which is tumorigenesis, is eliminated due to the fact that 
the purity of the differentiated cells is no longer an issue since PiPS cells do not form 
teratomas after subcutaneous implantation to SCID mice. Moreover, they are generated 
by using a non integrative method with only transient expression of the four 
reprogramming factors, and if required, they can be selected to obtain populations of 
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high purity, thus making them a more accessible and reliable source of cells for use in 
regenerative medicine. 
As demonstrated by our ex vivo experiments, PiPS-SMCs hold great promise for use in 
tissue engineering where stem cells and iPS cells prove to be unsafe and inefficient for 
clinical applications. Furthermore, their potential towards vascular injury repair and cell 
replacement therapies is vast.  
Their utilisation in mimicking SMC related genetic disorders in vitro as well their 
potential for cell based gene therapy and autologous transplantation, can revolutionise 
the field of disease modelling as well as tissue engineering.  
It can therefore be concluded that the strategy we used here for the first time to generate 
PiPS-SMCs is a fast, simple, efficient and reproducible method for obtaining SMCs, 
which can comprise a valuable tool for regenerative medicine, cell replacement therapy 
as well as tissue engineering. 
4.3 The role of DKK3 in PiPS-SMC differentiation 
Generation of PiPS-SMCs, lead to investigation of the underlying molecular mechanism 
of SMC differentiation. While searching for a possible candidate responsible to induce 
this differentiation, the involvement of a number of genes found to be differentially 
expressed in the microarray analysis, was investigated during differentiation of PiPS 
cells to SMCs. DKK3, was found to be upregulated during PiPS-SMC differentiation in 
parallel with the upregulation of SMC markers. Upregulation of DKK3 lead to increase 
of SMC specific markers, while downregulation of DKK3 by shRNA caused a 
significant downregulation of SMC markers in differentiating PiPS-SMCs. These data 
indicate a crucial role of DKK3 in PiPS-SMC differentiation. 
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DKK3 is a member of the Dickkopf family of Wnt inhibitors. The hallmark of the DKK 
family is their ability to modulate Wnt signalling and since Wnt signalling is involved 
in numerous processes during development, in the adult and in disease (Cadigan and 
Liu, 2006; Cadigan and Nusse, 1997; Moon et al., 2004), it is not surprising that one 
main function of DKKs is to control cell fate in vertebrates by highly regionalized 
expression (Niehrs, 2006). Although DKK1 is involved in key developmental processes 
such as antero-posterior (a-p) axial patterning (Glinka et al., 1998), limb formation 
(Mukhopadhyay et al., 2001), vertebral development (MacDonald et al., 2004) and 
concomitantly with DKK2 in osteoblast differentiation (van der Horst et al., 2005) as 
well as eye and skin development (Kazanskaya et al., 2000; Mukhopadhyay et al., 
2006), DKK3 has mainly been implicated in cancer disease (Hoang et al., 2004; 
Kobayashi et al., 2002; Tsuji et al., 2000). Interestingly, it wasn’t until recently that 
DKK3 was associated to tumor angiogenesis and was considered a putative pro-
angiogenic factor and marker for neo angiogenesis (Zitt et al., 2008) as well as a 
differentiation factor involved in the remodelling of the tumor vasculature (Fong et al., 
2009). Furthermore, it has been reported that elevated expression of DKK3 has been 
detected in tissues that mediate epithelial to mesenchymal transformation while in situ 
hybridization studies have revealed high levels of expression in the heart, brain and 
spinal cord. (Krupnik et al., 1999; Monaghan et al., 1999). Finally, DKK3 has been 
shown to modulate FGF and Activin/Nodal signalling to regulate mesoderm induction 
during early Xenopus development. (Pinho and Niehrs, 2007). Therefore, in the present 
study, demonstration of the importance of DKK3 in the differentiation towards SMCs, 
cells that can derive from both mesodermal and mesenchymal origins, comprises a 




4.4 Underlying mechanism of DKK3-mediated SMC differentiation 
 
In the present study, it is demonstrated that DKK3 can regulate the transcriptional 
patterns of SM22 via promoter activation. It is also demonstrated that DKK3 can act as 
a cytokine and that it can positively modulate canonical Wnt signalling and induce β 
catenin translocation and ultimately induction of Wnt signalling target genes. Finally, 
we also demonstrated that DKK3 interacts with the transmembrane protein Kremen 1 
and that the glycosylation status of DKK3 is important for the transcriptional induction 
of SM22 as well as the activation of Wnt signalling.  
In agreement with our findings, it has previously been remonstrated that Wnt3a 
enhances both genomic SM22 histone H3 acetylation and β catenin association, 
hallmarks of transcriptional activation. Analysis of a series of SM22 reporter constructs 
indicated that Wnt3a-regulated DNA transcriptional activation, occurred between 
nucleotides −213 to −192 relative to the transcription initiation site and DNA-protein 
complexes assembled on this element were disrupted with antibodies to β catenin, 
Smad2/3 and TCF7. Finally, mutation of a CAGAG motif within this region abrogated 
recognition by β-catenin and other DNA-binding proteins while RNAi “knockdown” of 
β catenin inhibited Wnt3a induction of SM22, suggesting that Wnt/β-catenin signalling 
controls SM22 gene transcription (Shafer and Towler, 2009). Therefore, transcriptional 
activation of SM22 by DKK3 in our system was postulated to occur through activation 





After employment of luciferase reporter assays as well as investigation of the 
transcriptional levels of Wnt target genes, it was shown that Wnt signalling is activated 
by DKK3 in our system of PiPS-SMC differentiation. In agreement with our studies it 
has previously been shown by Nakamura et al. that Wnt signalling is potentiated due to 
upregulation of DKK3 transcripts during photoreceptor death in a mouse model of 
retinal degeneration. Although DKK3 potentiated Wnt signalling in Müller glia cells 
and HEK293 cells it failed to do so in COS7 cells (monkey kidney cells), indicating a 
cell type specific regulation of Wnt signalling (Nakamura et al., 2007).  
As mentioned during the introduction, DKK3 is a highly N-glycosylated secretory 
protein (Krupnik et al., 1999). However, DKK3 specific receptors have not yet been 
identified. Our findings show that the levels of secreted DKK3 are elevated during 
differentiation to PiPS-SMC. Furthermore, stimulation of PiPS-SMC cells with human 
recombinant DKK3 further induced the expression of SMC specific markers suggesting 
that secreted DKK3 plays a role in the differentiation of PiPS to SMCs.  
The role of secreted DKK3 in the induction of SMC differentiation suggests that the 
protein could have pharmacological implications for in vitro and in vivo applications. 
Recent studies have shown that adult stem cells/progenitor cells are resident within the 
adventitia of the vessel wall that have the potential to give rise to both endothelial and 
SMCs (Hu et al., 2004; Zengin et al., 2006). Evaluation of the potential of DKK3 to 
induce SMC differentiation of the resident, within the adventitia, progenitor cells in the 
form of a soluble protein could lead to the utilisation of a novel tool for directed tissue 




It has recently been demonstrated that DKK3 could selectively be internalised by EBs 
during the differentiation of iPS cell colonies and that this internalization was confirmed 
to be endocytosis (Kataoka et al., 2010). According to related studies, internalization of 
the DKK1/LRP5/6 complex leads to modulation of the Wnt/β-catenin pathway 
(Yamamoto et al., 2008), therefore the authors postulated that DKK3 could function in a 
similar way, thus strongly supporting the existence of a DKK3 specific receptor. 
In an attempt to identify potential interacting partners of DKK3 with Wnt, Nakamura 
and his colleagues used a series of biochemical and functional assays to investigate the 
interaction between DKK3 and the Wnt pathway receptors Kremen1 (Krm1), Kremen 2 
(Krm2) and low-density lipoprotein receptor-related protein 6 (LRP6). It was shown 
that although DKK3 can interact with both Krm1 and Krm2 it does not bind with LRP6 
suggesting a novel mechanism by which DKK3 is potentiating Wnt signalling. 
Furthermore they demonstrated that binding of DKK3 with Kremen 1 occurred within 
the cells in a perinuclear pattern (Nakamura and Hackam, 2010). Since Kremens 
contribute to inhibition of Wnt signalling whereas LRP5/6 participates in its activation, 
it was postulated by the authors that the potentiation of Wnt by DKK3 could be a result 
of two scenarios. Firstly, isolation of the DKK3 and Kremen protein complex in 
intracellular membranes, such as in the ER and Golgi, resulted in reduced surface 
expression of Kremen receptors, a notion that was supported by previous evidence by 
Mao et al where recombinant DKK3 failed to bind to surface-expressed Kremen 
receptors in HEK293 cells (Mao et al., 2002). The second possibility is that DKK3 and 
Kremen complexes are co-expressed on the membrane surface and DKK3 physically 
blocks the ability of the aforementioned proteins to inhibit the Wnt pathway hence 
creating a favourable environment for its activation (Nakamura and Hackam, 2010). 
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Therefore in accordance to previously published studies, our data indicate that DKK3 
potentiation of Wnt signalling during PiPS-SMC differentiation occurs through 
interaction of DKK3 with Kremen 1. However, further elucidation as to the localization 
of said interaction needs to be conducted. 
Finally, in the present study, deglycosylation experiments revealed that the 
glycosylation status of DKK3 is important for PiPS-SMC differentiation and Wnt 
activation. Although it has previously been shown that the glycosylation state of DKK3 
or Kremen proteins does not affect their interaction (Nakamura and Hackam, 2010), we 
have demonstrated by using luciferase reporter assays that treatment of PiPS-SMCs 
with PNGase F lead to downregulation of the SM22 promoter activity as well as the 
TopFlash reporter activity. These data come to add to the already diverse and 
















Figure 51. Schematic representation of the generation of PiPS cells as well as 
the mechanism by which DKK3 governs PiPS differentiation towards SMCs. 
PiPS cells, given the appropriate stimulus can also differentiate into functional 










4.5 PiPS-SMC tissue engineered vessels 
One of the most promising and at the same time challenging fields of regenerative 
medicine is the generation of cell based tissue engineered vascular grafts that would 
retain the mechanical properties of native vessels in vivo for substantial periods of time. 
The vascular wall, with its unique mechanical properties, presents a challenge for tissue 
engineering approaches, since the source of the cells that could live up to the task is 
often an obstacle.  
Currently, the 2 strategies used to generate tissue engineered vascular grafts are cell 
seeded scaffolds (L'Heureux et al., 2006; Niklason et al., 1999) and cell self-assembly 
(L'Heureux et al., 1998). Recent studies have shown that mesenchymal stem cells were 
directed to form SMC-like and EC-like cells on a decellularised ovine carodid artery 
which was then implanted into an ovine host and contributed to vascular tissue 
regeneration (Zhao et al., 2010). Furthermore, adipose derived stem cells that were 
shown to differentiate into SMCs were seeded in a poluglycolic acid mesh and were 
exposed in pulsatile stimulation in a bioreactor where it exhibited improved 
biomechanical properties and resembled native vessels (Wang et al., 2010). In 
accordance to the previously publish data, we have shown here that decellularised 
vessel scaffolds within a specially constructed bioreactor were seeded with PiPS cells 
which were forced to differentiate ex vivo into SMCs by application of low sheer stress. 
The tissue engineered vessels which were harvested and stained 5 days later revealed 
that the PiPS-SMCs had incorporated within the scaffold and stained positive for SMC 
specific markers as indicated by indirect immunofluorescent staining. Furthermore, the 




Similarly, double seeded decellularised vessels where the first population of cells 
seeded were directed to differentiate towards SMCs in DM medium within the 
bioreactor, whereas the second was directed to differentiate towards ECs in EMB-2 
medium, were generated. In this case, a potent vessel exhibiting architecture similar to 
the one of the native vessel was generated.  As indicated by both HE staining as well as 
double indirect immunofluorescent staining PiPS-SMCs occupied the media of the 
vessel while PiPS-ECs the incorporated within the intimal region. Recent unpublished 
data within our laboratory reveal that double seeded recellularised vessels engrafted into 
mice are patent in vivo, with a 60% survival rate after 3 weeks of implantation, 
suggesting that PiPS-SMCs and PiPS-ECs are capable of maintaining vascular stability 
and tone These results suggest that PiPS cells are not only capable of differentiating 
towards vascular lineages with SMC and EC properties ex vivo, but also provide a new 
source of cells for efficiently and rapidly generating autologous patent tissue engineered 
vascular grafts for application in regenerative medicine.  However, comparison of in 
vivo engrafted TEVGs derived from iPS-SMCs and iPS-ECs would give us a more clear 
understanding of the functional differences between PiPS-SMCs and iPS-SMCs. 
 
4.6 In vivo applications of PiPS-SMCs 
Within the human body SMCs can be found in various tissues such as airways, the 
vasculature, the digestive tract and the genitourinary system. The SMCs in these tissues 
have the ability to contract and relax rapidly, contributing to physiological functions 
such as peristalsis, and simultaneously playing a critical role in the dimension change of 
hollow organs for regulating airflow, blood flow, organ perfusion and so on (Petschnik 
et al., 2010; Tanaka et al., 2008).  
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Therefore, all of the organs mentioned above could be potential targets for SMC 
replacement therapies in case of organ failure. Furthermore, SMCs could be used for 
cell replacement therapy in disorders such as auto-immune hepatitis (Dawkins and 
Joske, 1973), where anti smooth muscle antibodies are directed against actin, troponin 
and tropomyosin (Czaja et al., 1996) and other auto-immune disorders where SMCs 
could be targeted, such as Systemic lupus erythematosus, where 
the body’s immune system can attack the heart and blood vessels among other organs 
and tissues (Rahman and Isenberg, 2008). 
Although SMCs for the above applications could be obtained by dissociation of blood 
vessels and other organs, mature SMCs exhibit limited ability for proliferation and the 
necessary surgical procedure may cause complications at the donor site (Suzuki et al., 
2010). Therefore, PiPS-SMCs are a promising source of cells with many advantages. As 
opposed to stem cell and iPS cell derived SMCs, where as we have thoroughly 
discussed immunogenicity, tumorigenesis as well as low efficiencies and time 
consuming protocols comprise serious limitations for human applications, PiPS 
differentiation to vascular lineages constitutes a safe and efficient alternative for human 
in vivo applications.   
 
4.7 Limitations of PiPS generation 
Although the generation of PiPS cells and PiPS cell derived vascular cells comprises an 
easily repeatable system for the generation of cells with a striking potential for 




The efficiency of the protocol for the generation of PiPS cells and thus their successful 
response to the appropriate stimulus, highly depends on the delivery of the 
reprogramming transcription factors within the fibroblasts. Transfection efficiencies 
after nucleofection of human fibroblasts in our culture usually range between 30-33% 
(Margariti 2012, PNAS in press) which leads to the generation of smaller population of 
PiPS than the one desired. Therefore, the generation of techniques that would 
accommodate the need for high transfection efficiencies within our system would yield 
larger populations of PiPS cells available for differentiation. Furthermore, the initial 
number of fibroblasts required for the generation of an adequate number of PiPS cells 
would be smaller which would prove really useful in clinical applications since smaller 
samples from patient biopsies would be adequate and cells will not require prolonged 
culture expansions. 
Another concern, directly deriving from the ability to yield high nucleofection 
efficiencies is the purity of the PiPS cell population. Although impure populations of 
PiPS cells would not cause concern of tumorigenesis as we have already demonstrated 
during the characterization of PiPS cells (paragraph 3.2), impurity of the population 
would lead to lower efficiencies in the generation of differentiated cells both in vitro 
and in vivo. Selection with neomycin to obtain pure populations is indeed a successful 
solution, however, antibiotic selection can sometimes have undesired effects in the cells 
such as apoptosis of the transfected cells, toxicity, and decrease of proliferation (Gu et 
al., 1992; Kim et al., 1998). 
Subsequently, bypassing technique limitations such as reprogramming efficiencies and 
cell selection of successfully PiPS cells, would lead to an abundant source of cells with 
vasculogenic potential capable of safe application in regenerative medicine. 
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4.8 Future work 
4.8.1 Generation of PiPS cells from alternative donor cells 
In the present study, we demonstrated that “plastic” cells that have the ability to 
differentiate towards SMCs under the appropriate stimulus can be generated by short 
term reprogramming after overexpression of the four reprogramming factors. It would 
therefore be interesting to demonstrate that application of this protocol to other 
terminally differentiated cells such as ECs, combined with the correct environmental 
cues, could lead to direct reprogramming of one somatic cell type to another. This 
would suggest that shot term reprogramming is a universal process not only limited to 
fibroblasts broadening the application of PiPS cell generation from additional somatic 
cell sources. Furthermore, in case of successful generation of PiPS cells from alternative 
sources with the same properties as our already established PiPS, it would be interesting 
to investigate whether application of a SMC differentiation protocol could lead to 
successful generation of SMC with DKK3 mediating that differentiation. 
4.8.2 Comparison of PiPS-SMCs with iPS-SMCs 
To further characterize the PiPS cell model, it would be informative to compare PiPS 
and iPS in terms of gene expression (arrays), histone modifications, as well as the 
differentiation potential of the two populations towards SMCs. This information will 
elucidate any differences in terms of incidence, plasticity, maturation and function. 
Moreover, cell-based assays could be performed to assess maturity and functionality of 
PiPS and iPS derived SMCs. Finally, the functionality of these cells should be assessed 




4.8.3 Direct generation of SMC from fibroblasts through DKK3 
As it was demonstrated in the previous chapters, DKK3 is important for the induction of 
PiPS-SMCs by transcriptional activation of SM22 through potentiation of the Wnt/β 
catenin pathway. DKK3 exhibits a temporally and spatially regulated expression during 
development with involvement in the mesenchyme (epithelial-mesenchymal transition) 
as well as induction of the mesoderm (Monaghan et al., 1999; Pinho and Niehrs, 2007). 
It would therefore be interesting to investigate whether DKK3 could be sufficient to 
initiate a SMC specific program and transform fibroblasts into functional SMCs, 
bypassing the PiPS generation and eliminating the use of the reprogramming factors. 
Direct generation of SMC from one somatic cell type to another through expression of 
DKK3 would identify it as a global regulator of SMC differentiation, with great 
pharmacological potential for localised vascular repair. 
4.8.4 Regulation of DKK3 
Although, DKK3 has mostly been shown to be negatively regulated by histone 
modifications or promoter hypermethylations in cancers (Veeck and Dahl, 2012) it has 
recently been demonstrated that a cluster of miRNAs regulated by MYCN inhibited the 
secretion of DKK3 in neuroblastoma tumors. It was also found that DKK3 was 
expressed in the primary neuroblastoma endothelium but was absent in the tumors 
expressing MYCN (Haug et al., 2011). Interestingly, very little is known about the 
molecular mechanisms that induce the expression of DKK3. Therefore, it would be very 
interesting to investigate how DKK3 is positively regulated in our system leading to 





4.8.5 Localization of the interaction between Kremen 1 and DKK3 
As previously discussed, although the interaction between Kremen 1 and DKK3 has 
been demonstrated, there are 2 possibilities as to where this interaction may occur 
(Nakamura et al., 2007). One possibility would require the interaction of the 
aforementioned proteins to occur in the cell surface, where DKK3 would occupy 
Kremen 1 receptors making them unable to inhibit Wnt signalling, thus creating a 
favourable environment for its activation. The second possibility would require DKK3 
to bind Kremen 1 in the cytoplasm in a perinuclear pattern, inhibiting its externalization 
to the cell surface and yet again potentiating Wnt signalling (Nakamura et al., 2007). 
Since DKK3 in our study has been found to be localised in a perinuclear pattern in both 
ctl and PiPS-SMCs, but was also found to have a role as a cytokine during PiPS-SMC 
differentiation, it would be interesting to identify the localisation of DKK3-Kremen 1 







































       
Figure S1. Microarray analysis. (A) Microarray analysis showing the 
differential gene expression between control cells and sample cells at 4, 7, 14, 
and 21 days of reprogramming. Microarray analysis was performed in 
triplicates. (B) Functional classification of the genes altered at reprogramming 
days 4, 7, 14 and 21, analysed using the Ingenuity Systems Software. It is 
noted that genes differentially expressed during cell reprogramming are involved 







Table S1: Microarray analysis 




Regulation RefSeq ID 
770615 10.464787 up NM_002701.4 5460 POU5F1 
6620170 7.6432085 up NM_000517.3 3040 HBA2 
1690066 6.730706 up NM_002462.2 4599 MX1 
5340017 6.6276045 up NR_002196.1 283120 H19 
290136 6.079792 up NR_002304.1 5462 POU5F1P1 
2570154 5.9512553 up NM_003480.2 8076 MFAP5 
110181 5.403457 down NM_018689.1 57214 KIAA1199 
270152 5.3665814 up NM_003486.5 8140 SLC7A5 
2000148 5.2977405 up NM_001548.3 3434 IFIT1 
2190674 5.295693 up NM_000599.2 3488 IGFBP5 
2120524 5.142462 up NM_000599.2 3488 IGFBP5 
4780754 5.1085076 up XR_017655.1 645682 LOC645682 




2030577 4.786988 up NM_000362.4 7078 TIMP3 
6620487 4.645717 down NM_002993.2 6372 CXCL6 
3800161 4.6291366 up NM_005556.3 3855 KRT7 
5890347 4.6051726 up NM_017671.4 55612 FERMT1 
2100767 4.537159 down NM_130386.1 81035 COLEC12 
1010246 4.3276334 up NM_022872.2 2537 IFI6 
3420605 4.305336 up NM_007036.3 11082 ESM1 
6450746 4.0860243 up NR_002304.1 5462 POU5F1P1 




7320561 4.0224643 up NM_016817.2 4939 OAS2 
7650296 3.978758 down NM_133505.2 1634 DCN 
6480468 3.9634292 down NM_018476.3 55859 BEX1 
7550484 3.8748736 down NM_002727.2 5552 SRGN 
50368 3.8484042 down NM_001920.3 1634 DCN 
4280739 3.8371818 down NM_153000.3 147495 APCDD1 
3990170 3.8250356 up NM_005532.3 3429 IFI27 
5090215 3.7745323 down NM_022873.2 2537 IFI6 
360500 3.685463 down NM_002727.2 5552 SRGN 
3870338 3.6804771 up NM_006820.1 10964 IFI44L 
6860482 3.5597389 up NM_017912.3 55008 HERC6 
7610131 3.4570007 down NM_001430.3 2034 EPAS1 
1660673 3.3401217 down NM_032623.2 84709 OSAP 




5860630 3.3157146 down NM_016557.2 51554 CCRL1 
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1170709 3.3094552 up NM_001792.2 1000 CDH2 
870338 3.2915385 up NM_001964.2 1958 EGR1 




520408 3.2206852 up NM_001549.2 3437 IFIT3 
6250563 3.2015371 down NM_004105.3 2202 EFEMP1 
6590132 3.1604493 up NM_000598.4 3486 IGFBP3 
1030333 3.1129954 down NM_002982.3 6347 CCL2 








2940577 3.0694492 down NM_021979.3 3306 HSPA2 
2640735 3.02706 up NM_003670.1 8553 BHLHB2 
3830608 3.0222054 down NM_032623.3 84709 OSAP 
6840674 3.0089538 up NM_007150.2 7739 ZNF185 
7320669 2.9833608 down NM_015430.2 25891 
DKFZP586H212
3 
1070450 2.9692478 down NM_080591.1 5742 PTGS1 
1710142 2.9682157 up NM_005613.3 5999 RGS4 
7160253 2.962864 down NM_002290.2 3910 LAMA4 
1300326 2.9542146 up NM_000459.1 7010 TEK 
2600747 2.9455464 up NM_001547.4 3433 IFIT2 
1240142 2.9283273 up NM_017654.2 54809 SAMD9 
4040576 2.903735 down NM_000600.1 3569 IL6 
2100196 2.902231 up NM_005101.1 9636 ISG15 
360047 2.8936307 down NM_002048.1 2619 GAS1 
6620121 2.885797 down NM_005623.2 6355 CCL8 
7570176 2.8760169 up NM_000459.2 7010 TEK 
620102 2.8656907 up NM_005434.3 7851 MALL 
3400019 2.863984 up NM_002923.1 5997 RGS2 
870242 2.8310091 down NM_152999.3 261729 STEAP2 
4050326 2.8198087 down NM_139125.2 5648 MASP1 
1940162 2.7778716 down NM_004120.3 2634 GBP2 
580739 2.7288463 down NM_001996.2 2192 FBLN1 
290292 2.7286227 down NM_152999.2 261729 STEAP2 
6040494 2.7264404 down NM_006487.2 2192 FBLN1 




450189 2.6990933 up NM_199139.1 54739 XAF1 
2490364 2.6477358 down NM_002345.3 4060 LUM 




1260040 2.6160069 down NM_004105.3 2202 EFEMP1 
5890139 2.6075144 down NM_198148.1 119587 CPXM2 
430446 2.6060336 up NM_002281.2 3887 KRT81 
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6580551 2.6017988 up BX097797 
  
2640286 2.5986402 up NM_000517.3 3040 HBA2 
2570300 2.5933468 up NM_006417.3 10561 IFI44 
1570553 2.5871594 down NM_000584.2 3576 IL8 
1450400 2.587131 up NM_024786.1 79844 ZDHHC11 
3390372 2.568821 up NM_001843.2 1272 CNTN1 
4480035 2.5574949 up NM_005824.1 10234 LRRC17 
5090079 2.5520258 down NM_198594.1 114897 C1QTNF1 
5670674 2.5359259 down NM_000902.3 4311 MME 
1260138 2.5279663 down XM_941135.2 651872 LOC651872 
1470669 2.5154235 down NM_002160.2 3371 TNC 
7650672 2.5149841 down NM_012098.2 23452 ANGPTL2 




2680110 2.5071032 down NM_014220.2 4071 TM4SF1 
5700725 2.50364 up NM_033255.2 94240 EPSTI1 
4860224 2.5012639 up NM_004184.3 7453 WARS 
1340743 2.5006793 down NM_000584.2 3576 IL8 
6180554 2.4944072 down NM_153366.2 79987 SVEP1 
3460520 2.489744 up NM_001759.2 894 CCND2 
5550719 2.4882517 down NM_133503.2 1634 DCN 
6760037 2.4806926 down NM_206929.1 54843 SYTL2 
3830762 2.4640367 down NM_181724.1 338773 TMEM119 
5090671 2.4625998 up NM_004864.1 9518 GDF15 
5080139 2.4395237 up NM_002771.2 5646 PRSS3 
2480577 2.4282553 down NM_002600.3 5142 PDE4B 
4610431 2.4206407 up NM_001615.3 72 ACTG2 
5490408 2.4136531 down NM_005195.3 1052 CEBPD 
2680021 2.4058728 up NM_018421.2 55357 TBC1D2 
2060202 2.4041066 up NM_001884.2 1404 HAPLN1 
2370670 2.4029698 down NM_001733.4 715 C1R 




2370132 2.3995693 down NM_002546.3 4982 TNFRSF11B 
7210681 2.397199 up NM_006033.2 9388 LIPG 
6860347 2.3878953 down NM_017709.3 54855 FAM46C 
1690630 2.3793766 down NM_153690.4 131583 FAM43A 
5260474 2.377786 down NM_001733.4 715 C1R 
5490470 2.3755574 up NM_002463.1 4600 MX2 
3850692 2.372314 up NM_016270.2 10365 KLF2 
5720482 2.3619733 up NM_016323.2 51191 HERC5 
4280113 2.352967 down NM_020529.1 4792 NFKBIA 
7320382 2.3403485 up NM_030674.3 81539 SLC38A1 
7150019 2.333712 down NM_015441.1 25903 OLFML2B 
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3930551 2.3254528 up NM_018324.1 55301 OLAH 




3780193 2.311844 up NM_032738.3 84824 FCRLA 
940274 2.311018 down NM_000167.3 2710 GK 
2970019 2.3073983 up NM_003543.3 8365 HIST1H4H 
6980458 2.2985115 down NM_002153.1 3294 HSD17B2 
770408 2.293003 up NM_000602.1 5054 SERPINE1 
4150369 2.2865605 down NM_203391.1 2710 GK 
3710068 2.2608845 up NM_173701.1 7453 WARS 
5960438 2.2539449 down NM_139125.2 5648 MASP1 
3450180 2.2480204 up NM_002534.2 4938 OAS1 
3130240 2.24696 down NM_006206.3 5156 PDGFRA 
1260669 2.2418833 down NM_013434.4 30818 KCNIP3 
5910113 2.2399476 up NM_004385.2 1462 VCAN 
4150048 2.2323222 up NM_001444.1 2171 FABP5 
4670059 2.2269552 down NM_133646.2 51776 ZAK 
3170136 2.2082808 up NM_152703.2 219285 SAMD9L 




670386 2.197987 up NM_181353.1 3397 ID1 
5090156 2.1966922 down NM_182744.1 4681 NBL1 




6220746 2.1921287 up NM_006851.2 11010 GLIPR1 
2450435 2.1912944 down DN997246 
  
1230538 2.184826 up NM_032727.2 9118 INA 
6660601 2.174433 up NM_002133.1 3162 HMOX1 
4180307 2.1695504 down NM_014862.3 9915 ARNT2 
630609 2.1676695 up NM_022166.3 64131 XYLT1 
5720356 2.1654174 up NM_005092.2 8995 TNFSF18 
6510377 2.1577802 up NM_016639.1 51330 TNFRSF12A 
3360224 2.1443355 down NM_002421.2 4312 MMP1 
1980379 2.1277287 down NM_054110.3 117248 GALNTL2 
5080543 2.1243496 up NM_006528.2 7980 TFPI2 
6660131 2.1088002 up NM_014399.3 27075 TSPAN13 
6400176 2.1042762 up NM_004029.2 3665 IRF7 
4830685 2.1023817 down NM_006486.2 2192 FBLN1 
380370 2.1020696 up NM_016391.3 51491 HSPC111 
5670465 2.1019454 down NM_001124.1 133 ADM 




10768 2.0864952 up NM_004737.3 9215 LARGE 
3310504 2.0849087 down NM_002612.3 5166 PDK4 
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6840075 2.0837045 up NM_000270.1 4860 NP 
3870253 2.076963 down NM_000609.4 6387 CXCL12 
6840626 2.0762444 down NM_000962.2 5742 PTGS1 
2340072 2.0742311 up NM_022750.2 64761 PARP12 




7100010 2.0730824 down NM_005380.4 4681 NBL1 
5550220 2.067766 up NM_006392.2 10528 NOL5A 
670041 2.0630193 up NM_144497.1 9590 AKAP12 
4590370 2.0619998 up NM_006516.1 6513 SLC2A1 
7100139 2.0617127 down NM_198392.1 6943 TCF21 
10414 2.0589063 down NM_004219.2 9232 PTTG1 
6020255 2.0554085 up NM_000399.2 1959 EGR2 
5910154 2.0527813 up NM_006392.2 10528 NOL5A 
6560577 2.0508628 down NM_006308.1 8988 HSPB3 
1740291 2.0507843 down NM_021992.2 11013 TMSL8 
6650731 2.0492039 up NM_002899.2 5947 RBP1 
1510291 2.0474987 down NM_004219.2 9232 PTTG1 
7150563 2.047423 up NM_003633.1 8507 ENC1 
450491 2.043659 down NM_033294.2 834 CASP1 
5080192 2.043387 up NM_006216.2 5270 SERPINE2 
3840445 2.0425541 up NM_000422.1 3872 KRT17 
2510131 2.0401914 up NM_004102.3 2170 FABP3 
2260242 2.0369236 down NM_057179.1 117581 TWIST2 
6370541 2.034905 up NM_001898.2 1469 CST1 
6940102 2.0288663 down NM_002160.1 3371 TNC 
3180706 2.0286593 up NM_139235.3 65083 NOL6 
4390273 2.0286546 up NM_003475.2 8045 RASSF7 
2450167 2.0271757 up NM_000992.2 6159 RPL29 
240722 2.0253496 up NM_002535.2 4939 OAS2 
60121 2.0229847 down NM_001908.3 1508 CTSB 
4570441 2.0213137 up NM_022168.2 64135 IFIH1 
1980403 2.0210183 down NM_018660.2 55893 ZNF395 
2360356 2.0191083 up NM_005860.2 10272 FSTL3 
1260451 2.0167153 down NM_198315.2 4013 VWA5A 
7400707 2.0155354 down NM_001734.2 716 C1S 
4860646 2.010539 down NM_020223.2 56975 FAM20C 
990768 2.009299 up NM_006187.2 4940 OAS3 
6960379 2.0023494 down NM_003012.3 6422 SFRP1 
Genes differentially expressed after 7 Days of reprogramming (p<0.05) 
Probe ID Fold Changes Regulation RefSeq 
ILMN_1653934 2.192 up XR_019109.1 650517 LOC650517 
ILMN_1657039 3.192 up NM_015687.2 27145 FILIP1 
ILMN_1657234 2.456 up NM_004591.1 6364 CCL20 
ILMN_1658847 2.804 up XM_939432.1 441478 MGC61598 
186 
 
ILMN_1660709 3.512 up XR_017655.1 645682 LOC645682 
ILMN_1663866 0.218 down NM_000358.1 7045 TGFBI 




ILMN_1666733 3.837 up NM_000584.2 3576 IL8 
ILMN_1666845 3.239 up NM_000422.1 3872 KRT17 
ILMN_1667314 4.825 up NM_199048.1 387335 T1560 
ILMN_1667796 21.05 up NM_000517.3 3040 HBA2 
ILMN_1668521 2.103 up NM_030657.2 3982 LIM2 
ILMN_1669362 3.696 up NM_002178.2 3489 IGFBP6 
ILMN_1671971 2.454 up XR_016703.1 644743 LOC644743 
ILMN_1672148 0.465 down NM_020299.3 57016 AKR1B10 
ILMN_1674009 3.23 up NM_012253.2 8277 TKTL1 
ILMN_1677038 3.272 up NM_024913.3 79974 FLJ21986 
ILMN_1677092 0.425 down NM_181702.1 2669 GEM 
ILMN_1679262 3.947 up NM_001387.2 1809 DPYSL3 
ILMN_1681260 3.054 up XM_926633.1 643272 LOC643272 
ILMN_1682636 0.464 down NM_002089.3 2920 CXCL2 
ILMN_1683067 0.424 down XM_001134153.1 64100 ELSPBP1 
ILMN_1684886 2.687 up NM_013452.2 26609 VCX 
ILMN_1688722 3.303 up NM_000640.2 3598 IL13RA2 








ILMN_1694548 2.05 up NM_005139.2 306 ANXA3 
ILMN_1696749 2.069 up NM_005572.3 4000 LMNA 
ILMN_1699651 0.491 down NM_000600.1 3569 IL6 




ILMN_1702585 2.628 up XM_929774.2 646817 LOC646817 
ILMN_1705546 5.11 up NM_002701.4 5460 POU5F1 
ILMN_1711087 4.634 up XM_937579.1 648526 LOC648526 
ILMN_1712774 0.386 down NM_003604.1 8471 IRS4 
ILMN_1713636 2.958 up NM_014624.3 6277 S100A6 
ILMN_1715024 2.089 up NM_002340.3 4047 LSS 
ILMN_1726448 2.083 up NM_002421.2 4312 MMP1 
ILMN_1728049 3.165 up NM_080388.1 140576 S100A16 
ILMN_1737314 0.383 down NM_001706.2 604 BCL6 
ILMN_1742025 2.092 up NM_014279.4 10439 OLFM1 
ILMN_1742332 2.522 up NM_138444.3 115207 KCTD12 
ILMN_1746085 0.186 down NM_000598.4 3486 IGFBP3 
ILMN_1748124 0.489 down NM_198057.2 1831 TSC22D3 
ILMN_1751276 0.453 down NM_001709.3 627 BDNF 
ILMN_1751576 2.215 up NM_000459.1 7010 TEK 
ILMN_1752932 2.061 up NM_005797.2 10205 MPZL2 
187 
 
ILMN_1753584 2.275 up NM_002273.2 3856 KRT8 
ILMN_1753648 2.661 up NM_032681.1 84767 SPRYD5 
ILMN_1756573 2.355 up NM_020142.3 56901 NDUFA4L2 
ILMN_1759330 0.454 down NM_004321.4 547 KIF1A 
ILMN_1760199 2.7 up NM_004929.2 793 CALB1 
ILMN_1762899 0.47 down NM_001964.2 1958 EGR1 
ILMN_1764709 2.654 up NM_005461.3 9935 MAFB 
ILMN_1770505 2.168 up NM_001197.3 638 BIK 




ILMN_1781742 2.533 up NM_173698.1 286499 FAM133A 
ILMN_1783185 2.752 up NM_007084.2 11166 SOX21 
ILMN_1784459 2.051 up NM_002422.3 4314 MMP3 
ILMN_1787186 5.496 up NM_002514.2 4856 NOV 




ILMN_1789733 0.492 down NM_015526.1 25999 CLIP3 
ILMN_1790529 0.457 down NM_002345.3 4060 LUM 
ILMN_1791270 3.813 up NM_006727.2 1008 CDH10 




ILMN_1795679 10.59 up NM_007029.2 11075 STMN2 
ILMN_1797668 2.064 up NM_002196.2 3642 INSM1 
ILMN_1801216 7.898 up NM_005980.2 6286 S100P 
ILMN_1801703 2.233 up NM_006651.3 10815 CPLX1 




ILMN_1803945 2.513 up NM_006674.2 10866 HCP5 
ILMN_1806165 0.424 down NM_002155.3 3310 HSPA6 
ILMN_1813131 2.115 up XM_928128.1 643431 LOC643431 
ILMN_1815673 0.472 down NM_015881.5 27122 DKK3 
ILMN_1848974 2.746 up 
   
ILMN_1867119 3.16 up 
   
ILMN_1892403 2.598 up NR_003041.1 SNORD13 
 
ILMN_1907544 2.153 up 
   
ILMN_2059549 2.225 up NM_003177.3 6850 SYK 
ILMN_2065773 2.405 up NM_003020.1 6447 SCG5 
ILMN_2066151 2.269 up NM_000459.2 7010 TEK 
ILMN_2068498 4.059 up NR_002304.1 POU5F1P1 
 
ILMN_2068499 9.667 up NR_002304.1 POU5F1P1 
 
ILMN_2073758 2.193 up NM_002426.2 4321 MMP12 
ILMN_2076600 3.305 up NM_004867.3 9452 ITM2A 
ILMN_2088876 2.669 up NM_016249.2 51438 MAGEC2 
ILMN_2094266 2.434 up NM_019089.3 54626 HES2 
ILMN_2109371 3.323 up NM_000728.3 797 CALCB 
ILMN_2126038 6.47 up NM_007029.2 11075 STMN2 
188 
 
ILMN_2127842 10.91 up NM_000517.3 3040 HBA2 
ILMN_2148527 3.398 up NR_002196.1 H19 
 
ILMN_2150856 2.212 up NM_002575.1 5055 SERPINB2 
ILMN_2157099 2.896 up NM_003914.2 8900 CCNA1 




ILMN_2184373 3.012 up NM_000584.2 3576 IL8 
ILMN_2188862 0.438 down NM_004864.1 9518 GDF15 
ILMN_2206126 2.364 up NM_130900.2 154064 RAET1L 
ILMN_2206746 0.392 down NM_001711.3 633 BGN 
ILMN_2219002 6.156 up NM_005554.3 3853 KRT6A 
ILMN_2276952 0.399 down NM_004089.3 1831 TSC22D3 
ILMN_2366642 2.21 up NM_016379.2 51481 VCX3A 
ILMN_2367883 0.427 down NM_181702.1 2669 GEM 




ILMN_2376403 0.389 down NM_004089.3 1831 TSC22D3 








ILMN_2398159 0.447 down NM_013253.4 27122 DKK3 
ILMN_2406634 2.017 up NM_013369.2 29947 DNMT3L 
ILMN_2410038 0.368 down NM_022074.2 63901 FAM111A 
Genes differentially expressed at 14 Days of reprogramming (p<0.05) 
Probe ID Fold Changes Regulation RefSeq 
ILMN_1655334 2.667 up XM_939717.1 650628 LOC650628 
ILMN_1656386 0.492 down NM_014822.1 9871 SEC24D 
ILMN_1657039 3.038 up NM_015687.2 27145 FILIP1 
ILMN_1658383 0.489 down NM_002155.3 3310 HSPA6 
ILMN_1658847 2.151 up XM_939432.1 441478 MGC61598 
ILMN_1660544 0.468 down NM_183376.1 91947 ARRDC4 
ILMN_1660709 4.086 up XR_017655.1 645682 LOC645682 
ILMN_1663866 0.23 down NM_000358.1 7045 TGFBI 
ILMN_1665510 0.495 down NM_018948.2 54206 ERRFI1 
ILMN_1666733 3.734 up NM_000584.2 3576 IL8 
ILMN_1666845 2.393 up NM_000422.1 3872 KRT17 
ILMN_1667314 4.081 up NM_199048.1 387335 T1560 
ILMN_1667796 17.63 up NM_000517.3 3040 HBA2 
ILMN_1669362 2.858 up NM_002178.2 3489 IGFBP6 
ILMN_1669376 0.493 down NM_018370.2 55332 DRAM 
ILMN_1670807 0.462 down NM_174911.3 157638 FAM84B 
ILMN_1672148 0.486 down NM_020299.3 57016 AKR1B10 
ILMN_1673566 0.368 down NM_006988.3 9510 ADAMTS1 
ILMN_1674009 2.277 up NM_012253.2 8277 TKTL1 
ILMN_1677038 2.633 up NM_024913.3 79974 FLJ21986 
189 
 
ILMN_1677092 0.369 down NM_181702.1 2669 GEM 
ILMN_1679262 2.554 up NM_001387.2 1809 DPYSL3 
ILMN_1679984 0.407 down NM_173798.2 170261 ZCCHC12 
ILMN_1681260 2.906 up XM_926633.1 643272 LOC643272 
ILMN_1682636 0.46 down NM_002089.3 2920 CXCL2 
ILMN_1683067 0.391 down XM_001134153.1 64100 ELSPBP1 
ILMN_1683798 0.433 down XR_001389.1 LOC404266 
 
ILMN_1684886 2.672 up NM_013452.2 26609 VCX 
ILMN_1687538 0.474 down NM_005238.2 2113 ETS1 
ILMN_1688722 2.498 up NM_000640.2 3598 IL13RA2 




ILMN_1699651 0.482 down NM_000600.1 3569 IL6 
ILMN_1702585 2.121 up XM_929774.2 646817 LOC646817 
ILMN_1705546 5.795 up NM_002701.4 5460 POU5F1 
ILMN_1706028 2.003 up NM_016378.2 51480 VCX2 
ILMN_1711087 3.871 up XM_937579.1 648526 LOC648526 
ILMN_1712774 0.336 down NM_003604.1 8471 IRS4 
ILMN_1713636 2.459 up NM_014624.3 6277 S100A6 
ILMN_1728049 2.543 up NM_080388.1 140576 S100A16 
ILMN_1737314 0.309 down NM_001706.2 604 BCL6 
ILMN_1742332 2.112 up NM_138444.3 115207 KCTD12 
ILMN_1746085 0.187 down NM_000598.4 3486 IGFBP3 
ILMN_1748124 0.368 down NM_198057.2 1831 TSC22D3 
ILMN_1751276 0.459 down NM_001709.3 627 BDNF 
ILMN_1753342 0.453 down NM_002970.1 6303 SAT1 
ILMN_1753648 2.295 up NM_032681.1 84767 SPRYD5 
ILMN_1759330 0.443 down NM_004321.4 547 KIF1A 
ILMN_1760199 2.083 up NM_004929.2 793 CALB1 
ILMN_1762899 0.464 down NM_001964.2 1958 EGR1 




ILMN_1773865 0.47 down NM_005347.2 3309 HSPA5 
ILMN_1775304 0.497 down NM_006145.1 3337 DNAJB1 
ILMN_1781742 2.111 up NM_173698.1 286499 FAM133A 
ILMN_1782305 0.499 down NM_006186.2 4929 NR4A2 
ILMN_1783185 2.108 up NM_007084.2 11166 SOX21 
ILMN_1784459 2.039 up NM_002422.3 4314 MMP3 
ILMN_1787186 3.811 up NM_002514.2 4856 NOV 
ILMN_1787265 0.482 down NM_032772.3 84858 ZNF503 
ILMN_1789733 0.48 down NM_015526.1 25999 CLIP3 
ILMN_1790529 0.423 down NM_002345.3 4060 LUM 
ILMN_1791270 3.081 up NM_006727.2 1008 CDH10 
ILMN_1791280 0.472 down NM_014365.2 26353 HSPB8 
ILMN_1793474 0.45 down NM_198336.1 3638 INSIG1 
190 
 




ILMN_1795679 8.444 up NM_007029.2 11075 STMN2 
ILMN_1801216 7.14 up NM_005980.2 6286 S100P 
ILMN_1806165 0.329 down NM_002155.3 3310 HSPA6 
ILMN_1815673 0.38 down NM_015881.5 27122 DKK3 
ILMN_1848974 2.256 up 
   
ILMN_1867119 2.703 up 
   
ILMN_1892403 2.124 up NR_003041.1 SNORD13 
 
ILMN_2068498 4.201 up NR_002304.1 POU5F1P1 
 
ILMN_2068499 8.947 up NR_002304.1 POU5F1P1 
 
ILMN_2073758 2.169 up NM_002426.2 4321 MMP12 
ILMN_2076600 2.407 up NM_004867.3 9452 ITM2A 
ILMN_2088876 2.315 up NM_016249.2 51438 MAGEC2 
ILMN_2109371 2.936 up NM_000728.3 797 CALCB 
ILMN_2126038 5.374 up NM_007029.2 11075 STMN2 
ILMN_2127842 9.443 up NM_000517.3 3040 HBA2 
ILMN_2148527 2.11 up NR_002196.1 H19 
 
ILMN_2157099 2.213 up NM_003914.2 8900 CCNA1 




ILMN_2184064 0.429 down NM_183376.1 91947 ARRDC4 
ILMN_2184373 3.058 up NM_000584.2 3576 IL8 
ILMN_2188862 0.35 down NM_004864.1 9518 GDF15 
ILMN_2206126 2.062 up NM_130900.2 154064 RAET1L 
ILMN_2206746 0.335 down NM_001711.3 633 BGN 
ILMN_2215989 0.378 down NM_005382.1 4741 NEFM 
ILMN_2219002 5.339 up NM_005554.3 3853 KRT6A 
ILMN_2276952 0.342 down NM_004089.3 1831 TSC22D3 




ILMN_2366642 2.361 up NM_016379.2 51481 VCX3A 
ILMN_2367883 0.374 down NM_181702.1 2669 GEM 
ILMN_2376403 0.252 down NM_004089.3 1831 TSC22D3 








ILMN_2398159 0.381 down NM_013253.4 27122 DKK3 
ILMN_2410038 0.37 down NM_022074.2 63901 FAM111A 
Genes differentially expressed after 21 Days of reprogramming (p<0.05) 
Probe ID Fold Change Regulation RefSeq 
ILMN_1651358 2.243 up NM_005330.3 3046 HBE1 
ILMN_1657039 3.44 up NM_015687.2 27145 FILIP1 
ILMN_1657234 2.236 up NM_004591.1 6364 CCL20 
ILMN_1658847 2.475 up XM_939432.1 441478 MGC61598 
191 
 
ILMN_1660709 3.834 up XR_017655.1 645682 LOC645682 
ILMN_1663866 0.385 down NM_000358.1 7045 TGFBI 




ILMN_1666733 7.179 up NM_000584.2 3576 IL8 
ILMN_1667314 5.01 up NM_199048.1 387335 T1560 
ILMN_1667796 20.74 up NM_000517.3 3040 HBA2 
ILMN_1668521 2.151 up NM_030657.2 3982 LIM2 
ILMN_1669362 3.983 up NM_002178.2 3489 IGFBP6 
ILMN_1671971 2.088 up XR_016703.1 644743 LOC644743 
ILMN_1672148 0.464 down NM_020299.3 57016 AKR1B10 
ILMN_1673566 0.403 down NM_006988.3 9510 ADAMTS1 
ILMN_1674009 2.953 up NM_012253.2 8277 TKTL1 




ILMN_1677038 4.086 up NM_024913.3 79974 FLJ21986 
ILMN_1677092 0.377 down NM_181702.1 2669 GEM 
ILMN_1677402 0.453 down XM_941665.2 387763 LOC387763 
ILMN_1679262 4.598 up NM_001387.2 1809 DPYSL3 
ILMN_1679984 0.404 down NM_173798.2 170261 ZCCHC12 
ILMN_1681260 3.616 up XM_926633.1 643272 LOC643272 
ILMN_1683067 0.398 down XM_001134153.1 64100 ELSPBP1 
ILMN_1683798 0.388 down XR_001389.1 LOC404266 
 
ILMN_1684306 2.799 up NM_019554.2 6275 S100A4 
ILMN_1684886 2.889 up NM_013452.2 26609 VCX 
ILMN_1686362 2.4 up NM_001886.1 1413 CRYBA4 
ILMN_1687538 0.467 down NM_005238.2 2113 ETS1 
ILMN_1688335 2.111 up NM_002364.3 4113 MAGEB2 
ILMN_1688722 4.482 up NM_000640.2 3598 IL13RA2 
ILMN_1688780 2.036 up NM_019554.2 6275 S100A4 




ILMN_1693242 2.086 up NM_145288.1 162979 ZNF342 
ILMN_1693650 2.031 up NM_002005.2 2242 FES 
ILMN_1696749 2.015 up NM_005572.3 4000 LMNA 
ILMN_1701783 2.05 up NM_001922.2 1638 DCT 




ILMN_1702585 2.355 up XM_929774.2 646817 LOC646817 
ILMN_1705546 5.061 up NM_002701.4 5460 POU5F1 
ILMN_1706028 2.069 up NM_016378.2 51480 VCX2 
ILMN_1711087 4.676 up XM_937579.1 648526 LOC648526 
ILMN_1712774 0.312 down NM_003604.1 8471 IRS4 
ILMN_1713636 3.383 up NM_014624.3 6277 S100A6 
ILMN_1715024 2.1 up NM_002340.3 4047 LSS 
ILMN_1719759 0.496 down NM_002160.2 3371 TNC 
192 
 
ILMN_1725311 2.08 up NM_000160.2 2642 GCGR 
ILMN_1726448 4.926 up NM_002421.2 4312 MMP1 
ILMN_1728049 2.852 up NM_080388.1 140576 S100A16 
ILMN_1737314 0.348 down NM_001706.2 604 BCL6 
ILMN_1738450 2.222 up NM_001475.1 2577 GAGE5 
ILMN_1742025 2.167 up NM_014279.4 10439 OLFM1 
ILMN_1742332 2.193 up NM_138444.3 115207 KCTD12 
ILMN_1746085 0.192 down NM_000598.4 3486 IGFBP3 
ILMN_1748124 0.343 down NM_198057.2 1831 TSC22D3 
ILMN_1751576 2.401 up NM_000459.1 7010 TEK 
ILMN_1753342 0.451 down NM_002970.1 6303 SAT1 
ILMN_1753584 2.216 up NM_002273.2 3856 KRT8 
ILMN_1753648 3.039 up NM_032681.1 84767 SPRYD5 
ILMN_1756657 2.121 up NM_033342.2 81786 TRIM7 
ILMN_1758164 2.063 up NM_003155.2 6781 STC1 
ILMN_1759330 0.479 down NM_004321.4 547 KIF1A 
ILMN_1760199 2.801 up NM_004929.2 793 CALB1 
ILMN_1762899 0.41 down NM_001964.2 1958 EGR1 
ILMN_1764709 2.445 up NM_005461.3 9935 MAFB 




ILMN_1773079 2.082 up NM_000090.3 1281 COL3A1 
ILMN_1775336 0.485 down NM_022117.1 64061 TSPYL2 
ILMN_1775501 2.26 up NM_000576.2 3553 IL1B 
ILMN_1779252 2.507 up NM_006074.3 10346 TRIM22 
ILMN_1781742 3.033 up NM_173698.1 286499 FAM133A 
ILMN_1782705 2.048 up NM_001475.1 2577 GAGE5 
ILMN_1783185 2.911 up NM_007084.2 11166 SOX21 
ILMN_1783832 2.168 up NM_001476.1 2578 GAGE6 
ILMN_1784459 6.034 up NM_002422.3 4314 MMP3 
ILMN_1785272 2.249 up NM_000089.3 1278 COL1A2 
ILMN_1787186 6.336 up NM_002514.2 4856 NOV 
ILMN_1787265 0.453 down NM_032772.3 84858 ZNF503 




ILMN_1790338 2.376 up NM_016307.3 51450 PRRX2 
ILMN_1791270 4.507 up NM_006727.2 1008 CDH10 
ILMN_1791280 0.456 down NM_014365.2 26353 HSPB8 
ILMN_1793474 0.415 down NM_198336.1 3638 INSIG1 




ILMN_1795679 13.58 up NM_007029.2 11075 STMN2 
ILMN_1797668 2.568 up NM_002196.2 3642 INSM1 
ILMN_1801216 10.09 up NM_005980.2 6286 S100P 
ILMN_1801703 2.078 up NM_006651.3 10815 CPLX1 
ILMN_1802094 2.18 up NM_080740.3 129025 ZNF280A 
193 
 




ILMN_1803945 2.377 up NM_006674.2 10866 HCP5 
ILMN_1806165 0.493 down NM_002155.3 3310 HSPA6 
ILMN_1848974 3.626 up 
   
ILMN_1867119 3.411 up 
   
ILMN_1891878 2.248 up 
   
ILMN_1892403 2.082 up NR_003041.1 SNORD13 
 
ILMN_1907544 2.356 up 
   
ILMN_2058782 2.228 up NM_005532.3 3429 IFI27 
ILMN_2059549 2.28 up NM_003177.3 6850 SYK 
ILMN_2065773 2.521 up NM_003020.1 6447 SCG5 
ILMN_2066151 2.461 up NM_000459.2 7010 TEK 
ILMN_2068498 4.184 up NR_002304.1 POU5F1P1 
 
ILMN_2068499 9.278 up NR_002304.1 POU5F1P1 
 
ILMN_2076600 2.802 up NM_004867.3 9452 ITM2A 
ILMN_2088876 2.989 up NM_016249.2 51438 MAGEC2 
ILMN_2094266 2.313 up NM_019089.3 54626 HES2 
ILMN_2104356 5.059 up NM_000089.3 1278 COL1A2 
ILMN_2109371 2.605 up NM_000728.3 797 CALCB 
ILMN_2126038 7.141 up NM_007029.2 11075 STMN2 
ILMN_2127842 12.05 up NM_000517.3 3040 HBA2 
ILMN_2150851 2.127 up NM_002575.1 5055 SERPINB2 
ILMN_2150856 3.31 up NM_002575.1 5055 SERPINB2 
ILMN_2157099 2.744 up NM_003914.2 8900 CCNA1 




ILMN_2184373 4.876 up NM_000584.2 3576 IL8 
ILMN_2188862 0.348 down NM_004864.1 9518 GDF15 
ILMN_2204876 2.694 up NM_017791.1 55640 FLVCR2 
ILMN_2206126 2.613 up NM_130900.2 154064 RAET1L 
ILMN_2215989 0.43 down NM_005382.1 4741 NEFM 
ILMN_2219002 7.372 up NM_005554.3 3853 KRT6A 
ILMN_2233576 2.201 up NM_001477.1 26748 GAGE12I 
ILMN_2276952 0.323 down NM_004089.3 1831 TSC22D3 




ILMN_2347145 2.141 up NM_133505.2 1634 DCN 
ILMN_2366642 2.469 up NM_016379.2 51481 VCX3A 
ILMN_2367883 0.356 down NM_181702.1 2669 GEM 




ILMN_2376403 0.291 down NM_004089.3 1831 TSC22D3 








ILMN_2406634 2.352 up NM_013369.2 29947 DNMT3L 
ILMN_2410038 0.44 down NM_022074.2 63901 FAM111A 
 
Microarray analysis gene description 




POU5F1 Homo sapiens POU class 5 homeobox 1 (POU5F1), transcript variant 1, mRNA. 
HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
MX1 
Homo sapiens myxovirus (influenza virus) resistance 1, interferon-inducible 
protein p78 (MX1), mRNA. 
H19 
Homo sapiens H19, imprinted maternally expressed transcript (non-protein 
coding) (H19), non-coding RNA. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1), non-coding 
RNA. 
MFAP5 Homo sapiens microfibrillar associated protein 5 (MFAP5), mRNA. 
KIAA1199 Homo sapiens KIAA1199 (KIAA1199), mRNA. 
SLC7A5 
Homo sapiens solute carrier family 7 (cationic amino acid transporter, y+ 
system),member5 (SLC7A5), mRNA. 
IFIT1 
Homo sapiens interferon-induced protein with tetratricopeptide repeats 1 
(IFIT1), transcript 2, mRNA. 
IGFBP5 Homo sapiens insulin-like growth factor binding protein 5 (IGFBP5), mRNA. 
IGFBP5 Homo sapiens insulin-like growth factor binding protein 5 (IGFBP5), mRNA. 
LOC645682 PREDICTED: Homo sapiens hypothetical LOC645682 (LOC645682), mRNA. 
PODXL Homo sapiens podocalyxin-like (PODXL), transcript variant 1, mRNA. 
TIMP3 Homo sapiens TIMP metallopeptidase inhibitor 3 (TIMP3), mRNA. 
CXCL6 
Homo sapiens chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic 
protein 2) (CXCL6), mRNA. 
KRT7 Homo sapiens keratin 7 (KRT7), mRNA. 
FERMT1 Homo sapiens fermitin family homolog 1 (Drosophila) (FERMT1), mRNA. 
COLEC12 Homo sapiens collectin sub-family member 12 (COLEC12), mRNA. 
IFI6 
Homo sapiens interferon, alpha-inducible protein 6 (IFI6), transcript variant 2, 
mRNA. 
ESM1 Homo sapiens endothelial cell-specific molecule 1 (ESM1), mRNA. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1), non-coding 
RNA. 
IFIT3 
Homo sapiens interferon-induced protein with tetratricopeptide repeats 3 
(IFIT3), mRNA. 
OAS2 
Homo sapiens 2'-5'-oligoadenylate synthetase 2, 69/71kDa (OAS2), transcript 
variant 1, mRNA. 
DCN Homo sapiens decorin (DCN), transcript variant C, mRNA. 
BEX1 Homo sapiens brain expressed, X-linked 1 (BEX1), mRNA. 
SRGN Homo sapiens serglycin (SRGN), mRNA. 
DCN Homo sapiens decorin (DCN), transcript variant A1, mRNA. 




Homo sapiens interferon, alpha-inducible protein 27 (IFI27), transcript variant 
2, mRNA. 
IFI6 
Homo sapiens interferon, alpha-inducible protein 6 (IFI6), transcript variant 3, 
mRNA. 
SRGN Homo sapiens serglycin (SRGN), mRNA. 
IFI44L Homo sapiens interferon-induced protein 44-like (IFI44L), mRNA. 
HERC6 Homo sapiens hect domain and RLD 6 (HERC6), mRNA. 
EPAS1 Homo sapiens endothelial PAS domain protein 1 (EPAS1), mRNA. 
OSAP Homo sapiens ovary-specific acidic protein (OSAP), mRNA. 
EFEMP1 
Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 
(EFEMP1), transcript 2, mRNA. 
CCRL1 
Homo sapiens chemokine (C-C motif) receptor-like 1 (CCRL1), transcript variant 
2, mRNA. 
CDH2 Homo sapiens cadherin 2, type 1, N-cadherin (neuronal) (CDH2), mRNA. 
EGR1 Homo sapiens early growth response 1 (EGR1), mRNA. 
OAS1 
Homo sapiens 2',5'-oligoadenylate synthetase 1, 40/46kDa (OAS1), transcript 
variant 3, mRNA. 
IFIT3 
Homo sapiens interferon-induced protein with tetratricopeptide repeats 3 
(IFIT3), mRNA. 
EFEMP1 
Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 
(EFEMP1), transcript 1, mRNA. 
IGFBP3 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
variant 2, mRNA. 
CCL2 Homo sapiens chemokine (C-C motif) ligand 2 (CCL2), mRNA. 
IFIT3 
Homo sapiens interferon-induced protein with tetratricopeptide repeats 3 
(IFIT3), mRNA. 
IGFBP3 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
variant 1, mRNA. 
HSPA2 Homo sapiens heat shock 70kDa protein 2 (HSPA2), mRNA. 
BHLHB2 
Homo sapiens basic helix-loop-helix domain containing, class B, 2 (BHLHB2), 
mRNA. 
OSAP Homo sapiens ovary-specific acidic protein (OSAP), mRNA. 
ZNF185 Homo sapiens zinc finger protein 185 (LIM domain) (ZNF185), mRNA. 
DKFZP586H
2123 
Homo sapiens regeneration associated muscle protease (DKFZP586H2123), 
transcript variant 1, mRNA. 
PTGS1 
Homo sapiens prostaglandin-endoperoxide synthase 1 (PTGS1), transcript 
variant 2, mRNA. 
RGS4 Homo sapiens regulator of G-protein signalling 4 (RGS4), mRNA. 
LAMA4 H Homo sapiens laminin, alpha 4 (LAMA4), mRNA. 
TEK 
Homo sapiens TEK tyrosine kinase, endothelial (venous malformations, (TEK), 
mRNA. 
IFIT2 
Homo sapiens interferon-induced protein with tetratricopeptide repeats 2 
(IFIT2), mRNA. 
SAMD9 Homo sapiens sterile alpha motif domain containing 9 (SAMD9), mRNA. 
IL6 Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA. 
ISG15 Homo sapiens ISG15 ubiquitin-like modifier (ISG15), mRNA. 
GAS1 Homo sapiens growth arrest-specific 1 (GAS1), mRNA. 
CCL8 Homo sapiens chemokine (C-C motif) ligand 8 (CCL8), mRNA. 
TEK Homo sapiens TEK tyrosine kinase, endothelial (TEK), mRNA. 
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MALL Homo sapiens mal, T-cell differentiation protein-like (MALL), mRNA. 
RGS2 Homo sapiens regulator of G-protein signalling 2, 24kDa (RGS2), mRNA. 
STEAP2 
Homo sapiens six transmembrane epithelial antigen of the prostate 2 (STEAP2), 
transcript variant 1, mRNA. 
MASP1 
Homo sapiens mannan-binding lectin serine peptidase 1 (MASP1), transcript 
variant 2, mRNA. 
GBP2 Homo sapiens guanylate binding protein 2, interferon-inducible (GBP2), mRNA. 
FBLN1 Homo sapiens fibulin 1 (FBLN1), transcript variant C, mRNA. 
STEAP2 
Homo sapiens six transmembrane epithelial antigen of the prostate 2 (STEAP2), 
mRNA. 
FBLN1 Homo sapiens fibulin 1 (FBLN1), transcript variant A, mRNA. 
ENPP2 
Homo sapiens ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), 
transcript variant 2, mRNA. 
XAF1 Homo sapiens XIAP associated factor 1 (XAF1), transcript variant 2, mRNA. 
LUM Homo sapiens lumican (LUM), mRNA. 
ENPP2 
Homo sapiens ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), 
transcript variant 2, mRNA. 
EFEMP1 
Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 
(EFEMP1), transcript 1, mRNA. 
CPXM2 Homo sapiens carboxypeptidase X (M14 family), member 2 (CPXM2), mRNA. 
KRT81 Homo sapiens keratin 81 (KRT81), mRNA. 
SLC3A2 
Homo sapiens solute carrier family 3, member 2 (SLC3A2), transcript variant 6, 
mRNA. 
BX097797 
Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone 
IMAGp998N171164, mRNA sequence 
HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
IFI44 Homo sapiens interferon-induced protein 44 (IFI44), mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
ZDHHC11 Homo sapiens zinc finger, DHHC-type containing 11 (ZDHHC11), mRNA. 
CNTN1 H Homo sapiens contactin 1 (CNTN1), transcript variant 1, mRNA. 
LRRC17 
Homo sapiens leucine rich repeat containing 17 (LRRC17), transcript variant 2, 
mRNA. 
C1QTNF1 
Homo sapiens C1q and tumor necrosis factor related protein 1 (C1QTNF1), 
mRNA. 
MME 
Homo sapiens membrane metallo-endopeptidase (MME), transcript variant 1, 
mRNA. 
LOC651872 
PREDICTED: Homo sapiens similar to C-C chemokine receptor type 11 (CCRL1) 
(CCX CKR) (LOC651872), mRNA. 
TNC Homo sapiens tenascin C (TNC), mRNA. 
ANGPTL2 Homo sapiens angiopoietin-like 2 (ANGPTL2), mRNA. 
SLC3A2 
Homo sapiens solute carrier family 3, member 2 (SLC3A2), transcript variant 6, 
mRNA. 
TM4SF1 Homo sapiens transmembrane 4 L six family member 1 (TM4SF1), mRNA. 
EPSTI1 
Homo sapiens epithelial stromal interaction 1 (breast) (EPSTI1), transcript 
variant 2, mRNA. 
WARS 
Homo sapiens tryptophanyl-tRNA synthetase (WARS), transcript variant 1, 
mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
SVEP1 Homo sapiens sushi, von Willebrand factor type A, EGF and pentraxin domain 
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containing 1 (SVEP1), mRNA. 
CCND2 Homo sapiens cyclin D2 (CCND2), mRNA. 
DCN Homo sapiens decorin (DCN), transcript variant A2, mRNA. 
SYTL2 Homo sapiens synaptotagmin-like 2 (SYTL2), transcript variant e, mRNA. 
TMEM119 Homo sapiens transmembrane protein 119 (TMEM119), mRNA. 
GDF15 Homo sapiens growth differentiation factor 15 (GDF15), mRNA. 
PRSS3 Homo sapiens protease, serine, 3 (mesotrypsin) (PRSS3), mRNA. 
PDE4B 
Homo sapiens phosphodiesterase 4B, cAMP-specific (PDE4B), transcript variant 
a, mRNA. 
ACTG2 Homo sapiens actin, gamma 2, smooth muscle, enteric (ACTG2), mRNA. 
CEBPD Homo sapiens CCAAT/enhancer binding protein (C/EBP), delta (CEBPD), mRNA. 
TBC1D2 Homo sapiens TBC1 domain family, member 2 (TBC1D2), mRNA. 
HAPLN1 Homo sapiens hyaluronan and proteoglycan link protein 1 (HAPLN1), mRNA. 
C1R Homo sapiens complement component 1, r subcomponent (C1R), mRNA. 
IGF2 
Homo sapiens insulin-like growth factor 2 (somatomedin A) (IGF2), transcript 
variant 2, mRNA. 
TNFRSF11B 
Homo sapiens tumor necrosis factor receptor superfamily, member 11b 
(TNFRSF11B), mRNA. 
LIPG Homo sapiens lipase, endothelial (LIPG), mRNA. 
FAM46C Homo sapiens family with sequence similarity 46, member C (FAM46C), mRNA. 
FAM43A Homo sapiens family with sequence similarity 43, member A (FAM43A), mRNA. 
C1R Homo sapiens complement component 1, r subcomponent (C1R), mRNA. 
MX2 Homo sapiens myxovirus (influenza virus) resistance 2 (mouse) (MX2), mRNA. 
KLF2 Homo sapiens Kruppel-like factor 2 (lung) (KLF2), mRNA. 
HERC5 Homo sapiens hect domain and RLD 5 (HERC5), mRNA. 
NFKBIA 
Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, (NFKBIA), mRNA. 
SLC38A1 
Homo sapiens solute carrier family 38, member 1 (SLC38A1), transcript variant 
1, mRNA. 
OLFML2B Homo sapiens olfactomedin-like 2B (OLFML2B), mRNA. 
OCIAD2 Homo sapiens OCIA domain containing 2 (OCIAD2), transcript variant 1, mRNA. 
OLAH Homo sapiens oleoyl-ACP hydrolase (OLAH), transcript variant 1, mRNA. 
HCFC1R1 
Homo sapiens host cell factor C1 regulator 1 (XPO1 dependent) (HCFC1R1), 
transcript variant 3, mRNA. 
FCRLA Homo sapiens Fc receptor-like A (FCRLA), mRNA. 
GK Homo sapiens glycerol kinase (GK), transcript variant 2, mRNA. 
HIST1H4H Homo sapiens histone cluster 1, H4h (HIST1H4H), mRNA. 
HSD17B2 Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 (HSD17B2), mRNA. 
SERPINE1 
Homo sapiens serpin peptidase inhibitor, clade E, member 1 (SERPINE1), 
mRNA. 
GK Homo sapiens glycerol kinase (GK), transcript variant 1, mRNA. 
WARS 
Homo sapiens tryptophanyl-tRNA synthetase (WARS), transcript variant 2, 
mRNA. 
MASP1 
Homo sapiens mannan-binding lectin serine peptidase 1(MASP1), transcript 
variant 2, mRNA. 
OAS1 
Homo sapiens 2',5'-oligoadenylate synthetase 1, 40/46kDa (OAS1), transcript 




Homo sapiens platelet-derived growth factor receptor, alpha polypeptide 
(PDGFRA), mRNA. 
KCNIP3 
Homo sapiens Kv channel interacting protein 3, calsenilin (KCNIP3), transcript 
variant 1, mRNA. 
VCAN Homo sapiens versican (VCAN), mRNA. 
FABP5 
Homo sapiens fatty acid binding protein 5 (psoriasis-associated) (FABP5), 
mRNA. 
ZAK 
Homo sapiens sterile alpha motif and leucine zipper containing kinase AZK 
(ZAK), transcript variant 2, mRNA. 
SAMD9L Homo sapiens sterile alpha motif domain containing 9-like (SAMD9L), mRNA. 
OAS1 
Homo sapiens 2',5'-oligoadenylate synthetase 1, 40/46kDa (OAS1), transcript 
variant 3, mRNA. 
ID1 
Homo sapiens inhibitor of DNA binding 1 dominant negative helix-loop-helix 
protein (ID1) transcript 2, mRNA. 
NBL1 
Homo sapiens neuroblastoma, suppression of tumorigenicity 1 (NBL1), 
transcript variant 1, mRNA. 
SOD2 
Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), transcript 
variant 3, mRNA. 
GLIPR1 Homo sapiens GLI pathogenesis-related 1 (GLIPR1), mRNA. 
TC125227 
Human breast cancer tissue, large insert, pCMV expression (LOC387724), 
mRNA sequence 
INA 
Homo sapiens internexin neuronal intermediate filament protein, alpha (INA), 
mRNA. 
HMOX1 Homo sapiens heme oxygenase (decycling) 1 (HMOX1), mRNA. 
ARNT2 
Homo sapiens aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2), 
mRNA. 
XYLT1 Homo sapiens xylosyltransferase I (XYLT1), mRNA. 
TNFSF18 
Homo sapiens tumor necrosis factor (ligand) superfamily, member 18 
(TNFSF18), mRNA. 
TNFRSF12A 
Homo sapiens tumor necrosis factor receptor superfamily, member 12A 
(TNFRSF12A), mRNA. 
MMP1 
Homo sapiens matrix metallopeptidase 1 (interstitial collagenase) (MMP1), 
mRNA. 
GALNTL2 Homo sapiens UDP-N-acetyl-alpha-D-galactosamine: (GALNTL2), mRNA. 
TFPI2 Homo sapiens tissue factor pathway inhibitor 2 (TFPI2), mRNA. 
TSPAN13 Homo sapiens tetraspanin 13 (TSPAN13), mRNA. 
IRF7 Homo sapiens interferon regulatory factor 7 (IRF7), transcript variant b, mRNA. 
FBLN1 Homo sapiens fibulin 1 (FBLN1), transcript variant D, mRNA. 
HSPC111 Homo sapiens hypothetical protein HSPC111 (HSPC111), mRNA. 
ADM Homo sapiens adrenomedullin (ADM), mRNA. 
SOD2 
Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), transcript 
variant 2, mRNA. 
LARGE Homo sapiens like-glycosyltransferase (LARGE), transcript variant 1, mRNA. 
PDK4 Homo sapiens pyruvate dehydrogenase kinase, isozyme 4 (PDK4), mRNA. 
NP Homo sapiens nucleoside phosphorylase (NP), mRNA. 
CXCL12 
Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 
1), transcript variant 2, mRNA. 
PTGS1 
Homo sapiens prostaglandin-endoperoxide synthase 1 (PTGS1), transcript 




Homo sapiens poly (ADP-ribose) polymerase family, member 12 (PARP12), 
mRNA. 
PLEKHB2 
Homo sapiens pleckstrin homology domain containing, family B (evectins) 
(PLEKHB2), transcript 1, mRNA. 
NBL1 
Homo sapiens neuroblastoma, suppression of tumorigenicity 1 (NBL1), 
transcript variant 2, mRNA. 
NOL5A Homo sapiens nucleolar protein 5A (56kDa with KKE/D repeat) (NOL5A), mRNA. 
AKAP12 
Homo sapiens A kinase (PRKA) anchor protein (gravin) 12 (AKAP12), transcript 
variant 2, mRNA. 
SLC2A1 
Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 
1 (SLC2A1), mRNA. 
TCF21 Homo sapiens transcription factor 21 (TCF21), transcript variant 1, mRNA. 
PTTG1 Homo sapiens pituitary tumor-transforming 1 (PTTG1), mRNA. 
EGR2 
Homo sapiens early growth response 2 (Krox-20 homolog, Drosophila) (EGR2), 
mRNA. 
NOL5A Homo sapiens nucleolar protein 5A (56kDa with KKE/D repeat) (NOL5A), mRNA. 
HSPB3 Homo sapiens heat shock 27kDa protein 3 (HSPB3), mRNA. 
TMSL8 Homo sapiens thymosin-like 8 (TMSL8), mRNA. 
RBP1 Homo sapiens retinol binding protein 1, cellular (RBP1), mRNA. 
PTTG1 Homo sapiens pituitary tumor-transforming 1 (PTTG1), mRNA. 
ENC1 Homo sapiens ectodermal-neural cortex (with BTB-like domain) (ENC1), mRNA. 
CASP1 
Homo sapiens caspase 1, apoptosis-related cysteine peptidase (CASP1), 
transcript variant delta, mRNA. 
SERPINE2 
Homo sapiens serpin peptidase inhibitor, clade E , member 2 (SERPINE2), 
mRNA. 
KRT17 Homo sapiens keratin 17 (KRT17), mRNA. 
FABP3 Homo sapiens fatty acid binding protein 3, muscle and heart (FABP3), mRNA. 
TWIST2 Homo sapiens twist homolog 2 (Drosophila) (TWIST2), mRNA. 
CST1 Homo sapiens cystatin SN (CST1), mRNA. 
TNC Homo sapiens tenascin C (hexabrachion) (TNC), mRNA. 
NOL6 
Homo sapiens nucleolar protein family 6 (RNA-associated) (NOL6), transcript 
variant gamma, mRNA. 
RASSF7 
Homo sapiens Ras association (RalGDS/AF-6) domain family (N-terminal) 
member 7 (RASSF7), mRNA. 
RPL29 Homo sapiens ribosomal protein L29 (RPL29), mRNA. 
OAS2 
Homo sapiens 2'-5'-oligoadenylate synthetase 2, 69/71kDa (OAS2), transcript 
variant 2, mRNA. 
CTSB Homo sapiens cathepsin B (CTSB), transcript variant 1, mRNA. 
IFIH1 Homo sapiens interferon induced with helicase C domain 1 (IFIH1), mRNA. 
ZNF395 Homo sapiens zinc finger protein 395 (ZNF395), mRNA. 
FSTL3 Homo sapiens follistatin-like 3 (secreted glycoprotein) (FSTL3), mRNA. 
VWA5A 
Homo sapiens von Willebrand factor A domain containing 5A (VWA5A), 
transcript variant 2, mRNA. 
C1S 
Homo sapiens complement component 1, s subcomponent (C1S), transcript 
variant 1, mRNA. 
FAM20C Homo sapiens family with sequence similarity 20, member C (FAM20C), mRNA. 
OAS3 Homo sapiens 2'-5'-oligoadenylate synthetase 3, 100kDa (OAS3), mRNA. 
SFRP1 Homo sapiens secreted frizzled-related protein 1 (SFRP1), mRNA. 
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LOC650517 PREDICTED: Homo sapiens hypothetical LOC650517 (LOC650517), mRNA. 
FILIP1 Homo sapiens filamin A interacting protein 1 (FILIP1), mRNA. 
CCL20 Homo sapiens chemokine (C-C motif) ligand 20 (CCL20), mRNA. 
MGC61598 
. 
PREDICTED: Homo sapiens similar to ankyrin-repeat protein Nrarp 
(MGC61598), mRNA 
LOC645682 PREDICTED: Homo sapiens hypothetical LOC645682 (LOC645682), mRNA. 
TGFBI 
Homo sapiens transforming growth factor, beta-induced, 68kDa (TGFBI), 
mRNA. 
GAGE12G Homo sapiens G antigen 12G (GAGE12G), mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
KRT17 Homo sapiens keratin 17 (KRT17), mRNA. 
T1560 Homo sapiens T1560 protein (T1560), mRNA. 
HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
LIM2 Homo sapiens lens intrinsic membrane protein 2, 19kDa (LIM2), mRNA. 
IGFBP6 Homo sapiens insulin-like growth factor binding protein 6 (IGFBP6), mRNA. 
LOC644743 PREDICTED: Homo sapiens hypothetical LOC644743 (LOC644743), mRNA. 
AKR1B10 
Homo sapiens aldo-keto reductase family 1, member B10 (aldose reductase) 
(AKR1B10), mRNA. 
TKTL1 Homo sapiens transketolase-like 1 (TKTL1), mRNA. 
FLJ21986 Homo sapiens hypothetical protein FLJ21986 (FLJ21986), mRNA. 
GEM 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), 
transcript variant 2, mRNA. 
DPYSL3 Homo sapiens dihydropyrimidinase-like 3 (DPYSL3), mRNA. 
LOC643272 
PREDICTED: Homo sapiens hypothetical protein LOC643272 (LOC643272), 
mRNA. 
CXCL2 Homo sapiens chemokine (C-X-C motif) ligand 2 (CXCL2), mRNA. 
ELSPBP1 
PREDICTED: Homo sapiens epididymal sperm binding protein 1 (ELSPBP1), 
mRNA. 
VCX Homo sapiens variable charge, X-linked (VCX), mRNA. 
IL13RA2 Homo sapiens interleukin 13 receptor, alpha 2 (IL13RA2), mRNA. 
C21orf34 
Homo sapiens chromosome 21 open reading frame 34 (C21orf34), transcript 
variant 3, mRNA. 
NRARP Homo sapiens Notch-regulated ankyrin repeat protein (NRARP), mRNA. 
ANXA3 Homo sapiens annexin A3 (ANXA3), mRNA. 
LMNA Homo sapiens lamin A/C (LMNA), transcript variant 2, mRNA. 
IL6 Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA. 
C21orf34 
Homo sapiens chromosome 21 open reading frame 34 (C21orf34), transcript 
variant 1, mRNA. 
LOC646817 PREDICTED: Homo sapiens similar to Protein SET (LOC646817), mRNA. 
POU5F1 Homo sapiens POU class 5 homeobox 1 (POU5F1), transcript variant 1, mRNA. 
LOC648526 PREDICTED: Homo sapiens similar to epiplakin 1 (LOC648526), mRNA. 
IRS4 Homo sapiens insulin receptor substrate 4 (IRS4), mRNA. 
S100A6 Homo sapiens S100 calcium binding protein A6 (S100A6), mRNA. 
LSS Homo sapiens lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) (LSS), 
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transcript variant 1, mRNA. 
MMP1 
Homo sapiens matrix metallopeptidase 1 (interstitial collagenase) (MMP1), 
mRNA. 
S100A16 Homo sapiens S100 calcium binding protein A16 (S100A16), mRNA. 
BCL6 
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6), transcript 
variant 1, mRNA. 
OLFM1 Homo sapiens olfactomedin 1 (OLFM1), transcript variant 1, mRNA. 
KCTD12 
Homo sapiens potassium channel tetramerisation domain containing 12 
(KCTD12), mRNA. 
IGFBP3 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
variant 2, mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 1, 
mRNA. 
BDNF 
Homo sapiens brain-derived neurotrophic factor (BDNF), transcript variant 4, 
mRNA. 
TEK Homo sapiens TEK tyrosine kinase, endothelial (TEK), mRNA. 
MPZL2 Homo sapiens myelin protein zero-like 2 (MPZL2), transcript variant 1, mRNA. 
KRT8 . Homo sapiens keratin 8 (KRT8), mRNA 
SPRYD5 Homo sapiens SPRY domain containing 5 (SPRYD5), mRNA. 
NDUFA4L2 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 
(NDUFA4L2), mRNA. 
KIF1A Homo sapiens kinesin family member 1A (KIF1A), mRNA. 
CALB1 Homo sapiens calbindin 1, 28kDa (CALB1), mRNA. 
EGR1 Homo sapiens early growth response 1 (EGR1), mRNA. 
MAFB 
Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(avian) (MAFB), mRNA. 
BIK Homo sapiens BCL2-interacting killer (apoptosis-inducing) (BIK), mRNA. 
D4S234E 
Homo sapiens DNA segment on chromosome 4 (unique) 234 expressed seq 
(D4S234E), transcript2, mRNA. 
FAM133A 
Homo sapiens family with sequence similarity 133, member A (FAM133A), 
mRNA. 
SOX21 Homo sapiens SRY (sex determining region Y)-box 21 (SOX21), mRNA. 
MMP3 
Homo sapiens matrix metallopeptidase 3 (stromelysin 1, progelatinase) 
(MMP3), mRNA. 
NOV Homo sapiens nephroblastoma overexpressed gene (NOV), mRNA. 
CRMP1 
Homo sapiens collapsin response mediator protein 1 (CRMP1), transcript 
variant 1, mRNA. 
CLIP3 Homo sapiens CAP-GLY domain containing linker protein 3 (CLIP3), mRNA. 
LUM Homo sapiens lumican (LUM), mRNA. 
CDH10 Homo sapiens cadherin 10, type 2 (T2-cadherin) (CDH10), mRNA. 
HES5 Homo sapiens hairy and enhancer of split 5 (Drosophila) (HES5), mRNA. 
STMN2 Homo sapiens stathmin-like 2 (STMN2), mRNA. 
INSM1 Homo sapiens insulinoma-associated 1 (INSM1), mRNA. 
S100P Homo sapiens S100 calcium binding protein P (S100P), mRNA. 
CPLX1 Homo sapiens complexin 1 (CPLX1), mRNA. 
CD44 
Homo sapiens CD44 molecule (Indian blood group) (CD44), transcript variant 4, 
mRNA. 
HCP5 Homo sapiens HLA complex P5 (HCP5), mRNA. 
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HSPA6 Homo sapiens heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA. 
LOC643431 
PREDICTED: Homo sapiens similar to Keratin, type II cytoskeletal 8 (Cytokeratin-
8) (K8) (LOC643431), mRNA. 
DKK3 
Homo sapiens dickkopf homolog 3 (Xenopus laevis) (DKK3), transcript variant 1, 
mRNA. 
 
qk01b06.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1867667 3, 
mRNA sequence 
 
EST10539 Adipose tissue, white I Homo sapiens cDNA 5 end, mRNA sequence 
SNORD13 Homo sapiens small nucleolar RNA, C/D box 13 (SNORD13) on chromosome 8. 
 
UI-E-EJ1-ajw-b-16-0-UI.r1 UI-E-EJ1 Homo sapiens cDNA clone UI-E-EJ1-ajw-b-
16-0-UI 5, mRNA sequence 
SYK Homo sapiens spleen tyrosine kinase (SYK), mRNA. 
SCG5 Homo sapiens secretogranin V (7B2 protein) (SCG5), mRNA. 
TEK Homo sapiens TEK tyrosine kinase, endothelial (TEK), mRNA. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1) on 
chromosome 8. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1) on 
chromosome 8. 
MMP12 
Homo sapiens matrix metallopeptidase 12 (macrophage elastase) (MMP12), 
mRNA. 
ITM2A Homo sapiens integral membrane protein 2A (ITM2A), mRNA. 
MAGEC2 Homo sapiens melanoma antigen family C, 2 (MAGEC2), mRNA. 
HES2 Homo sapiens hairy and enhancer of split 2 (Drosophila) (HES2), mRNA. 
CALCB Homo sapiens calcitonin-related polypeptide beta (CALCB), mRNA. 
STMN2 Homo sapiens stathmin-like 2 (STMN2), mRNA. 
HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
H19 
Homo sapiens H19, imprinted maternally expressed transcript (H19) on 
chromosome 11. 
SERPINB2 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 2 
(SERPINB2), mRNA. 
CCNA1 Homo sapiens cyclin A1 (CCNA1), mRNA. 
VCX-C Homo sapiens variably charged X-C (VCX-C), mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
GDF15 Homo sapiens growth differentiation factor 15 (GDF15), mRNA. 
RAET1L Homo sapiens retinoic acid early transcript 1L (RAET1L), mRNA. 
BGN Homo sapiens biglycan (BGN), mRNA. 
KRT6A Homo sapiens keratin 6A (KRT6A), mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 2, 
mRNA. 
VCX3A Homo sapiens variable charge, X-linked 3A (VCX3A), mRNA. 
GEM 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), 
transcript variant 2, mRNA. 
IL32 Homo sapiens interleukin 32 (IL32), transcript variant 4, mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 2, 
mRNA. 
C17orf91 
Homo sapiens chromosome 17 open reading frame 91 (C17orf91), transcript 
variant 2, mRNA. 
IGFBP3 Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
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variant 1, mRNA. 
DKK3 
Homo sapiens dickkopf homolog 3 (Xenopus laevis) (DKK3), transcript variant 2, 
mRNA. 
DNMT3L 
Homo sapiens DNA (cytosine-5-)-methyltransferase 3-like (DNMT3L), transcript 
variant 1, mRNA. 
FAM111A 
Homo sapiens family with sequence similarity 111, member A (FAM111A), 
transcript variant 1, mRNA. 





PREDICTED: Homo sapiens hypothetical protein LOC650628 (LOC650628), 
mRNA. 
SEC24D 
Homo sapiens SEC24 related gene family, member D (S. cerevisiae) (SEC24D), 
mRNA. 
FILIP1 Homo sapiens filamin A interacting protein 1 (FILIP1), mRNA. 
HSPA6 Homo sapiens heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA. 
MGC61598 
PREDICTED: Homo sapiens similar to ankyrin-repeat protein Nrarp 
(MGC61598), mRNA. 
ARRDC4 Homo sapiens arrestin domain containing 4 (ARRDC4), mRNA. 
LOC645682 PREDICTED: Homo sapiens hypothetical LOC645682 (LOC645682), mRNA. 
TGFBI 
Homo sapiens transforming growth factor, beta-induced, 68kDa (TGFBI), 
mRNA. 
ERRFI1 Homo sapiens ERBB receptor feedback inhibitor 1 (ERRFI1), mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
KRT17 Homo sapiens keratin 17 (KRT17), mRNA. 
T1560 Homo sapiens T1560 protein (T1560), mRNA. 
HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
IGFBP6 Homo sapiens insulin-like growth factor binding protein 6 (IGFBP6), mRNA. 
DRAM Homo sapiens damage-regulated autophagy modulator (DRAM), mRNA. 
FAM84B Homo sapiens family with sequence similarity 84, member B (FAM84B), mRNA. 
AKR1B10 
Homo sapiens aldo-keto reductase family 1, member B10 (aldose reductase) 
(AKR1B10), mRNA. 
ADAMTS1 
Homo sapiens ADAM metallopeptidase with thrombospondin type 1 motif, 1 
(ADAMTS1), mRNA. 
TKTL1 Homo sapiens transketolase-like 1 (TKTL1), mRNA. 
FLJ21986 Homo sapiens hypothetical protein FLJ21986 (FLJ21986), mRNA. 
GEM 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), 
transcript variant 2, mRNA. 
DPYSL3 Homo sapiens dihydropyrimidinase-like 3 (DPYSL3), mRNA. 
ZCCHC12 Homo sapiens zinc finger, CCHC domain containing 12 (ZCCHC12), mRNA. 
LOC643272 
PREDICTED: Homo sapiens hypothetical protein LOC643272 (LOC643272), 
mRNA. 
CXCL2 Homo sapiens chemokine (C-X-C motif) ligand 2 (CXCL2), mRNA. 
ELSPBP1 
PREDICTED: Homo sapiens epididymal sperm binding protein 1 (ELSPBP1), 
mRNA. 
LOC404266 PREDICTED: Homo sapiens hypothetical LOC404266 (LOC404266), misc RNA. 
VCX Homo sapiens variable charge, X-linked (VCX), mRNA. 




IL13RA2 Homo sapiens interleukin 13 receptor, alpha 2 (IL13RA2), mRNA. 
C21orf34 
Homo sapiens chromosome 21 open reading frame 34 (C21orf34), transcript 
variant 3, mRNA. 
IL6 Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA. 
LOC646817 PREDICTED: Homo sapiens similar to Protein SET (LOC646817), mRNA. 
POU5F1 Homo sapiens POU class 5 homeobox 1 (POU5F1), transcript variant 1, mRNA. 
VCX2 Homo sapiens variable charge, X-linked 2 (VCX2), mRNA. 
LOC648526 PREDICTED: Homo sapiens similar to epiplakin 1 (LOC648526), mRNA. 
IRS4 Homo sapiens insulin receptor substrate 4 (IRS4), mRNA. 
S100A6 Homo sapiens S100 calcium binding protein A6 (S100A6), mRNA. 
S100A16 Homo sapiens S100 calcium binding protein A16 (S100A16), mRNA. 
BCL6 
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6), transcript 
variant 1, mRNA. 
KCTD12 
Homo sapiens potassium channel tetramerisation domain containing 12 
(KCTD12), mRNA. 
IGFBP3 . 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
variant 2, mRNA 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 1, 
mRNA. 
BDNF 
Homo sapiens brain-derived neurotrophic factor (BDNF), transcript variant 4, 
mRNA. 
SAT1 Homo sapiens spermidine/spermine N1-acetyltransferase 1 (SAT1), mRNA. 
SPRYD5 Homo sapiens SPRY domain containing 5 (SPRYD5), mRNA. 
KIF1A Homo sapiens kinesin family member 1A (KIF1A), mRNA. 
CALB1 Homo sapiens calbindin 1, 28kDa (CALB1), mRNA. 
EGR1 Homo sapiens early growth response 1 (EGR1), mRNA. 
D4S234E . 
Homo sapiens DNA segment on chromosome 4 (unique) 234 expressed 
sequence (D4S234E), transc 2, mRNA 
HSPA5 
Homo sapiens heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 
(HSPA5), mRNA. 
DNAJB1 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1), mRNA. 
FAM133A 
Homo sapiens family with sequence similarity 133, member A (FAM133A), 
mRNA. 
NR4A2 
Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), 
transcript variant 1, mRNA. 
SOX21 Homo sapiens SRY (sex determining region Y)-box 21 (SOX21), mRNA. 
MMP3 
Homo sapiens matrix metallopeptidase 3 (stromelysin 1, progelatinase) 
(MMP3), mRNA. 
NOV Homo sapiens nephroblastoma overexpressed gene (NOV), mRNA. 
ZNF503 Homo sapiens zinc finger protein 503 (ZNF503), mRNA. 
CLIP3 Homo sapiens CAP-GLY domain containing linker protein 3 (CLIP3), mRNA. 
LUM Homo sapiens lumican (LUM), mRNA. 
CDH10 Homo sapiens cadherin 10, type 2 (T2-cadherin) (CDH10), mRNA. 
HSPB8 Homo sapiens heat shock 22kDa protein 8 (HSPB8), mRNA. 
INSIG1 Homo sapiens insulin induced gene 1 (INSIG1), transcript variant 2, mRNA. 
HES5 Homo sapiens hairy and enhancer of split 5 (Drosophila) (HES5), mRNA. 
STMN2 Homo sapiens stathmin-like 2 (STMN2), mRNA. 
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S100P Homo sapiens S100 calcium binding protein P (S100P), mRNA. 
HSPA6 Homo sapiens heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA. 
DKK3 
Homo sapiens dickkopf homolog 3 (Xenopus laevis) (DKK3), transcript variant 1, 
mRNA. 
 
qk01b06.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1867667 3, 
mRNA sequence 
 
EST10539 Adipose tissue, white I Homo sapiens cDNA 5 end, mRNA sequence 
 
SNORD13 Homo sapiens small nucleolar RNA, C/D box 13 (SNORD13) on 
chromosome 8. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1) on 
chromosome 8. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1) on 
chromosome 8. 
MMP12 
Homo sapiens matrix metallopeptidase 12 (macrophage elastase) (MMP12), 
mRNA. 
ITM2A Homo sapiens integral membrane protein 2A (ITM2A), mRNA. 
MAGEC2 Homo sapiens melanoma antigen family C, 2 (MAGEC2), mRNA. 
CALCB Homo sapiens calcitonin-related polypeptide beta (CALCB), mRNA. 
STMN2 Homo sapiens stathmin-like 2 (STMN2), mRNA. 
HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
H19 
Homo sapiens H19, imprinted maternally expressed transcript (H19) on 
chromosome 11. 
CCNA1 Homo sapiens cyclin A1 (CCNA1), mRNA. 
VCX-C Homo sapiens variably charged X-C (VCX-C), mRNA. 
ARRDC4 Homo sapiens arrestin domain containing 4 (ARRDC4), mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
GDF15 Homo sapiens growth differentiation factor 15 (GDF15), mRNA. 
RAET1L Homo sapiens retinoic acid early transcript 1L (RAET1L), mRNA. 
BGN Homo sapiens biglycan (BGN), mRNA. 
NEFM Homo sapiens neurofilament, medium polypeptide 150kDa (NEFM), mRNA. 
KRT6A Homo sapiens keratin 6A (KRT6A), mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 2, 
mRNA 
RDM1 Homo sapiens RAD52 motif 1 (RDM1), transcript variant 2, mRNA. 
VCX3A . Homo sapiens variable charge, X-linked 3A (VCX3A), mRNA 
GEM 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), 
transcript variant 2, mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 2, 
mRNA. 
C17orf91 
Homo sapiens chromosome 17 open reading frame 91 (C17orf91), transcript 
variant 2, mRNA. 
IGFBP3 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
variant 1, mRNA. 
DKK3 
Homo sapiens dickkopf homolog 3 (Xenopus laevis) (DKK3), transcript variant 2, 
mRNA. 
FAM111A 
Homo sapiens family with sequence similarity 111, member A (FAM111A), 
transcript variant 1, mRNA. 






HBE1 Homo sapiens hemoglobin, epsilon 1 (HBE1), mRNA. 
FILIP1 Homo sapiens filamin A interacting protein 1 (FILIP1), mRNA. 
CCL20 Homo sapiens chemokine (C-C motif) ligand 20 (CCL20), mRNA. 
MGC61598 
PREDICTED: Homo sapiens similar to ankyrin-repeat protein Nrarp 
(MGC61598), mRNA. 
LOC645682 PREDICTED: Homo sapiens hypothetical LOC645682 (LOC645682), mRNA. 
TGFBI 
Homo sapiens transforming growth factor, beta-induced, 68kDa (TGFBI), 
mRNA. 
GAGE12G Homo sapiens G antigen 12G (GAGE12G), mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
T1560 Homo sapiens T1560 protein (T1560), mRNA. 
HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
LIM2 Homo sapiens lens intrinsic membrane protein 2, 19kDa (LIM2), mRNA. 
IGFBP6 Homo sapiens insulin-like growth factor binding protein 6 (IGFBP6), mRNA. 
LOC644743 PREDICTED: Homo sapiens hypothetical LOC644743 (LOC644743), mRNA. 
AKR1B10 
Homo sapiens aldo-keto reductase family 1, member B10 (aldose reductase) 
(AKR1B10), mRNA. 
ADAMTS1 
Homo sapiens ADAM metallopeptidase with thrombospondin type 1 motif, 1 
(ADAMTS1), mRNA. 
TKTL1 Homo sapiens transketolase-like 1 (TKTL1), mRNA. 
LOC645037 Homo sapiens similar to GAGE-2 protein (G antigen 2) (LOC645037), mRNA. 
FLJ21986 Homo sapiens hypothetical protein FLJ21986 (FLJ21986), mRNA. 
GEM 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), 
transcript variant 2, mRNA. 
LOC387763 PREDICTED: Homo sapiens hypothetical LOC387763 (LOC387763), mRNA. 
DPYSL3 Homo sapiens dihydropyrimidinase-like 3 (DPYSL3), mRNA. 
ZCCHC12 Homo sapiens zinc finger, CCHC domain containing 12 (ZCCHC12), mRNA. 
LOC643272 
PREDICTED: Homo sapiens hypothetical protein LOC643272 (LOC643272), 
mRNA. 
ELSPBP1 
PREDICTED: Homo sapiens epididymal sperm binding protein 1 (ELSPBP1), 
mRNA. 
LOC404266 PREDICTED: Homo sapiens hypothetical LOC404266 (LOC404266), misc RNA. 
S100A4 
Homo sapiens S100 calcium binding protein A4 (S100A4), transcript variant 2, 
mRNA. 
VCX Homo sapiens variable charge, X-linked (VCX), mRNA. 
CRYBA4 Homo sapiens crystallin, beta A4 (CRYBA4), mRNA. 
ETS1 
Homo sapiens v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 
(ETS1), mRNA. 
MAGEB2 Homo sapiens melanoma antigen family B, 2 (MAGEB2), mRNA. 
IL13RA2 Homo sapiens interleukin 13 receptor, alpha 2 (IL13RA2), mRNA. 
S100A4 
Homo sapiens S100 calcium binding protein A4 (S100A4), transcript variant 2, 
mRNA. 
C21orf34 
Homo sapiens chromosome 21 open reading frame 34 (C21orf34), transcript 
variant 3, mRNA. 
ZNF342 Homo sapiens zinc finger protein 342 (ZNF342), mRNA. 
FES Homo sapiens feline sarcoma oncogene (FES), mRNA. 
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LMNA Homo sapiens lamin A/C (LMNA), transcript variant 2, mRNA. 
DCT 
Homo sapiens dopachrome tautomerase (dopachrome delta-isomerase, 
tyrosine-related protein 2), mRNA. 
C21orf34 
Homo sapiens chromosome 21 open reading frame 34 (C21orf34), transcript 
variant 1, mRNA. 
LOC646817 PREDICTED: Homo sapiens similar to Protein SET (LOC646817), mRNA. 
POU5F1 Homo sapiens POU class 5 homeobox 1 (POU5F1), transcript variant 1, mRNA. 
VCX2 Homo sapiens variable charge, X-linked 2 (VCX2), mRNA. 
LOC648526 PREDICTED: Homo sapiens similar to epiplakin 1 (LOC648526), mRNA. 
IRS4 Homo sapiens insulin receptor substrate 4 (IRS4), mRNA. 
S100A6 Homo sapiens S100 calcium binding protein A6 (S100A6), mRNA. 
LSS 
Homo sapiens lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) (LSS), 
transcript variant 1, mRNA. 
TNC Homo sapiens tenascin C (hexabrachion) (TNC), mRNA. 
GCGR Homo sapiens glucagon receptor (GCGR), mRNA. 
MMP1 
Homo sapiens matrix metallopeptidase 1 (interstitial collagenase) (MMP1), 
mRNA. 
S100A16 Homo sapiens S100 calcium binding protein A16 (S100A16), mRNA. 
BCL6 
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6), transcript 
variant 1, mRNA. 
GAGE5 Homo sapiens G antigen 5 (GAGE5), mRNA. 
OLFM1 Homo sapiens olfactomedin 1 (OLFM1), transcript variant 1, mRNA. 
KCTD12 
Homo sapiens potassium channel tetramerisation domain containing 12 
(KCTD12), mRNA. 
IGFBP3 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
variant 2, mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 1, 
mRNA. 
TEK Homo sapiens TEK tyrosine kinase, endothelial (TEK), mRNA. 
SAT1 Homo sapiens spermidine/spermine N1-acetyltransferase 1 (SAT1), mRNA. 
KRT8 Homo sapiens keratin 8 (KRT8), mRNA. 
SPRYD5 Homo sapiens SPRY domain containing 5 (SPRYD5), mRNA. 
TRIM7 
Homo sapiens tripartite motif-containing 7 (TRIM7), transcript variant 6, 
mRNA. 
STC1 Homo sapiens stanniocalcin 1 (STC1), mRNA. 
KIF1A Homo sapiens kinesin family member 1A (KIF1A), mRNA. 
CALB1 Homo sapiens calbindin 1, 28kDa (CALB1), mRNA. 
EGR1 Homo sapiens early growth response 1 (EGR1), mRNA. 
MAFB 
Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(avian) (MAFB), mRNA. 
D4S234E 
Homo sapiens DNA segment on chromosome 4 (unique) 234 expressed 
sequence (D4S234E), trans 2, mRNA. 
COL3A1 
Homo sapiens collagen, type III, a 1 (Ehlers-Danlos syndrome type IV, 
autosomal dominant) (COL3A1), mRNA. 
TSPYL2 Homo sapiens TSPY-like 2 (TSPYL2), mRNA. 
IL1B Homo sapiens interleukin 1, beta (IL1B), mRNA. 
TRIM22 Homo sapiens tripartite motif-containing 22 (TRIM22), mRNA. 




GAGE5 Homo sapiens G antigen 5 (GAGE5), mRNA. 
SOX21 Homo sapiens SRY (sex determining region Y)-box 21 (SOX21), mRNA. 
GAGE6 Homo sapiens G antigen 6 (GAGE6), mRNA. 
MMP3 
Homo sapiens matrix metallopeptidase 3 (stromelysin 1, progelatinase) 
(MMP3), mRNA. 
COL1A2 Homo sapiens collagen, type I, alpha 2 (COL1A2), mRNA. 
NOV Homo sapiens nephroblastoma overexpressed gene (NOV), mRNA. 
ZNF503 Homo sapiens zinc finger protein 503 (ZNF503), mRNA. 
CRMP1 
Homo sapiens collapsin response mediator protein 1 (CRMP1), transcript 
variant 1, mRNA. 
PRRX2 Homo sapiens paired related homeobox 2 (PRRX2), mRNA. 
CDH10 Homo sapiens cadherin 10, type 2 (T2-cadherin) (CDH10), mRNA. 
HSPB8 Homo sapiens heat shock 22kDa protein 8 (HSPB8), mRNA. 
INSIG1 Homo sapiens insulin induced gene 1 (INSIG1), transcript variant 2, mRNA. 
HES5 Homo sapiens hairy and enhancer of split 5 (Drosophila) (HES5), mRNA. 
STMN2 Homo sapiens stathmin-like 2 (STMN2), mRNA. 
INSM1 Homo sapiens insulinoma-associated 1 (INSM1), mRNA. 
S100P Homo sapiens S100 calcium binding protein P (S100P), mRNA. 
CPLX1 Homo sapiens complexin 1 (CPLX1), mRNA. 
ZNF280A Homo sapiens zinc finger protein 280A (ZNF280A), mRNA. 
CD44 
Homo sapiens CD44 molecule (Indian blood group) (CD44), transcript variant 4, 
mRNA. 
HCP5 Homo sapiens HLA complex P5 (HCP5), mRNA. 
HSPA6 Homo sapiens heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA. 
 
qk01b06.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1867667 3, 
mRNA sequence 
 
EST10539 Adipose tissue, white I Homo sapiens cDNA 5 end, mRNA sequence 
 
yu38g09.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 
IMAGE:236128 5, mRNA sequence 
SNORD13 Homo sapiens small nucleolar RNA, C/D box 13 (SNORD13) on chromosome 8. 
 
UI-E-EJ1-ajw-b-16-0-UI.r1 UI-E-EJ1 Homo sapiens cDNA clone UI-E-EJ1-ajw-b-
16-0-UI 5, mRNA sequence 
IFI27 Homo sapiens interferon, alpha-inducible protein 27 (IFI27), mRNA. 
SYK Homo sapiens spleen tyrosine kinase (SYK), mRNA. 
SCG5 Homo sapiens secretogranin V (7B2 protein) (SCG5), mRNA. 
TEK Homo sapiens TEK tyrosine kinase, endothelial (TEK), mRNA. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1) on 
chromosome 8. 
POU5F1P1 
Homo sapiens POU class 5 homeobox 1 pseudogene 1 (POU5F1P1) on 
chromosome 8. 
ITM2A Homo sapiens integral membrane protein 2A (ITM2A), mRNA. 
MAGEC2 Homo sapiens melanoma antigen family C, 2 (MAGEC2), mRNA. 
HES2 Homo sapiens hairy and enhancer of split 2 (Drosophila) (HES2), mRNA. 
COL1A2 Homo sapiens collagen, type I, alpha 2 (COL1A2), mRNA. 
CALCB Homo sapiens calcitonin-related polypeptide beta (CALCB), mRNA. 
STMN2 Homo sapiens stathmin-like 2 (STMN2), mRNA. 
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HBA2 Homo sapiens hemoglobin, alpha 2 (HBA2), mRNA. 
SERPINB2 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 2 
(SERPINB2), mRNA. 
SERPINB2 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 2 
(SERPINB2), mRNA. 
CCNA1 Homo sapiens cyclin A1 (CCNA1), mRNA. 
VCX-C Homo sapiens variably charged X-C (VCX-C), mRNA. 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 
GDF15 Homo sapiens growth differentiation factor 15 (GDF15), mRNA. 
FLVCR2 
Homo sapiens feline leukemia virus subgroup C cellular receptor family, 
member 2 (FLVCR2), mRNA. 
RAET1L Homo sapiens retinoic acid early transcript 1L (RAET1L), mRNA. 
NEFM Homo sapiens neurofilament, medium polypeptide 150kDa (NEFM), mRNA. 
KRT6A Homo sapiens keratin 6A (KRT6A), mRNA. 
GAGE12I Homo sapiens G antigen 12I (GAGE12I), mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 2, 
mRNA. 
CXorf48 
Homo sapiens chromosome X open reading frame 48 (CXorf48), transcript 
variant 1, mRNA. 
DCN Homo sapiens decorin (DCN), transcript variant C, mRNA. 
VCX3A Homo sapiens variable charge, X-linked 3A (VCX3A), mRNA. 
GEM 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), 
transcript variant 2, mRNA. 
IL32 Homo sapiens interleukin 32 (IL32), transcript variant 4, mRNA. 
TSC22D3 
Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 2, 
mRNA. 
C17orf91 
Homo sapiens chromosome 17 open reading frame 91 (C17orf91), transcript 
variant 2, mRNA. 
IGFBP3 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript 
variant 1, mRNA. 
DNMT3L 
Homo sapiens DNA (cytosine-5-)-methyltransferase 3-like (DNMT3L), transcript 
variant 1, mRNA. 
FAM111A 
Homo sapiens family with sequence similarity 111, member A (FAM111A), 
transcript variant 1, mRNA. 
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Figure S2. Confirmation of optimal timepoint of reprogramming for SMC 
differentiation. (A) Fibroblasts were reprogrammed for 2, 4, 7 14 and 21 days 
and then differentiated for 4 days. Indirect immunoflueorescence for Calponin 
was then performed as indication of SMC differentiation. DAPI was used as 
counterstaining for identification of the nucleus. Images were obtained with the 
Olympus IX81 white field inverted microscope. (B) Quantification of Calponin 











































Figure S3. Confirmation of optimal day of reprogramming for SMC 
differentiation on the mRNA level. Fibroblasts were reprogrammed for 2, 4, 7, 
14 and 21 days and then differentiated for 4 days. Non reprogrammed fibroblasts 
were used as a ctl. Total mRNA was extracted and Q-PCR was performed for 


















































250 Calponin positive cells





































Figure S4. (A) Expression of SMC markers in differentiated iPS cells. Human 
iPS cells were cultured on Collagen IV and DM for 6 days. Samples were then 
harvested and subjected to Q-PCR. Undifferentiated iPS cells were used as a ctl 
(mean ±SEM of 3 individual experiments). (B) Overall efficiency of 
differentiation per culture. PiPS cells were differentiated on Collagen IV for 4 
days and then stained for SMC markers Calponin and SM22. The cells which 
stained positive for the aforementioned markers were quantified and compared to 




















Figure S5. Overexpression of DKK3 does not affect the proliferation rate of 
PiPS-SMCs. PiPS-SMCs were differentiated on Collagen IV and DM for 2 days 
and then nucleofected with an empty PCMV5 vector or a DKK3 vector. Cells 
were then trypsinised and counted (A) or subjected to a BrdU Elisa assay (B) to 




































































Figure S6. PiPS-SMCs present a reduced differentiation potential after 
lentiviral silencing of DKK3. PiPS cells were seeded on Collagen IV and DM 
and then infected with NT shRNA or shDKK3 for 72 hours. Indirect 
immunofluorescence for Calponin reveals that there is a reduced differentiation 
potential of PiPS to SMCs after 72 hours of DKK3 silencing. DAPI was used as 
counterstaining for identification of the nucleus.  Images were obtained with the 
Olympus IX81 white field inverted microscope. (B) Quantification of Calponin 
expression in differentiated cells using the Volocity Imaging software. 
 


















































Figure S7. Confirmation of activity of human recombinant DKK3 protein. 
Fibroblasts were stimulated for different timepoints with human recombinant 
DKK3 tagged with 6xHis Tag. Samples were harvested and subjected to western 
blot analysis for 6xHis Tag revealing that the recombinant protein is successfully 














Figure S8. Confirmation of successful DKK3 deglycosylation. Human 
recombinant DKK3 was deglycosylated with heat inactivated PNGase (boiled at 
96
o
C) and active PNGase for 5 hours. The samples were then subjected to western 
blot analysis for DKK3. The molecular weight of DKK3 was reduced under 








 Inactive Active 













Figure S9. Representative image of antibody specificity. Fibroblasts were 
infected with lentiviruses carrying Ex-SOX2/Ex-OCT4/Ex-KLF4/ex-cMyc or 
nucleofected with the pCAG2L-OSKM vector carrying all four factors. Fibroblasts 
were also infected/nucleofected with EX-GFP and ctl pCAG2L vector 
respectively. Samples were subjected to western blot analysis and were blotted for 
OCT4. The predicted molecular weight for OCT4 is 45 kDa. For the Ex-OCT4 
infected samples, the specific band appears at size ~72 due to the GFP included in 
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